

Secu G-L

Successful therapy with **secukinumab** in a patient with generalized pustular psoriasis carrying homozygous IL36RN p.His32Arg mutation.

Gabeff R, Safar R, Leducq S, Maruani A, Sarrabay G, Touitou I, Samimi M.

Int J Dermatol. 2019 Jan;58(1):e16-e17. Otettu 28.2.20

TH17 cells expressing CD146 are significantly increased in patients with Systemic sclerosis.

Gabsi A, et al. Sci Rep. 2019. PMID: 31776424 **Free PMC article.** Otettu 7.9.22

The association between IL17, fatigue and quality of life in psoriatic arthritis patients.

Gado SE, El-Khouly RM, Aboelhawa MA, Fouda MH, El-Banna HS.

Expert Rev Clin Immunol. 2021 May;17(5):539-544. doi: 10.1080/1744666X.2021.1905522. Epub 2021 Apr 2. PMID: 33734916 ei ole M

[Biology of recently discovered cytokines: interleukin-17--a unique inflammatory cytokine with roles in bone biology and arthritis.](#)

Gaffen SL.

Arthritis Res Ther. 2004;6(6):240-7. Epub 2004 Oct 8. Review.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Gaffen SL, Kramer JM, Yu JJ, Shen F: The IL-17 cytokine family. Vitam Horm 2006, 74:255-282. ei ole M

Ei oteta

Gaffen SL. An overview of IL 17 function and signaling.
Cytokine 2008;43:402–7. Otettu 4.3.16
Ref. ei otet.

Gaffen SL, Hajishengallis G (2008) A new inflammatory
cytokine on the block: re-thinking periodontal disease
and the Th1/Th2 paradigm in the context of Th17 cells
and IL-17. J Dent Res 87:817–828 Otettu 12.3.20

Ref. katsottu 13.3.20

[The role of **interleukin-17** in the pathogenesis of
rheumatoid arthritis.](#)

Gaffen SL.

Curr Rheumatol Rep. 2009 Oct;11(5):365-70. Review.

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Gaffen SL: Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9:556–567. Otettu

16.2.16

Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011;23(5):613–619.

Otettu 16.2.16

9. [Gaffen SL, Hernandez-Santos N, Peterson AC. IL-17 signaling in host defense against Candida albicans. Immunol Res. 2011; 50:181-187. Otettu 15.3.20](#)

Regulation of host-microbe interactions at oral mucosal barriers by type **17** immunity.

Gaffen SL, et al. *Sci Immunol*. 2020. PMID: 31901072

[Free PMC article](#). Review. Otettu 28.11.22

Gaffen SL. Life before seventeen: cloning of the IL-17 receptor. *J Immunol*. 2011;187(9):4389–91.

doi:10.4049/jimmunol. 1102576. Otettu 4.3.16

Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing.

Nat Rev Immunol 2014; 14:585– 600. Otettu 4.3.16

Real-world evidence for **secukinumab** in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA. Gaffney K, Gullick N, MacKay K, Patel Y, Sengupta R, Sheeran T, Hemmings L, Pamies P. *Rheumatol Adv Pract*. 2023 Aug 21;7(3):rkad055. doi: 10.1093/rap/rkad055. eCollection 2023. PMID: 37663578 [Free PMC article](#). Otettu 12.10.23

Gagliani N, Amezcu Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. *Nature*. (2015) 523:221–5 Otettu 8.3.20

Effectiveness and safety of **secukinumab** in patients with moderate-to-severe plaque psoriasis - a real life retrospective study.

Galica K, Lesiak A, Ciążyńska M, Noweta M, Bednarski I, Narbutt J.

Postepy Dermatol Alergol. 2021 Dec;38(6):973-978. doi: 10.5114/ada.2020.97066. Epub 2020 Jul 11.

PMID: 35126003 [Free PMC article.](#) Otettu 3.3.22

Secukinumab during pregnancy: a case report and review of literature.

Gallo L, Ruggiero A, Balato A, Megna M, Fabbrocini G.

J Dermatolog Treat. 2020 Apr 13:1-2. doi:

10.1080/09546634.2020.1750551. Online ahead of print.

PMID: 32233899 Otettu 21.9.20

Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature.

Galluzzo M, D'Adamio S, Teoli M, Bianchi L, Talamonti M. *Dermatol Ther*. 2019 May;32(3):e12899. doi: 10.1111/dth.12899. Epub 2019 Apr 29. PMID: 30969010 Otettu 23.9.20

Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study.

Galluzzo M, Talamonti M, Atzori L, Bardazzi F, Campanati A, Di Cesare A,, Flori ML, Mugheddu C, Offidani A, Piaserico S, Russo F, Sacchelli L, Bianchi L, Prignano F. *Expert Opin Biol Ther*. 2022 Jan 20:1-8. doi: 10.1080/14712598.2022.2029841. Online ahead of print. PMID: 35043741 Otettu 3.3.22

Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.

Galluzzo M, Talamonti M, De Simone C, D'Adamio S, Moretta G, Tambone S, Caldarola G, Fagnoli MC, Peris K, Bianchi L.

Expert Opin Biol Ther. 2018 Jul;18(7):727-735. doi:

Otettu 2.3.20

Ref. katsottu 16.3.20

Similar articles

A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with **secukinumab**.

Galluzzo M, D'Adamio S, Campione E, Mazzilli S, Bianchi L, Talamonti M.

Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with **secukinumab** and review of the literature.

Galluzzo M, D'Adamio S, Teoli M, Bianchi L, Talamonti M.

Dermatol Ther. 2019 May;32(3):e12899. **Free PMC Article Otettu 28.2.20**

Ref. katsottu 12.3.20

In which patients the best efficacy of **secukinumab**? Update of a real-life analysis after 136 weeks of treatment with **secukinumab** in moderate-to-severe plaque psoriasis.

Galluzzo M, D'Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M.

Expert Opin Biol Ther. 2020 Feb;20(2):173-182. Otettu 28.2.20

Ref. katsottu 1.3.2020

Long-Term Persistence Rate of **Secukinumab** in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study.

Galluzzo M, Trovato E, Talamonti M, Caldarola G, Di Nardo L, Lazzeri L, Mugheddu C, Burlando M, Balestri R, Bernardini N, Biondi G, Vellucci L, Russo F, De Simone C, Paganini C, Rech G, Cozzani EC, Atzori L, Montesu MA, Potenza C, Chiricozzi A, Rubegni P.

J Clin Med. 2024 Jun 30;13(13):3864. doi:

10.3390/jcm13133864.

PMID: 38999429 **Free PMC article.** Otettu 27.9.24

The role of Th17 cells in chronic lymphocytic leukemia:
friend or foe?

Gamal W, Sahakian E, Pinilla-Ibarz J.

Blood Adv. 2023 Jun 13;7(11):2401-2417. doi:
10.1182/bloodadvances.2022008985.

PMID: 36574293 **Free PMC article**. Review. Otettu
14.6.23

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy.

Gambardella A.

Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):11-16.

Free PMC Article Otettu 28.2.20

Ref. katsottu 12.3.20

CMV Infection: A Clinical Challenge in Biological
Therapy? The Case of Asymptomatic Patients with
Persistent Positive Immunoglobulin M Anti-CMV Treated
with **Secukinumab**.

Gambardella A, Licata G, Calabrese G, De Rosa A,
Pagliuca F, Alfano R, Argenziano G.

Psoriasis (Auckl). 2020 Nov 27;10:57-60. doi:
10.2147/PTT.S284701. eCollection 2020.
PMID: 33282718 [Free PMC article.](#) Otettu 13.12.20

Systemic immune-inflammation biomarkers in psoriasis
patients under **interleukin** 17A-inhibitor treatment.

Gambichler T, Würfel L, Abu Rached N, Mansour R,
Bechara FG, Scheel CH.

J Eur Acad Dermatol Venereol. 2023

Jul;37(7):e837-e839. doi: 10.1111/jdv.18895. Epub 2023
Feb 25.

PMID: 36682043 Otta M

Secukinumab use in the treatment of Netherton's
syndrome.

Gan C, King E, Orchard D.

Australas J Dermatol. 2022 Aug;63(3):365-367. doi:

10.1111/ajd.13880. Epub 2022 May 27.

PMID: 35622930 Otettu 28.11.22

Secukinumab-Induced Lymphocytic Colitis.

Gandu SSK, Khan MH, Vasikaran A, Pandit S.

J Investig Med High Impact Case Rep. 2022

Jan-Dec;10:23247096221110399. doi:

10.1177/23247096221110399.

PMID: 35801542 **Free PMC article.** Otettu 26.8.22

Hidradenitis Suppurativa: New Targets and Emerging Treatments.

Gao JL, Otto TS, Porter ML, Kimball AB.

Am J Clin Dermatol. 2024 Sep;25(5):765-778. doi: 10.1007/s40257-024-00880-1.

Epub 2024 Jul 26.

PMID: 39060744 Review. Otta M

Garaude J, Blander JM. ICOSstimulating immunotherapies with TH17. Sci Transl Med 2010;2:55ps52. ei aukea

Science ei auence ei aukea Ei oteta

.

[Anti-IL-17 mAbs herald new options in psoriasis.](#)

Garber K.

Nat Biotechnol. 2012 Jun 7;30(6):475-7. d

PMID: Otettu 4.3.16

[Similar articles](#)

Association of Gender, Diagnosis, and Obesity With Retention Rate of **Secukinumab** in Spondyloarthropathies: Results Form a Multicenter Real-World Study.

García-Dorta A, León-Suarez P, Peña S, Hernández-Díaz M, Rodríguez-Lozano C, González-Dávila E, Hernández-Hernández MV, Díaz-González F.

Front Med (Lausanne). 2022 Jan 13;8:815881. doi: 10.3389/fmed.2021.815881. eCollection 2021.

PMID: 35096907 [Free PMC article.](#) [Otettu 3.3.22](#)

New Insights into the Pathogenesis of Psoriatic Arthritis.

Garcia-Hernandez ML, Ritchlin CT, Guy DR, Wechalekar M.

Rheum Dis Clin North Am. 2025 Aug;51(3):397-415. doi: 10.1016/j.rdc.2025.05.001. Epub 2025 Jun 11.

PMID: 40681278 Review. [Otta M](#)

Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors.

García-Martín E, Romero-Jiménez RM, Baniandrés-Rodríguez O, Escudero-Vilaplana V, Benedí-González J, de Los Ríos Luna PM, Herranz-Alonso A, Sanjurjo-Sáez M.

Eur J Hosp Pharm. 2023 Apr 24:ejhpharm-2022-003594. doi: 10.1136/ejhpharm-2022-003594. Online ahead of print.

PMID: 37094886 Otta M

The role of **secukinumab** in the treatment of psoriatic arthritis and ankylosing spondylitis.

García-Montoya L, Marzo-Ortega H.

[Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO \(Italian landscape psoriasis\).](#)

Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Mercuri SR, Travaglini M, Costanzo A, Narcisi A.

Front Immunol. 2024 Jan 11;14:1341708. doi: 10.3389/fimmu.2023.1341708. eCollection 2023. PMID: 38274801 Free PMC article. Otettu 4.3.24

[**Secukinumab: a review in moderate to severe plaque psoriasis.**](#)

Garnock-Jones KP.

Am J Clin Dermatol. 2015 Aug;16(4):323-30. doi:

Ref. katsottu 8.3.20

Otettu 7.3.20

Ref. katsottu 9.3.20

[Similar articles](#)

L.A. Garrett-Sinha, S. John, S.L. Gaffen, IL-17 and the Th17 lineage in systemic lupus erythematosus, Curr. Opin. Rheumatol. 20 (2008) 519–525. Otettu 4.3.16

Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and/or spondyloarthritis and initiating treatment with **secukinumab**.

Garrido JJJ, Pérez AG, Torres AP, Cid AR, Almela CM, Cubillo MDP, Fernández CC, Trull IB, Carmona L, Catalá JC.

Reumatol Clin (Engl Ed). 2022 Jan;18(1):25-29. doi: 10.1016/j.reumae.2020.07.010. Epub 2021 Apr 7. PMID: 35090609 Otettu 3.3.22

Gaspari AA, Tying S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatologic therapy. 2015; 28(4):179–93. Otettu 2.3.20

4. <https://doi.org/10.1111/dth.12251> PMID: 26201310

Interleukin-17A Triggers the Release of Platelet-Derived Factors Driving Vascular Endothelial Cells toward a Pro-Angiogenic State.

Gatsiou A, Sopova K, Tselepis A, Stellos K.

Cells. 2021 Jul 22;10(8):1855. doi:
10.3390/cells10081855.

PMID: 34440624 **Free PMC article.** Otettu 29.8.22

Gaublomme, J. T. *et al.* Single-cell genomics unveils critical regulators of Th17 cell pathogenicity. *Cell* **163**, 1400–1412 (2015). Otettu 12.3.20

Ref. katsottu 26.3.20

Successful treatment of type II pityriasis rubra pilaris with **secukinumab**.

Gauci ML, Jachiet M, Gottlieb J, Madeleine-Chambrin I, Rybojad M, Bagot M, Bouaziz JD.

JAAD Case Rep. 2016 Dec 5;2(6):462-464. Otettu 27.5.18

Free PMC Article

Similar articles

Cutting Edge: Intestinal IL-17A Receptor Signaling Specifically Regulates High-Fat Diet-Mediated, Microbi-Driven Metabolic Disorders.

Gaudino SJ, Huang H, Jean-Pierre M, Joshi P, Beaupre M, Kempen C, Wong HT, Kumar P.

J Immunol. 2021 Oct 15;207(8):1959-1963. doi: 10.4049/jimmunol.2000986. Epub 2021 Sep 20. PMID: 34544802 Otettu 28.11.22

Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database.

Ge L, Huang X, Dong Z, Zhong T.

Sci Rep. 2025 May 24;15(1):18102. doi:
10.1038/s41598-025-03114-4.

PMID: 40413262 [Free PMC article.](#) Otettu 4.6.25

Ge S, Hertel B, Koltsova EK, Sörensen-Zender I, Kielstein JT, Ley K, et al. Increased atherosclerotic lesion formation and vascular leukocyte accumulation in renal impairment are mediated by Interleukin-17A. Circulation Research 2013;113(8):965-74. Otettu 7.3.20

New onset inflammatory bowel disease after initiation of anti-IL-17a treatment: a case series.

Geldof J, Truyens M, Strubbe B, Claeys S, Dewitte G, Glorieus E, Hoorens A, Lobaton T.

Acta Gastroenterol Belg. 2024 Jul-Sep;87(3):413-417.
doi: 10.51821/87.3.12874.

PMID: 39411795 **Free article.** Otettu 24.10.24

A Randomized Placebo Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate to Severe Plaque Psoriasis (VIP-S).

Gelfand JM, Shin DB, Duffin KC, Armstrong AW, Blauvelt A, Tying SK, Menter A, Gottlieb S, Lockshin BN, Simpson EL, Kianifard F, Sarkar RP, Muscianisi E, Steadman J, Ahlman MA, Playford MP, Joshi AA, Dey AK, Werner TJ, Alavi A, Mehta NN.

J Invest Dermatol. 2020 Feb 20. pii: S0022-202X(20)30157-3. Otettu 3.3.20

Ref. katsottu 6.3.20

Segmental stiff skin syndrome treated with **secukinumab**.

Gelinas A, Powell J, Lapointe C, Coulombe J.

Pediatr Dermatol. 2023 Feb 24. doi: 10.1111/pde.15274.

Online ahead of print.

PMID: 36825671 Otettu 12.6.23

LY2439821, a humanized anti-**interleukin-17** monoclonal antibody, in the treatment of patients with rheumatoid **arthritis**: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.

Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J.

Arthritis Rheum. 2010 Apr;62(4):929-39. doi: Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Genovese, M., Greenwald, M., Cho, C., Berman, A., Jin, L., Cameron, G. et al. (2011) A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors [abstract]. Arthritis Rheum 63(10 Suppl.): S1017. Otettu 4.3.16

Genovese MC, Durez P, Richards HB et al. One year efficacy and safety results of a phase II trial of secukinumab in patients with rheumatoid arthritis. Arthritis Rheum 2011;63(Suppl):S149-50. Otettu 20.9.20

[Efficacy and safety of **secukinumab** in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.](#)

Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Coddling CE, Kellner H, Ikawa T, Hugot S, Mpofu S.
Ann Rheum Dis. 2013 Jun;72(6):863-9.

Otettu 3.2.16

[Similar articles](#)

[One-year efficacy and safety results of **secukinumab** in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.](#)

Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Coddling CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S.
J Rheumatol. 2014 Mar;41(3):414-21. doi:

Otettu 4.3.16

[Similar articles](#)

Genovese MC, Greenwald M, Cho C-S, et al. A phase II randomized study of && subcutaneous ixekizumab, an antiinterleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. *Arthritis Rheumatol*

2014; 66:1693 – 1704. Otettu 4.3.16

[**Secukinumab** for the Treatment of Axial Spondyloarthritis: Long-Term Real-Life Data from Five Italian Referral Centers.](#)

Gentileschi S, Cannistrà C, Gaggiano C, Damiani A, Carli L, Benucci M, Cantini F, Niccoli L, Vitale A, Baldi C, Delle Sedie A, Cantarini L, Mosca M, Frediani B, Guiducci S.

J Pers Med. 2024 Nov 14;14(11):1105. doi: 10.3390/jpm14111105.

PMID: 39590597 Free PMC article. Otettu 21.1.25

Long-Term Effectiveness of **Secukinumab** in Patients with Axial Spondyloarthritis.

Gentileschi S, Rigante D, J, Lopalco G,, Emmi G, Di Scala G, Iannone F, Fabiani C, Frediani B, Cantarini L.

Mediators Inflamm. 2020 Mar 31;2020:6983272. doi: 10.1155/2020/6983272. eCollection 2020.

PMID: 32317863 Otettu 19.9.20

Prompt Clinical Response to **Secukinumab** in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers.

Gentileschi S, Vitale A, Rigante D, Lopalco G, Emmi G, Orlando I, Di Scala G, J, Fabiani C, Frediani B, Galeazzi M, Lapadula G, Iannone F, Cantarini L.

Isr Med Assoc J. 2018 Jul;20(7):438-441.

Otettu 3.9.2018

Free Article

Similar articles

Georgakopoulos JR, Ighani A, Zhou LL, et al. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e32–e34.

Otettu 3.3.20

Patient-Centred Care When Treating Plaque Psoriasis With **Secukinumab**: Reasons for Discontinuing Treatment Outside of Randomized Controlled Trials.

Georgakopoulos JR, Ighani A, Phung M, Yeung J.

Georgakopoulos JR, Phung M, Ighani A, Yeung J. Efficacy and safety of switching to ixekizumab in secukinumab non- responders with plaque psoriasis: a multicenter retrospective study of interleukin 17A antagonist therapies. J Am Acad Dermatol 2018; 79: 155–157. Otettu 8.3.20

Ref. katsottu 13.3.20

2. Georgakopoulos JR, Ighani A, Phung M, Yeung J. Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study. J Am Acad Dermatol. 2018;78(5):1019-1020. Otettu 2.3.20

Current and novel therapeutic targets in the treatment of rheumatoid arthritis.

George G, Shyni GL, Raghu KG.

Inflammopharmacology. 2020 Sep 18. doi:

10.1007/s10787-020-00757-9. Online ahead of print.

PMID: 32948901 Otettu 21.9.20

Effectiveness and safety of **secukinumab** for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement.

Ger TY, Huang YH, Hui RC, Tsai TF, Chiu HY.

Ther Adv Chronic Dis. 2019 Apr: **Free PMC Article**
Otettu 28.2.20

Effects of **secukinumab** on metabolic and liver parameters in plaque psoriasis patients.

Gerdes S, Pinter A, Papavassilis C, Reinhardt M.

J Eur Acad Dermatol Venereol. 2019 Oct 10. Otettu 28.2.20

Gerhardt S, Abbott WM, Hargreaves D, Pauptit RA, Davies RA, Needham MR, et al. Structure of IL-17A in complex with a potent, fully human neutralizing antibody. J Mol Biol 2009;394(5):905–21. Otettu 4.3.16

Geri G, Terrier B, Rosenzweig M, Wechsler B, Touzot M, Seilhean D, Tran TA, Bodaghi B, Musset L, Soumelis V, Klatzmann D, Cacoub P, Saadoun D (2011) Critical role of IL-21 in modulating T(H)17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 128:655–664
Otettu 20.3.20

Erythrodermic Psoriasis: Excellent Management
Avoiding Hospitalization.

Gerosa S, Ravaglia G, Fantini C, Feliciani C, Satolli F.
Acta Dermatovenereol Croat. 2024 Dec;32(4):214-216.
PMID: 40657657 Otta M

T cell functions of psoriatic arthritis patients are regulated differently by TNF, IL-17A and IL-6 receptor blockades in vitro.

Gertel S, Polachek A, Furer V, Levartovsky D, Sidis H, Pel S, Paran D, Elkayam O.

Clin Exp Rheumatol. 2022 Jan;40(1):120-128. doi: 10.55563/clinexprheumatol/jdhe41. Epub 2021 Feb 25. Otettu 31.8.22

Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010;185:302–12. Otettu 28.5.18

Intra-class switch among **interleukin-17** inhibitors for the treatment of plaque psoriasis: a single-center experience.

Ghezzi G, Ibba L, Gargiulo L, Narcisi A, Costanzo A, Valenti M.

Dermatol Reports. 2024 Nov 12. doi: 10.4081/dr.2024.10080. Online ahead of print. PMID: 39969045 **Free article.** Otettu 4.6.25

Simultaneous onset of Crohn's disease and Psoriasis in a Multiple Sclerosis patient treated with Teriflunomide: A novel case report highlighting potential autoimmune interactions.

Ghiasian M, Rastgoo Haghi A, Borzouei S, Bawand R.

Heliyon. 2024 Feb 9;10(4):e26195. doi: 10.1016/j.heliyon.2024.e26195. eCollection 2024 Feb 29.

PMID: 38375254 **Free PMC article.** Otettu 13.3.24

Ghilardi N, Ouyang W: Targeting the development and effector functions of TH17 cells. *Semin Immunol* 2007, 19:383-393. Otettu 16.2.16

[Generation of pathogenic T\(H\)17 cells in the absence of TGF- \$\beta\$ signalling.](#)

Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N, Grainger JR, Chen Q, Kanno Y, Watford WT, Sun HW, Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O'Shea JJ.

Nature. 2010 Oct 21;467(7318):967-71. doi:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.

Ghoreschi K, Balato A, Enerbäck C, Sabat R.

Lancet. 2021 Feb 20;397(10275):754-766. doi:

10.1016/S0140-6736(21)00184-7. Epub 2021 Jan 27.

PMID: 33515492 Review. Otettu 28.11.22

.

[T helper 17 cell heterogeneity and pathogenicity in autoimmune disease.](#)

Ghoreschi K, Laurence A, Yang XP, Hirahara K, O'Shea JJ.

Trends Immunol. 2011 Sep;32(9):395-401. doi:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Interleukin-17A derived from mast cells: evidence for an autoinflammatory loop in hidradenitis suppurativa?

Giamarellos-Bourboulis EJ. Otta M

Treatment of necrobiosis lipoidica with **secukinumab** (Cosentyx): a case series.

Gibson RS, Salian P, Beckles A, Stavert R, Tahan S, Kimball AB, Porter ML.

Int J Dermatol. 2023 Sep;62(9):1198-1201. doi: 10.1111/ijd.16780. Epub 2023 Jul 1.

PMID: 37392065 Otta M

Gilliet M, Conrad C, Geiges M et al. Arch Dermatol 2004; 140: 1490–1495. doi: 10.1001/archderm.140.11.1490

Immunobiology of IL-26.

Gilliet M, Modlin RL.

J Invest Dermatol. 2024 Jan 8:S0022-202X(23)03124-X.

doi: 10.1016/j.jid.2023.10.038. Online ahead of print.

PMID: 38206272 Review. Otta M

Vitiligo with Progressive Repigmentation during
Secukinumab Treatment in a Patient with Psoriatic
Arthritis: A Case Report.

Giordano D, Magri F, Persechino F, Lepore A, Verde R, Capalbo A, Persechino S.

Case Rep Dermatol. 2021 Apr 12;13(1):209-215. doi: 10.1159/000510831. eCollection 2021 Jan-Apr.

PMID: 34703429 [Free PMC article](#). Otettu 3.3.22

.

[Psoriasis: rationale for targeting interleukin-17.](#)

Girolomoni G, Mrowietz U, Paul C.

Br J Dermatol. 2012 Oct;167(4):717-24. dReview.

Otettu 16.2.16

[Similar articles](#)

Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, Prinz JC (2017) The role of IL-23 and

the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol 31:1616–1626. Otettu 7.3.20

<https://doi.org/10.1111/jdv.14433>

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving **secukinumab**: a literature review.

Gisondi P, Simon D, Alarcon I, Pournara E, Puig L.

J Dermatolog Treat. 2023 Dec;34(1):2167487. doi: 10.1080/09546634.2023.2167487.

PMID: 36625506 **Free article**. Review. Otettu 12.6.23

Methotrexate vs **secukinumab** safety in psoriasis patients with metabolic syndrome.

Gisondi P, Bellinato F, Bruni M, De Angelis G, Girolomoni G.

Dermatol Ther. 2020 Sep 5:e14281. doi: 10.1111/dth.14281. Online ahead of print.
PMID: 32888370 Otettu 19.9.20

[Efficacy and safety of **secukinumab** in chronic plaque psoriasis and psoriatic arthritis therapy.](#)

Gisondi P, Dalle Vedove C, Girolomoni G.

Dermatol Ther (Heidelb). 2014 Jun;4(1):1-9. doi:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Efficacy of **secukinumab** without the initial weekly loading dose in patients with chronic plaque psoriasis.

Gisondi P, Rovaris M, Piaserico S, Girolomoni G.

Br J Dermatol. 2019 Apr 20. doi: 10.1111/bjd.18015.

Otettu 28.2.20

A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with **Secukinumab**.

Giuseppe P, Nicola P, Valentina C, Elena C, Salvatrice C, Rosario G, Rita BM.

Ann Dermatol. 2018 Aug;30(4):462-464. doi: Otettu 3.9.18

Free PMC Article

Similar articles

Gladiator, A., N. Wangler, K. Trautwein-Weidner, and S. LeibundGut- Landmann. 2013. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J. Immunol. 190: 521–525. Otettu 22.3.20

Ref. ei katsot

Real-World Retention and Clinical Effectiveness of **Secukinumab** for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network.

Gladman DD, Choquette D, Khraishi M, Inman RD, Hussein S, Neish D, Leclerc P.

J Rheumatol. 2023 May;50(5):641-648. doi: 10.3899/jrheum.220823. Epub 2022 Dec 15. PMID: 36521913 Otta M

Is the risk of infection higher during treatment with **secukinumab** than with TNF-inhibitors? An observational study from the Nordic countries.

Glintborg B, Di Giuseppe D, Wallman JK, Provan SA, Nordström D, Hokkanen AM, Österlund J, Kristianslund E, Kvien TK, Gudbjornsson B, Hetland ML, Michelsen B, Jacobsson L, Askling J, Lindström U.

Rheumatology (Oxford). 2022 Jun 20:keac358. doi: 10.1093/rheumatology/keac358. Online ahead of print. PMID: 35723604 Otettu 26.8.22

One-year treatment outcomes of **secukinumab** versus tumor necrosis factor inhibitors in Spondyloarthritis.

Glintborg B, Lindstrom U, De Giuseppe D, Provan SA, Gudbjornsson B, Hetland ML, Michelsen B, Wallman J, Aaltonen K, Hokkanen AM, Nordström D, Jørgensen TS, Hansen RL, Jon Geirsson A, Grøn K, Krogh NS, Askling J, Kristensen LE, Jacobsson L; DANBIO (Denmark), ARTIS/SRQ (Sweden), ICEBIO (Iceland), ROB-FIN (Finland), NOR-DMARD (Norway) registries.

Arthritis Care Res (Hoboken). 2020 Nov 30. doi:
10.1002/acr.24523. Online ahead of print.
PMID: 33253491 Otta M Otta M Otta myöhemmin

High-dimensional profiling reveals Tc17 cell enrichment
in active Crohn's disease and identifies a potentially
targetable signature.

Globig AM, Hipp AV, Otto-Mora P, Heeg M, Mayer LS, Ehl
S, Schwacha H, Bewtra M, Tomov V, Thimme R,
Hasselblatt P, Bengsch B.

Nat Commun. 2022 Jun 27;13(1):3688. doi:
10.1038/s41467-022-31229-z.

PMID: 35760777 **Free PMC article.** Otettu 27.8.22

Erythema gyratum repens-like eruption after anti-IL-17
therapy of pityriasis rubra pilaris.

Gloor AD, van Rhyn M, Schlapbach C.

J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e38-e40.
doi: 10.1111/jdv.16785. Epub 2020 Jul 9.

PMID: 32580240 Otettu 28.11.22

Severe hidradenitis suppurativa successfully treated with **secukinumab**.

Głowaczewska A, Szepietowski JC, Matusiak Ł.

Dermatol Ther. 2020 Jun 16:e13845. doi:

10.1111/dth.13845. Online ahead of print.

PMID: 32544258 Otettu 19.9.20

Gocke, A. R., Cravens, P. D., Ben, L. H., Hussain, R. Z., Northrop, S. C., Racke, M. K., et al. (2007). T-bet regulates the fate of Th1 and Th17 lymphocytes in

autoimmunity. J. Immunol. 178, 1341–1348. doi: Otettu 29.2.16

Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis.

Godse K.

Indian J Dermatol. 2017 Mar-Apr;62(2):195-199. doi: Otettu 27.5.18

Free PMC Article

[Similar articles](#)

Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy.

Godzenko AA, Agafonova EM, Dimitreva AE, Razumova IY, Urumova MM.

Dokl Biochem Biophys. 2024 Aug;517(1):166-172. doi: 10.1134/S1607672924700868. Epub 2024 Jun 10.

PMID: 38861150 Otta M

Small molecule interleukin (IL) 17A/A antagonists and antibodies blocking both IL17A/A and IL17A/F demonstrate equivalent degrees of efficacy in preclinical models of skin and joint inflammation.

Goedken ER, Su Z, Lipovsky A, Kannan A, Chu KL, Ciura S, Foley SE, Frank KE, Goess CA, Gopalakrishnan S, Greszler SN, Khan HA, Leys LJ, King JJ, Mathieu SL, Panchal SC, Paulsboe S, Perham M, Ramos AL, Slivka PF, Srikumaran M, Webster MP, Wambeke EL, Zhu H, Scott VE, McGaraughty S, Honore P.

J Pharmacol Exp Ther. 2025 Feb 28;392(4):103525. doi: 10.1016/j.jpet.2025.103525. Online ahead of print.

PMID: 40127522 Otta M

The jigsaw puzzle of chronic non-bacterial osteomyelitis: are anti-IL17 therapies the next piece?

Goenka A, et al. *Rheumatology (Oxford)*. 2020. Otta M
Otta myöhemmin

IL-17-induced dimerization of IL-17RA drives the formation of the IL-17 signalosome to potentiate signaling.

Goepfert A, Barske C, Lehmann S, Wirth E, Willemsen J, Gudjonsson JE, Ward NL, Sarkar MK, Hemmig R, Kolbinger F, Rondeau JM.

Cell Rep. 2022 Oct 18;41(3):111489. doi: 10.1016/j.celrep.2022.111489.

PMID: 36260993 [Free PMC article](#). Otettu 12.10.23

Cost-effectiveness analysis of **secukinumab** for the treatment of active psoriatic arthritis: a Canadian perspective.

Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD.

J Med Econ. 2018 Feb;21(2):163-173. doi: ei ole M

[Similar articles](#) [Ei oteta](#)

Update on biologic therapies in ankylosing spondylitis: a literature review.

Goh L, Samanta A.

Int J Rheum Dis. 2012 Oct;15(5):445-54. doi:

10.1111/j.1756-185X.2012.01765.x. Epub 2012 Jul 9.

Review.

PMID:

23083034 Otettu 3.2.16

[Similar articles](#)

Gokmen, M. R. et al. Genome-wide regulatory analysis reveals that T-bet controls Th17 lineage differentiation through direct suppression of IRF4. J. Immunol. 191, 5925–5932 (2013). Otettu 19.9.20

Goldberg M, Nadiv O, Luknar-Gabor N, Agar G, Beer Y, Katz Y. Synergism between tumor necrosis factor ' and interleukin-17 to induce IL-23 p19 expression in fibroblast-like synoviocytes. Mol Immunol 2009;46:1854–9. Otettu 16.2.16

Golden JB, McCormick TS, Ward NL. IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine. 2013;62:195–201. Otettu 15.3.20

Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review.

Gómez-Gómez A, Loza E, Rosario MP, Espinosa G, de Morales JMGR, Herrera JM, Muñoz-Fernández S, Rodríguez-Rodríguez L, Cordero-Coma M; Spanish Society of Ocular Inflammation (SEIOC).

Semin Arthritis Rheum. 2020 Dec;50(6):1299-1306. doi: 10.1016/j.semarthrit.2020.08.010. Epub 2020 Aug 28. PMID: 33065425 Otettu 13.12.20

Amino terminal recognition by a CCR6 chemokine receptor antibody blocks CCL20 signaling and IL-17 expression via β -arrestin.

Gómez-Melero S, García-Maceira FI, García-Maceira T, Luna-Guerrero V, Montero-Peñalvo G, Túnez-Fiñana I, Paz-Rojas E.

BMC Biotechnol. 2021 Jul 5;21(1):41. doi: 10.1186/s12896-021-00699-2.

PMID: 34225700 [Free PMC article.](#) Otettu 30.8.22

Gomez-Rodriguez J, Sahu N, Handon R, et al. Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase [see comment]. Immunity. 2009;31(4):587-597. Otettu 16.2.16

Secukinumab (Anti-IL-17) induces clinical regression in early diagnosed type 1 diabetes: A case report.

Gómez-Zaragoza B, Ruiz-Rodríguez M, Rodríguez de Vera Gómez P, Decan-Bardasz D, Martínez-Brocca MA.

Diabetes Metab. 2025 May;51(3):101643. doi:

10.1016/j.diabet.2025.101643. Epub 2025 Apr 4.

PMID: 40188942 Otta M

IL-7 is a Key Driver Cytokine in Spondyloarthritis?

Gonçalves RSG, Duarte ALBP.

J Immunol Res. 2019 May 29;2019:7453236. doi:

10.1155/2019/7453236. eCollection 2019.

PMID: 31276000 Otettu 23.9.20

González-Alvaro I, Ortiz AM, Domínguez-Jiménez C, Aragón-Bodi A, Díaz Sánchez B, Sánchez-Madrid F. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. *Ann Rheum Dis* 2009;68: 1644–50. Otettu 4.3.16

Endogenous stimulation is responsible for the high frequency of **IL-17A**-producing neutrophils in patients with rheumatoid **arthritis**.

Gonzalez-Orozco M, Barbosa-Cobos RE, Santana-Sanchez P, Becerril-Mendoza L, Limon-Camacho L, Juarez-Estrada AI, Lugo-Zamudio GE, Moreno-Rodriguez J, Ortiz-Navarrete V.

Allergy Asthma Clin Immunol. 2019 Aug 1;15:44. doi: 10.1186/s13223-019-0359-9. eCollection 2019.

PMID: 31388340 Otettu 21.9.20

[Interleukin-17 \(IL-17\) inhibitors in the treatment of plaque psoriasis: a review.](#)

Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA, Papp K.

Skin Therapy Lett. 2015 Jan-Feb;20(1):1-5.

PMID:

25807214 Ei oteta

[Free Article](#)

[Similar articles](#)

Real-world NHS drug survival and efficacy data for **Secukinumab** in chronic plaque psoriasis.

Goon PKC, Banfield CC, Bello O, Abraham T, Lim HY, Summerfield E, Shalders K, Sudhoff H, Mallett RB.

J Eur Acad Dermatol Venereol. 2020 Apr 28. doi: 10.1111/jdv.16538. Online ahead of print.

PMID: 32343430 Otettu 19.9.20

[Human Intestinal Dendritic Cells Can Overcome Retinoic Acid Signaling to Generate Proinflammatory CD4 T Cells with Both Gut and Skin Homing Properties.](#)

Gordon H, Wichmann K, Lewis A, Sanders T, Wildemann M, Hoti I, Hornsby E, Kok KB, Silver A, Lindsay JO, Stagg AJ.

J Immunol. 2024 Jan 1;212(1):96-106. doi: 10.4049/jimmunol.2300340.

PMID: 37955427 Otta M

[European League Against Rheumatism \(EULAR\) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.](#)

Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien

TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D.

Ann Rheum Dis. 2015 Dec 7. pii:

annrheumdis-2015-208337. doi: Otettu 3.2.16

[Similar articles](#)

Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.

Gossec L, Coates LC, de Wit M, Kavanaugh A, Ramiro S, Mease PJ, Ritchlin CT, van der Heijde D, Smolen JS.

Nat Rev Rheumatol. 2016 Dec;12(12):743-750. doi: 10.1038/nrrheum.2016.183. Epub 2016 Nov 10.

Review.

PMID:

27829672 Otettu 28.5.18

[Similar articles](#)

Gottlieb AB, Mease P, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, Nash P, Pricop L, Yuan J, Richards H, Mpofu S. Secukinumab, a human anti-interleukin-17A monoclonal antibody, significantly reduces psoriasis burden in patients with psoriatic arthritis: results from a phase 3 randomized controlled trial. *Arthritis Rheumatol.* 2014;66:S233. Ei oteta

Long-term Safety of **Secukinumab** Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.

Gottlieb AB, Deodhar A, Mcinnes IB, Baraliakos X, Reich K, Schreiber S, Bao W, Marfo K, Richards HB, Pricop L, Shete A, Trivedi V, Keefe D, Papavassilis CC, Jagiello P, Papanastasiou P, Mease PJ, Lebwohl M.

Acta Derm Venereol. 2022 Apr 27;102:adv00698. doi: 10.2340/actadv.v102.563.

PMID: 35146532 [Free article.](#) Otettu 26.8.22

.

[Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.](#)

Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, Papavassilis C, Mpofu S.

J Drugs Dermatol. 2015 Aug;14(8):821-33.

PMID:

ei ole M

[Similar articles](#)

Gottlieb AB BA, Langley RG, Meng X, Fox T, Nyirady J. Secukinumab decreases inflammation as measured by hscrp in patients with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: Pooled analysis of 4 phase 3 trials. American Academy of Dermatology Summer meeting. New York, USA 2015.

Ei oteta

Gottlieb A, McInnes IB, Mease P, Rahman P, Kandala S, Patekar M, Mpofu S. THU0418 secukinumab significantly reduces psoriasis burden in patients with psoriatic arthritis: results from the phase 3 future 2 study. Ann Rheum Dis. 2015;74:349–50. Abstrakti. Ei oteta

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.

Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, Hugot S, Milutinovic M.

J Am Acad Dermatol. 2017 Jan;76(1):70-80. doi: 10.1016/j.jaad.2017.05.018

Free Article

Similar articles

Sustained Efficacy of **Secukinumab** in Subjects with Moderate-to-Severe Palmoplantar Psoriasis: 2·5-Year Results from GESTURE, a Randomized, Double-blind, Placebo-controlled Trial.

Gottlieb AB, Kubanov A, van Doorn M, Sullivan J, Papp KA, You R, Regnault P, Frueh JA.

Br J Dermatol. 2019 Jul 8. Otettu 28.2.20

Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials.

Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa AC, Combe B, Rech J, Zhu X, James D, Martin R, Ligozio G, Abrams K, Pricop L.

J Clin Rheumatol. 2020 Feb 3. Otettu 3.3.20

Efficacy of **secukinumab** and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.

Gottlieb AB, Merola JF, Reich K, Behrens F, Nash P, Griffiths CEM, Bao W, Pellet P, Pricop L, McInnes IB.

Br J Dermatol. 2021 Apr 29. doi: 10.1111/bjd.20413.

Online ahead of print.

PMID: 33913511 Otettu 8.8.21

Initial C-reactive protein level: Discriminating between anti-TNF and anti-IL-17 agents as the first biologic treatment for axial spondyloarthritis?

Goupille P, Wendling D.

Joint Bone Spine. 2023 Nov 15;91(3):105662. doi: 10.1016/j.jbspin.2023.105662. Online ahead of print. PMID: 37977524 Otta M

Assessment of transcriptional activity genes associated with the IL-17 signaling pathway in skin fibroblasts under the influence of adalimumab.

Grabarek BO, et al. Dermatol Ther. 2019. PMID: 31605567 Otettu 28.11.22

Gracey E, Yao Y, Green B, *et al.* Sexual dimorphism in the Th17 signature of ankylosing spondylitis. *Arthritis Rheumatol* 2016; 68: 679–689. Otettu 28.3.20

Graeber K E, Olsen N J. *Inflamm Res* 2012: 61: 87–96. Otettu 16.2.16

Biologic drug survival rates in the era of anti-IL-17 antibodies: a time period-adjusted registry analysis.

Graier T, Salmhofer W, Jonak C, Weger W, Kölli C, Gruber B, Sator PG, Prillinger K, Mlynec A, Schütz-Bergmayr M, Richter L, Ratzinger G, Painsi C, Selhofer S, Häring N, Wippel-Slupetzky K, Skvara H, Trattner H, Tanew A, Inzinger M, Tatarski R, Bangert C, Ellersdorfer C, Lichem

R, Gruber-Wackernagel A, Hofer A, Legat F,
Schmiedberger E, Strohal R, Lange-Asschenfeldt B,
Schmuth M, Vujic I, Hoetzenecker W, Trautinger F,
Saxinger W, Müllegger R, Quehenberger F, Wolf P.
Br J Dermatol. 2020 Dec 1. doi: 10.1111/bjd.19701.
Online ahead of print.
PMID: 33289075 Otettu 25.12.20

Granet C, Maslinski W, Miossec P, Increased AP-1 and
NF- kappaB activation and recruitment with the
combination of the proinflammatory cytokines IL-1beta,
tumor necrosis factor alpha and IL-17 in rheumatoid
synoviocytes, Arthritis Res Ther, 2004,
6(3):R190–R198. Otettu 29.2.16

Gratchev A, Kzhyshkowska J, Duperrier K et al. The receptor for interleukin-17E is induced by Th2 cytokines in antigen-presenting cells. Scand J Immunol 2004;60:233–7.
Otettu 28.5.18

Gratz IK, et al. Cutting Edge: memory regulatory T cells require IL-7 and not IL-2 for their maintenance in peripheral tissues. J Immunol. 2013; 190(9):4483–4487.
Ei oteta

1. Gravallesse EM, Schett G. Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol. 2018;14:631–40. Otettu 27.3.20

Granuloma Annulare Following Initiation of Interleukin 17A Antagonist.

Gray AR, Davies OMT, White K, Ortega Loayza AG.

Clin Exp Dermatol. 2021 Jan 28. doi: 10.1111/ced.14579. Online ahead of print.

PMID: 33511635 Otettu 28.11.22

Clinical and Molecular Effects of **Interleukin-17** Pathway Blockade in Psoriasis.

Green L, Weinberg JM, Menter A, Soung J, Lain E, Jacobson A.

J Drugs Dermatol. 2020 Feb 1;19(2):138-143. doi: 10.36849/JDD.2020.4645.

PMID: 32129957 Review. Otettu 6.9.22

Role for IL-17A in adipocyte biology.

Greenhill C.

Nat Rev Endocrinol. 2021 Jul;17(7):383. doi:
10.1038/s41574-021-00504-2.

PMID: 33953373 Otettu 30.8.22

Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis

Green L, Weinberg JM, Menter A, Soung J, Lain E, Jacobson A.

J Drugs Dermatol. 2020 Feb 1;19(2):138-143. ei ole GS

Ei ole PUBMED ei ole M

Clinical Pharmacokinetic and Pharmacodynamic
Considerations in the Treatment of Moderate-to-Severe
Psoriasis.

Greenzaid J, Feldman S.

Clin Pharmacokinet. 2024 Feb;63(2):137-153. doi:
10.1007/s40262-023-01341-4. Epub 2024 Jan 27.

PMID: 38280146 Review. Otta M

New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation.

Greigert H, Genet C, Ramon A, Bonnotte B, Samson M.
J Clin Med. 2022 May 20;11(10):2905. doi:
10.3390/jcm11102905.
PMID: 35629030 [Free PMC article](#). Otettu 27.8.22

The forgotten key players in rheumatoid arthritis: IL-8 and IL-17 - Unmet needs and therapeutic perspectives.

Gremese E, Tolusso B, Bruno D, Perniola S, Ferraccioli G, Alivernini S.

Front Med (Lausanne). 2023 Mar 22;10:956127. doi:
10.3389/fmed.2023.956127. eCollection 2023.
PMID: 37035302 [Free PMC article](#). Review. Otettu
14.6.23

Practical experience of **secukinumab** in the treatment of psoriasis: experience from a single centre.

Griffin L, Boggs J, Ramsay B, Hackett C, Ahmad K, Lynch M.

Ir J Med Sci. 2020 Aug 11. doi:

10.1007/s11845-020-02336-x. Online ahead of print.

PMID: 32783092 Otettu 19.9.20

G. K. Griffin, G. Newton, M. L. Tarrio et al., "IL-17 and TNF- α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation," *Journal of Immunology*, vol. 188, no. 12, pp. 6287–6299, 2012. Otettu 25.3.20

Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118-28. Ei oteta

Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixel-

umab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet (London, England). 2015;386:541–51. Ei ole GS Ei oteta

Grine L, Dejager L, Libert C, Vandenbroucke RE. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. *Cytokine Growth Factor Rev.* 2015;26(1):25-33.

Otettu 6.3.20

Ref. katsottu 6.3.20

Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers.

Groen SS, Sinkeviciute D, Bay-Jensen AC, Thudium CS, Karsdal MA, Thomsen SF, Schett G, Nielsen SH.

Autoimmun Rev. 2021 Mar;20(3):102760. doi: 10.1016/j.autrev.2021.102760. Epub 2021 Jan 22.

PMID: 33485992 **Free article.** Otettu 1.9.22

[Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1 \$\beta\$ by Canakinumab or IL-17A by Secukinumab.](#)

Grosskreutz CL, Hockey HU, Serra D, Dryja TP.

Cornea. 2015 Dec;34(12):1551-6. doi:
10.1097/ICO.0000000000000627.

PMID:

26418434

[Free PMC Article](#)

[Similar articles](#)

Otettu 3.2.16

[Colitis induced by IL-17A-inhibitors.](#)

Grümme L, Dombret S, Knösel T, Skapenko A,
Schulze-Koops H.

Clin J Gastroenterol. 2023 Dec 7. doi:
10.1007/s12328-023-01893-9. Online ahead of print.
PMID: 38060157 Otettu 4.3.24

Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and
signaling. Cytokine 2013;64: 477–85. Otettu 16.2.16

Interleukin 17 as a therapeutic target of acute
generalized exanthematous pustulosis (AGEP).
Gualtieri B, et al. J Allergy Clin Immunol Pract. 2020.
PMID: 32014613 Otta

Wirksamkeit des IL-17-Hemmers **SECUKINUMAB**
bei akuter generalisierter exanthematische Pustulose
(AGEP).

Gualtieri B, Möbs C, Solimani F, Hertl M, Pfützner W.

J Dtsch Dermatol Ges. 2019 May;17 Suppl 2:22-24.

Otettu 28.2.20

Regulatory T cells and IL-17A levels in noninfectious
uveitis.

Guedes MCE, Arroz MJ, Martins C, Angelo-Dias M,
Proença RD, Borrego LM.

Graefes Arch Clin Exp Ophthalmol. 2020
Jun;258(6):1269-1278. doi:
10.1007/s00417-020-04649-0. Epub 2020 Mar 21.
PMID: 32200408
Otettu 28.11.22

44. Guedes MC, Borrego LM, Proenca RD. Roles of interleukin-17 in uveitis.
Indian J Ophthalmol 2016; 64:628–634. Otettu
2.3.20

Guenova E, Skabytska Y, Hoetzenecker W, Weindl G,
Sauer K, Tham M, et al. IL-4 abrogates T(H)17

cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. *Proc Natl Acad Sci U S A* (2015) 112(7):2163–8 Otettu 15.3.20

Ref. katsottu 23.3.20

[The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review.](#)

Guermazi D, Shah A, Yumeen S, Saliba E.

Arch Dermatol Res. 2024 May 25;316(6):259. doi: 10.1007/s00403-024-03121-x.

PMID: 38795234 Review. Otta M

Infantile generalized pustular psoriasis with excellent response to **secukinumab**: A case report.

Guevara BEK, Aquino JM RM, Diaz RBS, Contreras AIT, Jeng YC, Huang HY, Hsu CK, Pandita-Reyes BSB.

Exp Dermatol. 2023 Feb 27. doi: 10.1111/exd.14784. Online ahead of print.

PMID: 36847294 Otta M

Gullick NJ, Evans HG, Church LD, Jayaraj DM, Filer A, Kirkham BW, Taams LS:

Linking power Doppler ultrasound to the presence of th17 cells in the

rheumatoid arthritis joint. PLoS One 2010, 5:e12516.

Otettu 29.2.16

Enhanced and persistent levels of interleukin (IL)-17⁺ CD4⁺ T cells and serum IL-17 in patients with early inflammatory arthritis.

Gullick NJ, Abozaid HS, Jayaraj DM, Evans HG, Scott DL, Choy EH, Taams LS.

Clin Exp Immunol. 2013 Nov;174(2):292-301. doi: 10.1111/cei.12167.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Impact of topical and systemic therapy on carotid-intima media thickness in psoriasis.

Gumus EC, Celik U, Gumus S, Engin B.

Arch Dermatol Res. 2025 Jan 18;317(1):286. doi: 10.1007/s00403-025-03818-7.

PMID: 39825924 Otta M

Switching patterns of **secukinumab** in psoriasis treatment from a Chinese nationwide registry cohort.

Guo J, Zhang H, Wang W.

Chin Med J (Engl). 2025 Jul 2. doi:

10.1097/CM9.0000000000003653. Online ahead of print.

PMID: 40596777 No abstract available. Otettu 28.7.25

Hypoxia-induced RHCG as a key regulator in psoriasis and its modulation by **secukinumab**.

Guo S, Zhang Q, Liu YJ, Hu YY, Liu C, Shen H, Liu J.

APL Bioeng. 2025 May 9;9(2):026115. doi:

10.1063/5.0250742. eCollection 2025 Jun.

PMID: 40351602 Free PMC article. Otettu 4.6.25

L. Guo, G. Wei, J. Zhu et al., “IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 32, pp. 13463–13468, 2009. Otettu 18.3.20
Ref. ei oteta

[\$\gamma\delta\$ T cell antigen receptor polyspecificity enables T cell responses to a broad range of immune challenges.](#)

Guo J, Chowdhury RR, Mallajosyula V, Xie J, Dubey M, Liu Y, Li J, Wei YL, Palanski BA, Wang C, Qiu L, Ohanyan M, Kask O, Sola E, Kamalyan L, Lewis DB, Scriba TJ, Davis MM, Dodd D, Zeng X, Chien YH.

Proc Natl Acad Sci U S A. 2024 Jan

23;121(4):e2315592121. doi:

10.1073/pnas.2315592121. Epub 2024 Jan 16.

PMID: 38227652 [Free PMC article.](#) Otettu 13.3.24

Guo L, Junttila IS, Paul WE. Cytokine-induced cytokine production by conventional and innate lymphoid cells. Trends Immunol. 2012; 33:598–606. [PubMed: 22959641] Otettu 4.3.16

Guo B. IL-10 modulates Th17 pathogenicity during autoimmune diseases. J Clin Cell Immunol 2016;7:400. Otettu 13.12.20

Exploring the role of immune cell traits and circulating inflammatory cytokines in the development of diabetic neuropathy.

Guo N, Li Q, Wang H, Li P.

Cytokine. 2025 Jul 1;194:156985. doi:

10.1016/j.cyto.2025.156985. Online ahead of print.

PMID: 40602047 Otta M

COSENTYX (Secukinumab).

Gupta AK, Foley KA, Abramovits W.

Skinmed. 2015 Aug 1;13(4):303-6. eCollection 2015

Jul-Aug. No abstract available.

PMID:

26861430 ei ole M Ei oteta

Switching to **secukinumab** in difficult-to-treat psoriasis recalcitrant to methotrexate, cyclosporine and leflunomide, in a tuberculosis-endemic country.

Gupta A, Sardana K, Gautam RK.

Trop Doct. 2019 Jul;49(3):215-217. doi: 10.1016/j.trodo.2019.05.001

PMID: 31111111

Gutcher I, et al. Autocrine Transforming Growth Factor-beta1 Promotes In Vivo Th17 Cell Differentiation. Immunity. 2011; 34:396–408. [PubMed: 21435587]
Otettu 16.2.16

[Novel Regimen of IL-17A Inhibitor **Secukinumab** for the Remission of Severe Hidradenitis Suppurativa: Case Report.](#)

Gutierrez E, Issa N, Resnik B.

J Drugs Dermatol. 2022 Dec 1;21(12):1358-1360. doi: 10.36849/JDD.6752.

PMID: 36468954 otta M

Guttman-Yassky E, Lowes M A, Fuentes-Duculan J et al. J Immunol 2008; 181: 7420–7427. Otettu
29.2.16

Efficacy and safety of **secukinumab** treatment in adults with extensive alopecia areata.

Guttman-Yassky E, Nia JK, Hashim PW, Mansouri Y, Alia E, Taliercio M, Desai PN, Lebwohl MG.

Arch Dermatol Res. 2018 Aug 18. doi: Otettu 3.9.18

Similar articles

Immune and inflammatory mechanisms in hypertension.

Guzik TJ, Nosalski R, Maffia P, Drummond GR.

Nat Rev Cardiol. 2024 Jan 3. doi: 10.1038/s41569-023-00964-1. Online ahead of print.

PMID: 38172242 Review. Otta M

IL-17 blockade by **secukinumab** was not effective in controlling lichen planus in a randomized controlled clinical trial.

Günther C.

Br J Dermatol. 2024 May 8;ljae186. doi: 10.1093/bjd/ljae186. Online ahead of print.

PMID: 38715466 Otta M

Ha, H. L., H. Wang, P. Pisitkun, J. C. Kim, I. Tassi, W. Tang, M. I. Morasso, M. C. Udey, and U. Siebenlist. 2014. IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms. Proc. Natl. Acad. Sci. USA 111: E3422– E3431. Otettu 22.3.20

[Efficacy and Safety of IL-17 and IL-23 Inhibitors in Elderly Patients With Plaque Psoriasis: A Real-World Study.](#)

Hacınecipoğlu F, Çelik G, Kartal SP.

J Dermatol. 2025 Apr 26. doi:
10.1111/1346-8138.17755. Online ahead of print.
PMID: 40285439 Otta M

Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs).

Hadfield MJ, Merkin RD, Rouhani SJ, Reynolds KL.
Best Pract Res Clin Haematol. 2025 Jun;38(2):101625.
doi: 10.1016/j.beha.2025.101625. Epub 2025 Apr 16.
PMID: 40701736 Review. Otta M

Interleukin-17A immune pattern across genetic acantholytic and blistering disorders.

Haghighi Javid A, Li D, Technau-Hafsi K, Has C.

Clin Exp Dermatol. 2023 Apr 27;48(5):518-523. doi:
10.1093/ced/llad012.
PMID: 36632755 Otta M

[Asymptomatic Crohn's disease identified in a patient being treated with
secukinumab: A case report.](#)

Haidari W, Al-Naqshabandi S, Ahn CS, Bloomfeld RS, Feldman SR.

SAGE Open Med Case Rep. 2019 Dec 6;7:2050313X19893580. doi: 10.1177/2050313X19893580. eCollection 2019.

PMID: 31839950 **Free PMC Article** **Otettu 28.2.20**

[Biologic therapy targeting IL-17 ameliorates a case of congenital ichthyosiform
cornification disorder.](#)

Haiges D, Fischer J, Hörer S, Has C, Schempp CM.

J Dtsch Dermatol Ges. 2019 Jan;17(1):70-72. **Otettu 28.2.20**

Haines CJ, Cua DJ. Orphan cytokine reveals IL-17 family secret. *Immunity*. 2011;35(4):498–500. Otettu 29.2.16

Haines, C. J., Chen, Y., Blumenschein, W. M., Jain, R., Chang, C., Joyce- Shaikh, B., Porth, K., Boniface, K., Mattson, J., Basham, B., Anderton, S. M., McClanahan, T. K., Sadekova, S., Cua, D. J., McGeachy, M. J. (2013) Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23. *Cell Reports* 3, 1378–1388. Otettu 4.3.16

[Delving into the adytum of the IL-17 defense pathway.](#)

Hajishengallis G.

Cell Host Microbe. 2023 Oct 11;31(10):1599-1601. doi: 10.1016/j.chom.2023.08.021.

PMID: 37827120 Otta M

[Interleukin-15 induces interleukin-17 production by synovial T cell lines from patients with rheumatoid arthritis.](#)

Halvorsen EH, Strønen E, Hammer HB, Goll GL, Sollid LM, Molberg O.

Scand J Immunol. 2011 Mar;73(3):243-9. doi:

Otettu 3.2.16

[Similar articles](#)

Hamada, S. et al. IL-17A produced by $\gamma\delta$ T cells plays a critical role in innate immunity against listeria

monocytogenes infection in the liver. J. Immunol. **181**, 3456–3463 (2008). Otettu 25.3.20

12-week **secukinumab** treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post-hoc analysis of six randomized trials.

Hampton P, Halliday A, Aassi M, Subramanian S, Jain M, Griffiths CEM.

J Eur Acad Dermatol Venereol. 2020 Oct 8. doi:

10.1111/jdv.16982. Online ahead of print.

PMID: 33030755 Otettu 4.2.21

Hamzaoui K, Bouali E, Ghorbel I, Khanfir M, Houman H, Hamzaoui A (2011) Expression of Th-17 and ROR γ t

mRNA in Behçet's disease. Med Sci Monit
17:CR227–CR234 Otettu 20.3.20

Treatment of refractory pityriasis rubra pilaris with
biologic therapy: a case series.

Han R, Spratt WR, Yang H, Lai FYX, Lee S.

Clin Exp Dermatol. 2025 Jun 9:llaf246. doi:

10.1093/ced/llaf246. Online ahead of print.

PMID: 40488550 Otta M

1. Han, L.; Yang, J.; Wang, X.; Li, D.; Lv, L.; Li, B.
Th17 cells in autoimmune diseases. *Front. Med.*

2015, 9, 10–19. [[CrossRef](#)] [[PubMed](#)] ei ole M
Ei ole GS Ei oteta

[Assessment and monitoring of biologic drug adverse events in patients with psoriasis.](#)

Hanley T, Handford M, Lavery D, Yiu ZZ.

Psoriasis (Auckl). 2016 Apr 1;6:41-54. doi:

10.2147/PTT.S68869. eCollection 2016. Review.

PMID:

29387593 Otettu 27.5.18

[Free PMC Article](#)

[Similar articles](#)

Adherence to therapy of ixekizumab and **secukinumab** in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: A Danish population-based cohort study.

Hansen RL, Jørgensen TS, Egeberg A, Rosenø NAL, Skougaard M, Stisen ZR, Dreyer L, Kristensen LE. Rheumatology (Oxford). 2023 Aug 30:kead434. doi: 10.1093/rheumatology/kead434. Online ahead of print. PMID: 37647648 Otta M

Effects of disease-modifying anti-rheumatic drugs on sacroiliac MRI score in axial spondyloarthritis: a systematic review and meta-analysis.

Hansmaennel A, Fakih O, Gerazime A, Prati C, Chouk M, Wendling D, Verhoeven F. Clin Rheumatol. 2024 Mar;43(3):1045-1052. doi: 10.1007/s10067-023-06849-5. Epub 2023 Dec 29. PMID: 38158505 Otta M

Happel, K. I., M. Zheng, E. Young, L. J. Quinton, E. Lockhart, A. J. Ramsay, J. E. Shellito, J. R. Schurr, G. J. Bagby, S. Nelson, and J. K. Kolls. 2003. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to

Klebsiella pneumoniae infection. *J. Immunol.* 170: 4432–4436. Otettu 15.3.20

Ref. ei otet.

Harbour SN, Maynard CL, Zindl CL, Schoeb TR, Weaver CT. Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. *Proc Natl Acad Sci USA.* (2015) 112:7061–6 Otettu 8.3.20

Ref. katsottu 18.3.20

[Expression of lncRNA NEAT1, miR-21, and IL17 in Rheumatoid Arthritis Patients.](#)

Haroon MM, Hegazy GA, Hassanien MA, Shaker OG, Labib S, Hussein WH.

Biologics. 2025 Apr 15;19:201-211. doi: 10.2147/BTT.S519558. eCollection 2025.

PMID: 40256764 [Free PMC article.](#) Otettu 31.7.25

Harper E G, Guo C, Rizzo H et al. J Invest Dermatol 2009; 129: 2175–2183. Otettu 16.2.16

Harrington LE et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat Immunol* 2005;6:1123–32. Otettu 16.2.16

Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. *Curr Opin Immunol* 2006;18:349-56. Otettu 16.2.16

Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, Hipkiss EL, Getnet D, Goldberg MV, Maris CH, Housseau F, Yu H, Pardoll DM, Drake CG. Cutting

edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol. 2007; 179:4313–4317. [PubMed:] Otettu 16.2.16

Hartupée J, Liu C, Novotny M, Li X, Hamilton T. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007;179:4135–41. Otettu 29.2.16

Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?

Hasan MJ, Rabbani R, Anam AM, Huq SMR.

J Infect. 2021 Jul;83(1):e11-e13. doi:

10.1016/j.jinf.2021.05.011. Epub 2021 May 21.

PMID: 34029628 **Free PMC article.** Otettu 8.8.21

Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with **Secukinumab**: A Real-World Study.

Haselgruber S, Fernández-Crehuet-Serrano P, Fernández-Ballesteros MD, Padial-Gómez A, Hernández-Rodríguez JC, Ortiz-Álvarez J, Navarro-Guillamón P, Membrive-Jiménez C, Cuenca-Barrales C, Molina-Leyva A.

Dermatol Ther (Heidelb). 2024 Jul;14(7):1875-1890. doi: 10.1007/s13555-024-01209-w. Epub 2024 Jun 19.

PMID: 38896382 **Free PMC article.** Otettu 27.9.24

Hashimoto T, Akiyama K, Kobayashi N, Mori A.
Comparison of IL-17 production by helper T cells among atopic and nonatopic asthmatics and control subjects.

Int Arch Allergy Immunol 2005;137(suppl 1):51-4. Otettu 17.3.20

Ref. katsottu 18.3.20

Hashimoto, M. et al. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. 207, 1135–1143 (2010). Otettu 29.2.16

Hashizume, M., Hayakawa, N. & Mihara, M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- α and IL-17. Rheumatology (Oxford) **47**, 1635–1640 (2008). Otettu 29.3.20

Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response.

Hassane M, et al. *Mucosal Immunol.* 2020. PMID: 31628425 Otettu 8.9.22

Hatton R: TGF-beta in Th17 cell development: The truth is out there. *Immunity* 2011, 34:288-290. Otettu 28.5.18

Treatment with an **interleukin-17** inhibitor resulted in complete remission of psoriasis and flare-up of atopic dermatitis.

Hattori N, Koike Y,.

J Dermatol. 2022 May;49(5):e173-e174. doi:
10.1111/1346-8138.16308. Epub 2022 Jan 17.
PMID: 35037280 Otettu 28.11.22

Secukinumab Causing Medication-Related
Osteonecrosis of the Jaw, in a Patient Diagnosed with
Psoriasis and Rheumatoid Arthritis.

Hauer L, Moztarzadeh O, Baghalipour N, Gencur J.

Psoriasis (Auckl). 2024 Sep 23;14:115-120. doi:
10.2147/PTT.S490982. eCollection 2024.

PMID: 39347517 **Free PMC article.** Otettu 24.10.24

Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis.

Hawkes JE, Yan BY, Chan TC, Krueger JG.
J Immunol. 2018 Sep 15;201(6):1605-1613.

Free PMC Article Otettu 28.2.20

Ref. katsot

Havrdova E, Belova A, Goloborodko A, et al. Sensitivity analysis of a phase IIa study of secukinumab in relapsing remitting multiple sclerosis. Mult Scler. 2013;1:210– ei ole M Ei oteta

HAVRDOVÁ E, BELOVA A, GOLOBORODKO A *et al.*:
Activity of secukinumab, an anti-IL-17A antibody, on

brain lesions in RRMS: results from a randomized, proof-of-concept study. *J Neurol* 2016; 263: 1287-95.

Otta M Otta myöhemmin

[Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris.](#)

Hayashi M, Igarashi A, Okamura K, Suzuki T.

Br J Dermatol. 2019 Mar;180(3):684-685. Otettu 28.2.20

Pleural Fluid Eosinophilia: A Possible Adverse Event of **Interleukin-17** Inhibition.

Hayashi W, et al. *Acta Derm Venereol*. 2019. PMID:

31502653 **Free article.** Otettu 8.9.22

[IL-23R rs11209026 polymorphism modulates IL-17A expression in patients with rheumatoid arthritis.](#)

Hazlett J, Stamp LK, Merriman T, Highton J, Hessian PA.

Genes Immun. 2012 Apr;13(3):282-7. doi: 10.1038/gene.2011.80. Epub 2011 Dec 1.

PMID:

Otettu 3.2.16

[Similar articles](#)

Trauma Induces **Interleukin-17A** Expression on Th17 Cells and CD4+ Regulatory T Cells as Well as Platelet Dysfunction.

Hefele F, et al. *Front Immunol.* 2019. PMID: 31681282

Free PMC article. Otettu 8.9.22

Efficacy of ixekizumab in patients with resistance or incomplete response to **secukinumab**.

Hegazy S, Konstantinou MP, Bulai Livideanu C, Tauber M, Paul C.

J Eur Acad Dermatol Venereol. 2019 Apr 18. doi:

Otettu 28.2.20

A systematic review of the role of interleukin-17 inhibitors in bullous pemphigoid: therapeutic and paradoxical effects.

Heidari N, Hosseini S, Heidari A, Ghane Y, Daneshpazhooh M, Mahmoudi H.

Arch Dermatol Res. 2025 Mar 11;317(1):544. doi: 10.1007/s00403-025-04052-x.

PMID: 40067544 Review. Otta M

The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials.

Heidari N, Heidari A, Eghbali S, Pishraft-Sabet H, Hajikarim-Hamedani A, Ghane Y, Lotfi Z, Goodarzi A. Autoimmun Rev. 2025 Apr 21;24(7):103818. doi: 10.1016/j.autrev.2025.103818. Online ahead of print. PMID: 40268126 Review. Otta M

A systematic review of the role of interleukin inhibitors in lichen planus: therapeutic and paradoxical effects.

Heidari A, Fathabadi F, Ghanavati K, Rasouli A, Soleimani S, Heidari N. Inflammopharmacology. 2025 Aug 12. doi: 10.1007/s10787-025-01853-4. Online ahead of print. PMID: 40794374 Review. Otta M

Heink, S. *et al.* Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. *Nat. Immunol.* **18**, 74–85 (2017). Otettu 12.3.20

Ref. katsottu 15.3.20

Effects of **secukinumab** on skeletal microarchitecture and vertebral fractures in patients with axial spondyloarthritis using HR-pQCT.

Heiting C, McMahon D, Mintz DN, Russell L, Ashany D, Yuan W, Mannstadt I, Stein EM, Goodman SM.

Arch Osteoporos. 2025 Jun 7;20(1):73. doi: 10.1007/s11657-025-01565-w.

PMID: 40481972 [Free PMC article.](#) Otettu 28.7.25

[Interleukin-17 inhibition in psoriatic arthritis.](#)

Helliwell P, Coates L.

Lancet. 2015 Sep 19;386(9999):1114-6. doi: 1. Epub

Otettu 16.2.16

[Similar articles](#)

Hemdan NY, Birkenmeier G, Wichmann G, Abu El-Saad AM, Krieger T, Conrad K, et al. Interleukin-17-producing T helper cells in autoimmunity. *Autoimmun Rev* 2010;9(11):785–92. Otettu 16.2.16

T reg cell-intrinsic requirements for ST2 signaling in health and neuroinflammation.

Hemmers S, Schizas M, Rudensky AY.

J Exp Med. 2021 Feb 1;218(2):e20201234. doi: 10.1084/jem.20201234.

PMID: 33095261 [Free PMC article](#). Otettu 3.9.22

Staphylococcus aureus-Specific Tissue-Resident Memory CD4⁺ T Cells Are Abundant in Healthy Human Skin.

Hendriks A, Mnich ME, Clemente B, Cruz AR, Tavarini S, Bagnoli F, Soldaini E.

Front Immunol. 2021 Mar 16;12:642711. doi:

10.3389/fimmu.2021.642711. eCollection 2021.

PMID: 33796109 [Free PMC article.](#) Otettu 30.8.22

Henes J C, Ziupa E, Eisfelder M et al. Rheumatol Int 2014; 34: 227–234. Otettu 16.2.16

Henriques A, Inês L, Couto M, Pedreiro S, Santos C, Magalhães M, Santos P, Velada I, Almeida A, Carvalheiro T, Laranjeira P, Morgado JM, Pais ML, da Silva JA, Paiva A: Frequency and functional activity of Th17, Tc17 and other T-cell subsets in systemic lupus erythematosus. Cell Immunol 2010, 264:97-103. Otettu 16.2.16

Heo YJ, Joo YB, Oh HJ, Park MK, Heo YM, Cho ML, et al. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. Immunol Lett 2010;127:150–6.
Otettu 4.3.16

[Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors.](#)

Her M, Kavanaugh A.

Curr Opin Rheumatol. 2013 Jul;25(4):455-9. doi:

Otettu 3.2.16

[Similar articles](#)

Herkenne C, Alberti I, Naik A et al. Pharm Res 2008: 25: 87–103. ei oteta

[IL-17-Dependent Dysregulated Cutaneous Immune Homeostasis in the Absence of the Wiskott-Aldrich Syndrome Protein.](#)

Herman KE, Yoshida T, Hughson A, Grier A, Gill SR, Beck LA, Fowell DJ.

Front Immunol. 2022 Feb 21;13:817427. doi: 10.3389/fimmu.2022.817427.

eCollection 2022.

[Free PMC article.](#) Otettu 27.8.22

Hermann-Kleiter, N., Gruber, T., Lutz-Nicoladoni, C., Thuille, N., Fresser, F., Labi, V., Schiefermeier, N., Warnecke, M., Huber, L., Villunger, A., et al. (2008). The nuclear orphan receptor NR2F6 suppresses lymphocyte activation and T helper 17-dependent autoimmunity. Immunity 29, 205–216. Otettu 29.2.16

Imbalance in T-Helper 17 Cells and Targeted Therapy in an Infant with SAM-like Syndrome.

Hernández-Martín A, Kennedy-Batalla R, Cañedo E, Bernaldo-de-Quirós E, Carazo-Gallego B, Vera A, Torrelo A, Noguera-Morel L, González-Sarmiento R, Bolling M, Martínez-Bonet M, Pion M, Correa-Rocha R.

N Engl J Med. 2019 Nov 28;381(22):2176-2178. Otettu 3.3.20

Ref. katsottu 8.3.20

Hernandez-Santos, N. & Gaffen, S.L. Th17 cells in immunity to *Candida albicans*. Cell Host Microbe 11, 425–435 (2012). Otettu 18.3.20

Ref. katsottu 21.3.20

Hernandez-Santos, N. *et al.* Th17 cells confer long-term adaptive immunity to oral mucosal

Candida albicans infections. *Mucosal Immunol.* **6**, 900–910 (2013). Otettu 12.3.20

Ref. katsottu 18.3.20

Herrath J, Chemin K, Albrecht I, Catrina AI, Malmstrom V. Surface expression of CD39 identifies an enriched Treg-cell sub- set in the rheumatic joint, which does not suppress IL-17A secretion. *Eur J Immunol* 2014;44:2979–89. Otettu 29.2.16

[Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab.](#)

Herrero-Moyano M, Capusan TM, Martínez-Mera C, Llamas-Velasco M, Daudén E. *JAAD Case Rep.* 2018 Sep 19;4(8):842-844.

Free PMC Article Otettu 28.2.20

Ref. katsottu 8.3.20

Hickman-Brecks, C. L., Racz, J. L., Meyer, D. M., LaBranche, T. P., Allen, P. M. (2011) Th17 cells can provide B cell help in autoantibody induced arthritis. J. Autoimmun. 36, 65–75. Otettu 29.2.16

Role of **interleukin-23/interleukin-17** axis in T-cell-mediated actions in hypertension.

Higaki A, Mahmoud AUM, Paradis P, Schiffrin EL. Cardiovasc Res. 2021 Apr 23;117(5):1274-1283. doi: 10.1093/cvr/cvaa257. PMID: 32870976 Review. Otettu 2.9.22

Systemic therapy for psoriasis and the risk of cutaneous infections.

Higashi Y, Imafuku S, Tsuruta N,; Western Japan Inflammatory Skin Disease Research Group.

J Dermatol. 2024 Apr 25. doi:
10.1111/1346-8138.17245. Online ahead of print.
PMID: 38660962 Otettu 29.5.24

Hijnen D, Knol EF, Gent YY et al. (2013) CD8(p) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. J Invest Dermatol 133: 973–9 Otettu 29.2.16

Hill, G. R., S. D. Olver, R. D. Kuns, A. Varelias, N. C. Raffelt, A. L. Don, K. A. Markey, Y. A. Wilson, M. J. Smyth, Y. Iwakura, et al. 2010. Stem cell mobilization with G-CSF induces type 17 differentiation and

promotes sclero- derma. Blood 116: 819–828. Otettu
29.2.16

[Investigating the role of the interleukin-23/-17A axis in
rheumatoid arthritis.](#)

Hillyer P, Larché MJ, Bowman EP, McClanahan TK, de
Waal Malefyt R, Schewitz LP, Giddins G, Feldmann M,
Kastelein RA, Brennan FM.

Rheumatology (Oxford). 2009 Dec;48(12):1581-9. doi:
10.1093/rheumatology/kep293. Epub 2009 Oct 8.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

The societal impact of a biologic treatment of
ankylosing spondylitis: a case study based on
secukinumab.

Himmeler S, Branner JC, Ostwald DA.
J Comp Eff Res. 2020 Nov 30. doi:
10.2217/ce-2020-0077. Online ahead of print.
PMID: 33252266 Otettu 4.2.21

[Signal transduction pathways and transcriptional regulation in Th17 cell differentiation.](#)

Hirahara K, Ghoreschi K, Laurence A, Yang XP, Kanno Y, O'Shea JJ.

Cytokine Growth Factor Rev. 2010 Dec;21(6):425-34.

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

[T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.](#)

Hirta K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, Iwakura Y, Sakaguchi N, Sakaguchi S. J Exp Med. 2007 Jan 22;204(1):41-7. Epub 2007 Jan
Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Hiroi K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007;204:2803–12. Otettu 16.2.16

Hiroi, K., Martin, B. & Veldhoen, M. Development, regulation and functional capacities of Th17 cells. Semin. Immunopathol. 32, 3–16 (2010). Otettu 29.2.16

Hiroi K, et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol. 2011; 12:255–263. Otettu 16.2.16

Hiroi K, Ahlfors H, Duarte JH, Stockinger B. Regulation and function of innate and adaptive interleukin-17-producing cells. EMBO Rep. 2012;13(2):113–20. Emphasises the crucial importance of resident $\gamma\delta$ T cells in chronic inflammation and as a major source of IL-17A. Otettu 29.2.16

Blockade of the IL-17 signaling pathway increased susceptibility of psoriasis patients to superficial fungal infections.

Hiruma J, Harada K, Hirayama M, Egusa C, Tobita R, Masuda-Kuroki K, Abe N, Tsuboi R, Okubo Y.

J Dermatol Sci. 2021 Feb;101(2):145-146. doi: 10.1016/j.jdermsci.2020.12.003. Epub 2020 Dec 14. PMID: 33358579 Otettu 28.11.22

Recurrent angular cheilitis after **secukinumab** injections.

Hitaka T, Sawada Y, Okada E, Nakamura M.

Australas J Dermatol. 2018 Feb;59(1):e79-e80. doi: Otettu 28.5.18

[Similar articles](#)

Secukinumab-induced scar sarcoidosis in a patient with plaque psoriasis.

Hlaca N, Zagar T, Kastelan M, Brajac I, Prpic-Massari L.

Australas J Dermatol. 2022 Feb 9. doi:

10.1111/ajd.13799. Online ahead of print.

PMID: 35139232 No Otettu 3.3.22

RORC overexpression as a sign of Th17 lymphocytes accumulation in multiple myeloma bone marrow.

Ben Hmid A, Selmi O, Rekik R, Lamari H, Zamali I, Ladeb S, Safra I, Ben Othman T, Ben Romdhane N, Ben Ahmed M.

Cytokine. 2020 Oct;134:155210. doi:

10.1016/j.cyto.2020.155210. Epub 2020 Jul 21.

PMID: 32707421 Otettu 28.11.22

A.W.Ho and S.L.Gaffen,

“IL-17RC:a partner in IL-17signaling and beyond,”
Seminars in Immunopathology, vol. 32, no. 1, pp. 33–42,
2010. Otettu 15.3.20

Development of bullous pemphigoid during
secukinumab treatment for psoriasis.

Ho PH, Tsai TF.

J Dermatol. 2017 Sep;44(9):e220-e221. doi: Otettu
28.5.18 Maksullinen

[Similar articles](#)

Impact of biologics on health-related quality of life in patients with Ankylosing
spondylitis: A systematic review and meta-analysis of randomized controlled trials.

Ho A, Younis I, Le QA.

Semin Arthritis Rheum. 2022 Jun;54:151996. doi: 10.1016/j.semarthrit.2022.151996.

Epub 2022 Mar 19.

PMID: 35339841 Otettu 28.11.22

Successful treatment of refractory juvenile generalized pustular psoriasis with **secukinumab** monotherapy: A case report and review of published work.

Ho PH, Tsai TF.

J Dermatol. 2018 Nov;45(11):1353-1356. Otettu 28.2.20

Hoechst, B. *et al*. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. *Blood* **117**, 6532–6541

(2011). Otettu 8.3.20

Ref. katsottu 12.3.20

Granzyme B prevents aberrant IL-17 production and intestinal pathogenicity in CD4⁺ T cells.

Hoek KL, Greer MJ, McClanahan KG, Nazmi A, Piazuelo MB, Singh K, Wilson KT, Olivares-Villagómez D.

Mucosal Immunol. 2021 Sep;14(5):1088-1099. doi: 10.1038/s41385-021-00427-1. Epub 2021 Jun 28.

PMID: 34183776 [Free PMC article.](#) Otettu 30.8.22

Hoeve MA, Savage ND, de Boer T, Langenberg DM, de Waal Malefyt R, OttenhoV TH, et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006;36:661–70. Otettu 29.2.16

Dramatic early improvement of psoriasis in an 11-year old boy after four doses of **secukinumab** following an alternative dosing scheme.

Hoff J, Spora L, Fang Y, Brüggen MC, Möhrenschrager M.
J Eur Acad Dermatol Venereol. 2023 Nov 1. doi:
10.1111/jdv.19620. Online ahead of print.
PMID: 37909322 No abstract available. Otta M

Polymyalgia rheumatica-A challenge in geriatrics :
Interdisciplinary presentation of diagnostics and
treatment].

Hofmann W, Kötter I, Winterhalter S, Krupp S.
Z Rheumatol. 2024 Mar;83(2):112-121. doi:
10.1007/s00393-024-01484-0.
PMID: 38285216 German. Otta M

Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018;29:13–8. Otettu 3.3.20

Ref. katsottu 13.3.20

Adjuvant treatment with **secukinumab** induced long term remission in a patient with severe bullous pemphigoid.

Holtsche MM, Hammers CM, Chakievska L, Ludwig RJ, Thaci D, Zillikens D, Schmidt E.

J Dtsch Dermatol Ges. 2020 Sep 24. doi:

10.1111/ddg.14291. Online ahead of print.

PMID: 32975029 No abstract available. Otettu 28.11.22

Mitigated suppressive function of regulatory T cells (Treg) upon Th17-inducing cytokines in oligo- and polyarticular Juvenile Idiopathic Arthritis (JIA) patients.

Holzer MT, Almanzar G, Woidich R, Hügler B, Haas JP, Prelog M.

Pediatr Rheumatol Online J. 2022 Apr 11;20(1):26. doi: 10.1186/s12969-022-00680-z.

PMID: 35410224 [Free PMC article.](#) Otettu 27.8.22

Holzer, U., Reinhardt, K., Lang, P., Handgretinger, R., and Fischer, N. (2013). Influence of a mutation in IFN-g receptor 2 (IFNGR2) in human cells on the generation of Th17 cells in memory T cells. Hum. Immunol. 74, 693–700. Otettu 19.9.20

Homey B: After Th1/Th2 now comes Treg/
Th17:Significance of T helper cells in im- mune
response organization (in German). Hautarzt
2006;57:730–732. Ei oteta

Honda K: IL-22 from T cells: better late than never.
Immunity 2012;37:952–954. Otettu 12.3.20

Serum levels of **interleukin-17**, -18, -22, and -25 in patients with bullous pemphigoid before and after treatment.

Hong X, Wang X, Cheng Y, Song H, Xu C, Wang P.
Front Med (Lausanne). 2025 Jul 29;12:1559372. doi:
10.3389/fmed.2025.1559372. eCollection 2025.
PMID: 40800128 **Free PMC article.** Otettu 22.8.25

Secukinumab in the treatment of noninfectious uveitis.

Hong J, Liu Z, Sun X, Xu J.
Ophthalmology. 2013 Dec;120(12):e86. doi:
10.1016/j.opthta.2013.08.019. No abstract available.
PMID:

Otettu 3.2.16

[Similar articles](#)

[Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab.](#)

Honma M, Nozaki H, Hayashi K, Inuma S, Ishida-Yamamoto A.

J Dermatol. 2019 Dec;46(12):e468-e469. Otettu 28.2.20

[High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients.](#)

Honorati MC, Meliconi R, Pulsatelli L, Canè S, Frizziero L, Facchini A.

Rheumatology (Oxford). 2001 May;40(5):522-7.

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

M. C. Honorati, M. Bovara, L. Cattini, A. Piacentini, and A. Facchini, "Contribution of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis," *Osteoarthritis and Cartilage*, vol. 10, no. 10, pp. 799–807, 2002. Otettu 29.2.16

Honorati MC, Cattani L, Facchini A: IL-17, IL-1b and TNF-a stimulate VEGF production by dedifferentiated chondrocytes. *Osteoarthritis Cartilage* 2004, 12:683-691. Otettu 16.2.16

Honorati MC, Neri S, Cattini L, Facchini A. 2006. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. *Osteoarthritis Cartilage* 14(4):345–352. Otettu 29.2.16

Augmented IFN γ producing ILC1 and IL 17 producing ILC3 in pemphigus vulgaris: Plausible therapeutic target.

Hooda V, Khandpur S, Sharma A.

Cell Immunol. 2025 Feb;408:104910. doi:

10.1016/j.cellimm.2024.104910. Epub 2024 Dec 18.

PMID: 39718308 Otta M

Interleukin-17: A Social Cytokine.

Hoogenraad CC, Rioll-Bianco L.

Cell. 2020 Apr 30;181(3):517-519. doi:

10.1016/j.cell.2020.03.060.

PMID: 32359435 **Free article.** Otettu 5.9.22

Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis.

Hornick N, Wang A, Lim Y, Gehlhausen J, Siegel J, Wang J, Foss F, Lim I, Zubek A, Milstone L, Galan A, King B, Damsky W.

J Eur Acad Dermatol Venereol. 2020

Oct;34(10):e583-e585. doi: 10.1111/jdv.16451. Epub 2020 May 19.

PMID: 32277505 Otettu 28.11.22

Horreau C, Pouplard C, Brenaut E et al. J Eur Acad Dermatol Venereol 2013; 27(Suppl 3): 12–29. ei oteta

N.J.Horwood,V.Kartsogiannis,J.M.W.Quinn,E.Romas,T.J. Martin, and M. T. Gillespie, “Activated T lymphocytes support osteoclast formation in vitro,” *Biochemical and Biophysical Research Communications*, vol. 265, no. 1, pp. 144–150, 1999. Otettu 15.3.20
Ref. ei katsot

[Paradoxical localized exacerbation of psoriatic eruptions triggered by **secukinumab**.](#)

Hoshina D, Haga N, Furuya K, Sakai M.

Clin Exp Dermatol. 2018 Jan 4. Otettu 28.5.18

[Similar articles](#)

[IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes.](#)

Hot A, Zrioual S, Toh ML, Lenief V, Miossec P.

Ann Rheum Dis. 2011 Feb;70(2):341-8. doi:

Otettu 3.2.16,,

[Similar articles](#)

.

[Effects of interleukin \(IL\)-17A and IL-17F in human rheumatoid **arthritis** synoviocytes.](#)

Hot A, Miossec P.

Ann Rheum Dis. 2011 May;70(5):727-32. do Epub 2011

Otettu 29.2.16

[Similar articles](#)

Hot A, Zrioual S, Lenief V, Miossec P. IL-17 and tumour necrosis factor alpha combination induces a

HIF-1alpha-dependent invasive phenotype in synoviocytes. Ann Rheum Dis. 2012;71:1393–401. Otettu 16.2.16

Hot A, Lenief V, Miossec P. Combination of IL-17 and TNF γ induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis 2012;71: 768–76. Otettu 29.2.16

Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of **Secukinumab**.

Houghton K, Patil D, Gomez B, Feldman SR.

Dermatol Ther (Heidelb). 2021 Aug;11(4):1373-1384. doi: 10.1007/s13555-021-00564-2. Epub 2021 Jun 10. PMID: 34110605 Otettu 8.8.21

Hovhannisyan Z, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. *Gastroenterology*. 2011; 140:957–965. Otettu 17.3.20

Immunomodulation with IL-17 and TNF- α in spondyloarthritis: focus on the eye and the central nervous system.

How Shing Koy E, Labauge P, Baillet A, Prati C, Marotte H, Pers YM.

Ther Adv Musculoskelet Dis. 2021 Jul

9;13:1759720X211025894. doi:

10.1177/1759720X211025894. eCollection 2021.

PMID: 34290832 [Free PMC article](#). Review. Otettu

30.8.22

Disease Modification of Pustular Psoriasis by
Secukinumab: A 20-Year Follow-Up of Von
Zumbusch-Type Generalized Pustular Psoriasis With
Evolution Into Annular Pustular Psoriasis-A Case Report.

Hsu YA, Lan CE, Lin SY.

Kaohsiung J Med Sci. 2025 Aug 12:e70083. doi:
10.1002/kjm2.70083. Online ahead of print.

PMID: 40798863 **Free article.** Otettu 22.8.25

Hu Y, Shen F, Crellin NK, Ouyang W: The IL-17 pathway
as a major therapeutic target in autoimmune diseases.
Ann N Y Acad Sci 2011, 1217:60-76. Otettu 16.2.16

Maksullinen

$\gamma\delta$ T cells and adipocyte IL-17RC control fat innervation and thermogenesis.

Hu B, et al. *Nature*. 2020. PMID: 32076265 [Free PMC article](#). Otettu 6.9.22

Safety of interleukin-17A inhibitors in 306 patients with psoriasis with or without latent tuberculosis: a dual-centre retrospective study in China.

Hu K, Liu Y, Sha Y, Zhang M, Jian L, Duan Y, Lv C, Kuang Y.

Clin Exp Dermatol. 2025 May 23;50(6):1107-1115. doi: 10.1093/ced/llae549.

PMID: 39918838 Otta M

Hu R, O'Connell RM. MiR-23b is a safeguard against autoimmunity. Nat Med 2012;18(7):1009–10. Otettu 29.2.16

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.

Huang F, Sun F, Wan WG, Wu LJ, Dong LL, Zhang X, Kim TH, Sengupta R, Šenolt L, Wang Y, Qiu HM, Porter B, Haemmerle S.

Chin Med J (Engl). 2020 Sep 10. doi: 10.1 Otettu 19.9.20

Effectiveness of **secukinumab** versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli et al.

Huang JX, Leong PY, Wei JC.

Ann Rheum Dis. 2020 Sep

15:annrheumdis-2020-218779. doi: 10.11 Otettu

19.9.20

Preliminary Report on **Interleukin-22**, GM-CSF, and IL-17F in the Pathogenesis of Acute Anterior Uveitis.

Huang JC, et al. Ocul Immunol Inflamm. 2021. PMID:

31763950 Free PMC article. Otettu 28.11.22

Huang F, Kao CY, Wachi S, et al. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF- kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. Immunol. 2007;179:6504–6513.
Otettu 12.3.20

Ref. katsottu 15.3.2020

Huang Z, van Velkinburgh JC, Ni B, Wu Y. Pivl roles of the interleukin-23/T helper 17 cell axis in hepatitis B. Liver Int 2012; 32: 894–901.
Otettu 9.3.20

Loss of efficacy of **secukinumab** for psoriasis at 24 to 32 weeks.

Huang YYM, Ruth JS, Hsu S.

J Am Acad Dermatol. 2016 Oct;75(4):e169. doi:

Otettu 28.5.18

[Similar articles](#)

[Efficacy and safety of **secukinumab** in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials.](#)

Huang Y, Fan Y, Liu Y, Xie W, Zhang Z.

Clin Rheumatol. 2019 May 14. doi: Otettu 28.2.20

Optimizing biologics for chronic plaque psoriasis:
insights on non-medical interruptions of IL-17, IL-12/23,
and IL-23 inhibitors.

Huang HY, Tseng IL, Yang CC, Wong TW, Lai EC, Lee CN.
J Dtsch Dermatol Ges. 2025 Jul 28. doi:
10.1111/ddg.15787. Online ahead of print.
PMID: 40719449 Otta M

Huber M, Heink S, Grothe H et al. A Th17-like
developmental pro- cess leads to CD8+ Tc17 cells with

reduced cytotoxic activity. Eur J Immunol 2009;
39:1716–25. Otettu 29.2.16

Huber S, Gagliani N, Esplugues E, O'Connor Jr W,
Huber FJ, Chaudhry A, et al.
Th17 cells express interleukin-10 receptor and are
controlled by Foxp3– and Foxp3+ regulatory CD4+ T
cells in an interleukin-10-dependent manner. Immunity
2011;34:554–65. Otettu 29.2.16

[Mast cells express IL-17A in rheumatoid arthritis
synovium.](#)

Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe
J, Melendez AJ, McInnes IB.

J Immunol. 2010 Apr 1;184(7):3336-40. doi:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

[Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.](#)

Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH; Psoriasis Study Group, Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group, Rose K, Haider A, Di Padova F. Sci Transl Med. 2010 Oct 6;2(52):52ra72. doi:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Hueber, W. et al. Inhibition of IL-17A by secukinumab is ineffective for Crohn's disease (CD). J. Crohn's Colitis 5, S7 (2011). Otta M ei ole GS Eiole PUBMED

Otta myöhemmin

[Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.](#)

Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP; **Secukinumab** in Crohn's Disease Study Group.

Gut. 2012 Dec;61(12):1693-700. doi:

Otettu 3.2.16 [Similar articles](#)

Wolfgang Hueber DB. Anti-interleukin-17A monoclonal antibody Secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. *Lancet* 2013; 382: 1705–1713.
Otettu 28.3.20

[Type 17-specific immune pathways are active in early spondyloarthritis.](#)

Hughes CD, Ryan SE, Steel KJA, van den Beukel MD, Trouw LA, van Schie KAJ, Toes REM, Menon B, Kirkham BW, Taams LS.

RMD Open. 2023 Dec 20;9(4):e003328. doi: 10.1136/rmdopen-2023-003328.

PMID: 38123480 **Free PMC article.** Otettu 13.3.24

Huh, J.R., Leung, M.W., Huang, P., Ryan, D.A., Krout, M.R., Malapaka, R.R., Chow, J., Manel, N., Ciofani, M., Kim, S.V., et al. (2011). Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing ROR γ t activity. *Nature* 472, 486–490. Otettu 29.3.20

[Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.](#)

Hull DN, Williams RO, Pathan E, Alzabin S, Abraham S, Taylor PC.

Clin Exp Immunol. 2015 Sep;181(3):401-6. doi: 10.1111/cei.12626. Epub 2015 Jun 23.

PMID:

25766640 Otettu 3.2.16

[Similar articles](#)

Hundorfean, G., Neurath, M.F., and Mudter, J. (2012).
Functional relevance of T helper 17 (Th17) cells and the
IL-17 cytokine family in inflammatory bowel disease.
Inflamm. Bowel Dis. 18, 180–186. Otettu 27.3.20

[Mucocutaneous candidiasis: the IL-17 pathway and
implications for targeted immunotherapy.](#)

Huppler AR, Bishu S, Gaffen SL.

Arthritis Res Ther. 2012 Jul 23;14(4):217. doi:

[Free PMC Article](#)

[Similar articles](#)

Select item. Otettu 3.2.16

Potential role of **INTERLEUKIN-17** in the pathogenesis of oral lichen planus: a systematic review with META-analysis.

Husein-ElAhmed H, Steinhoff M.

J Eur Acad Dermatol Venereol. 2022 May 15. doi: 10.1111/jdv.18219. Online ahead of print.

PMID: 35570406 Review. Otta M Otta myöhemmin

Some Drugs Have Two Faces: Paradoxical Colitis in a Patient with Psoriatic Arthritis Previously Treated with Etanercept and IL-17 Inhibitors.

Huynh S, Achalu S, Berry R, Lin J, Wang CX, Gubatan J, Cheng AG.

Dig Dis Sci. 2024 Mar 19. doi:

10.1007/s10620-024-08380-2. Online ahead of print.

PMID: 38502378 Otta M

Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, Kim HY: IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF- B- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 2004, 6:R120-R128.

Otettu 28.5.18

[IL-17 and CCR9+α4β7- Th17 Cells Promote Salivary Gland Inflammation, Dysfunction, and Cell Death in Sjögren's Syndrome.](#)

Hwang SH, Woo JS, Moon J, Yang S, Park JS, Lee J, Choi J, Lee KH, Kwok SK, Park SH, Cho ML.

Front Immunol. 2021 Sep 1;12:721453. doi: 10.3389/fimmu.2021.721453. eCollection 2021.

PMID: 34539657 [Free PMC article.](#) Otettu 29.8.22

[Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients.](#)

Hwang SY, Kim HY.

Mol Cells. 2005 Apr 30;19(2):180-4.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Hyffmeier, U., Lascorz, J., Böhm, B., Lohmann, J., Wendler, J., Mössner, R., Reich, K., Traupe, H., Kurrat, W., Burkhardt, H., and Reis, A. (2009). Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J. Invest. Dermatol. 129, 355–358. Otettu

16.3.20

REf. ei katsot

Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, Pan G, Gurney AL, de Vos AM, Starovasnik MA. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001;20:5332–41. Otettu 16.2.16

The role of **interleukin-17** in asthma: a protective response?

Hynes GM, Hinks TSC.

ERJ Open Res. 2020 May 26;6(2):00364-2019. doi: 10.1183/23120541.00364-2019. eCollection 2020 Apr. PMID: 32494573 **Free PMC article.** Otettu 4.9.22

"I Was Almost in Disbelief" - Qualitative Analysis of Experiences and Expectations Among Psoriasis Patients Undergoing Biologic Treatment with **Secukinumab**.

Hölsken S, Benthin C, Krefting F, Mühlhaus S, Nestoriuc Y, Schedlowski M, Sondermann W.

Patient Prefer Adherence. 2024 Jun 24;18:1299-1310.

doi: 10.2147/PPA.S458643. eCollection 2024.

PMID: 38947870 **Free PMC article.** Otettu 27.9.24

Shaping Treatment Expectation to Optimize Efficacy of Interleukin 17A Antagonist **Secukinumab** in Psoriasis Patients.

Hölsken S, Krefting F, Mühlhaus S, Bese D, Schedlowski M, Sondermann W.

Psoriasis (Auckl). 2025 Jan 10;15:9-22. doi:

10.2147/PTT.S486338. eCollection 2025.

PMID: 39810930 **Free PMC article.** Clinical Trial. Otettu 21.1.25

Hölttä, V. *et al.* IL-23/IL-17 immunity as a hallmark of Crohn's disease. *Inflamm. bowel Dis.* **14**, 1175–1184 (2008). Otettu 8..3.20

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study.

Ibba L, Gargiulo L, Alfano A, Cascio Ingurgio R, Narcisi A, Costanzo A, Valenti M.

J Dermatolog Treat. 2023 Dec;34(1):2199108. doi: 10.1080/09546634.2023.2199108.

PMID: 37010456 **Free article.** Otettu 14.6.23

Ichiyama, K., Yoshida, H., Wakabayashi, Y., Chinen, T., Saeki, K., Nakaya, M., et al. (2008). Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J. Biol. Chem. 283, 17003–17008. doi: Otettu 12.3.20 Ref. ei oteta.

Ikeda K, Nakajima H, Suzuki K et al. Blood 2003; 101: 3594–3596. Otettu 29.2.16

Ikeda, S., Saijo, S., Murayama, M. A., Shimizu, K., Akitsu, A., and Iwakura, Y. (2014). Excess IL-1 signaling enhances the development of Th17 cells by downregulating TGF-beta-induced Foxp3 expression. J. Immunol. 192, 1449– 1458. doi: 10.4049/jimmunol.1300387 Otettu 29.2.16

Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. *Arthritis Rheum* 2005;52:1037– 46. Otettu 29.2.16

Efficacy of **Secukinumab** for Plaque Psoriasis in a Patient on Hemodialysis.

Ikuma D, Oguro M, Hoshino J, Mizuno H, Sekine A, Kawada M, Hiramatsu R, Sumida K, Hasegawa E, Hayami N, Yamanouchi M, Suwabe T, Sawa N, Takaichi K, Ubara Y.

CEN Case Rep. 2020 Feb;9(1):55-58. doi: 10.1007/s13730-019-00426-z. Epub 2019 Oct 25.

PMID: 31654299 **Free PMC Article** Otettu 28.2.20

When IL-17 gets on your nerves.

Iliev ID, Lin WY, Gaffen SL.

Cell. 2023 Feb 2;186(3):466-468. doi: 10.1016/j.cell.2022.12.048.

PMID: 36736299 Otta M

[Efficacy and safety of **secukinumab** in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.](#)

Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, Seko N, Kawashima N, Ito S, Shima T, Nakagawa H.

J Dermatol. 2016 Feb 26. doi:

[J Dermatol. 2016;43\(9\):1011-1017.](#)

Otettu 28.5.18

[Similar articles](#)

C. Infante-Duarte, H. F. Horton, M. C. Byrne, and T. Kamradt, "Microbial lipopeptides induce the production of IL-17 in Th cells," The Journal of Immunology, vol. 165, no. 11, pp. 6107–6115, 2000. Otettu 25.3.20

Assessing Long-Term Pain Reduction with
Secukinumab in Moderate to Severe Hidradenitis
Suppurativa: A Post Hoc Analysis of the SUNSHINE and
SUNRISE Phase 3 Trials.

Ingram JR, Szepietowski JC, Matusiak L, Kokolakis G,
Wozniak MB, Ortmann CE, Martinez AL, Ravichandran S,
Thomas N, Alarcon I, Pieterse CC, Alam MS, Ioannides D,
Kimball AB.

Dermatol Ther (Heidelb). 2025 Jul;15(7):1833-1849. doi:
10.1007/s13555-025-01426-x. Epub 2025 May 15.

PMID: 40372667 [Free PMC article.](#) Otettu 4.6.25

Real-World Retention and Clinical Effectiveness of
Secukinumab for Axial Spondyloarthritis: Results From
the Canadian Spondyloarthritis Research Network.

Inman RD, Choquette D, Khraishi M, Gladman DD,
Hussein S, Neish D, Leclerc P.

J Rheumatol. 2023 May;50(5):634-640. doi:
10.3899/jrheum.220824. Epub 2023 Jan 15.
PMID: 36642434 Otta M

D. Inoue, M. Numasaki, M. Watanabe et al., "IL-17A
promotes
the growth of airway epithelial cells through
ERK-dependent signaling pathway," *Biochemical
and Biophysical Research Com- munications*, vol.
347, no. 4, pp. 852–858, 2006.
Ei oteta

Intlekofer, A. M., A. Banerjee, N. Takemoto, S. M. Gordon, C. S. Dejong, H. Shin, C. A. Hunter, E. J. Wherry, T. Lindsten, and S. L. Reiner. 2008. Anomalous type 17 response to viral infection by CD8⁺ T cells lacking T-bet and eomesodermin. *Science* 321: 408–411. Otettu 21.3.20

Ref. ei otet.

[Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development.](#)

Iorio L, Padoan R, Bond M, Dejaco C.

Expert Opin Investig Drugs. 2024 Jul;33(7):671-676. doi:

10.1080/13543784.2024.2366847. Epub 2024 Jun 16.

PMID: 38879822 Review. Otta M

[Interleukin-17 and innate immunity in infections and chronic inflammation.](#)

Isailovic N, Daigo K, Mantovani A, Selmi C.

J Autoimmun. 2015 Jun;60:1-11. doi: Otettu 3.2.16

[Similar articles](#)

[Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis.](#)

Isailovic N, Ceribelli A, Cincinelli G, Vecellio M, Guidelli G, Caprioli M, Luciano N, Moa F, Selmi C, De Santis M.

Clin Exp Immunol. 2021 Aug;205(2):142-149. doi: 10.1111/cei.13609. Epub 2021 May 28.

PMID: 33899926 [Free PMC article.](#) Otettu 30.8.22

[IL-17A inhibitor-induced ulcerative colitis treated with an anti-IL-23 antibody.](#)

Ishida N, Asai Y, Takebe T, Takahashi K, Sugiura K, Matsuura T, Kurihara K, Suzuki T, Honda T, Sugimoto K. Clin J Gastroenterol. 2025 Jun 2. doi: 10.1007/s12328-025-02153-8. Online ahead of print. PMID: 40455166 Otta M

Successful treatment of refractory enteritis and arthritis with combination of TNF and IL-6 inhibition in patients with ulcerative colitis.

Ishigaki S, Kondo Y,, Chu PS, Hanaoka H, Takeuchi T, Kaneko Y.

Mod Rheumatol Case Rep. 2023 Jun 10:rxad031. doi: 10.1093/mrcr/rxad031. Online ahead of print. PMID: 37300554 Otettu 12.10.23

Ishigame, H. *et al.* Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. *Immunity* 30, 108–119 (2009). Otettu 20.3.20

Ref. ei katsot.

[Reduced Major Adverse Cardiovascular Events \(MACE\) with **Interleukin-17** Inhibitors Compared to Methotrexate in Psoriasis Patients: A multi-center retrospective cohort analysis.](#)

Islam RK, Maltese A, Islam KN, Wu JJ.

J Am Acad Dermatol. 2025 Mar

13:S0190-9622(25)00432-3. doi:

10.1016/j.jaad.2025.03.014. Online ahead of print.

PMID: 40089023 Otta M

[Successful treatment of refractory folliculitis decalvans with secukinumab.](#)

Ismail FF, Sinclair R.

Australas J Dermatol. 2019 Oct 24. Otettu 28.2.20

[Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis.](#)

Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, Yoshitomi H, Nakamura T, Shimizu M, Kawabata D, Yukawa N, Hashimoto M, Sakaguchi N, Sakaguchi S, Yoshifuji H, Nojima T, Ohmura K, Fujii T, Mimori T.

Arthritis Rheum. 2009 Aug;60(8):2294-303. doi: 10.1002/art.24687.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Activated type 17 helper T cells affect tofacitinib treatment outcomes

Ito, Yuki ; Watanabe, Daisuke ; Okamoto, Norihiro ; Miyazaki, Haruka ; Tokunaga, Eri ; Ku, Yuna ; Ooi, Makoto ; Hoshi, Namiko ; Kohashi, Michitaka ; Kanzawa, Maki ; Kodama, Yuzo

Scientific reports, 2025-02, Vol.15 (1), p.6112-10 Otettu 4.6.25

612.

Dual role of interleukin-17 in pannus growth and osteoclastogenesis in rheumatoid arthritis.

Ito H, Yamada H, Shibata TN, Mitomi H, Nomoto S, Ozaki S.

Arthritis Res Ther. 2011 Feb 4;13(1):R14. doi: 10.1186/ar3238.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Th17 and effector CD8 T cells relate to disease progression in amyotrophic lateral sclerosis: a case control study.

Itou T, Fujita K, Okuzono Y, Warude D, Miyakawa S, Mihara Y, Matsui N, Morino H, Kikukawa Y, Izumi Y.

J Neuroinflammation. 2024 Dec 27;21(1):331. doi: 10.1186/s12974-024-03327-w.

PMID: 39731185 [Free PMC article.](#) Otettu 21.1.25

Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006;116(5):1218–22.

Otettu 29.2.16

[The roles of IL-17A in inflammatory immune responses and host defense against pathogens.](#)

Iwakura Y, Nakae S, Saijo S, Ishigame H.

Immunol Rev. 2008 Dec;226:57-79. doi:

Otettu 29.2.16

[Similar articles](#)

Iwakura, Y., Ishigame, H., Saijo, S. and Nakae, S.
(2011). Functional specialization of interleukin-17 family members. Immunity 34: 149–162. Otettu 29.2.16

Iwamoto S, Iwai S, Tsujiyama K, Kurahashi C, Takeshita K, Naoe M, et al. TNF- α drives human CD14 + monocytes to differentiate into CD70 + dendritic cells evoking Th1 and Th17 responses. J Immunol 2007;179:1449–57. Otettu 29.2.16

Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor ROR γ t directs the differentiation program of proinflammatory IL-17⁺ T helper cells. *Cell* 126 (6): 1121-1133 Otettu 12.3.20

Ivanov, I.I., L. Zhou, and D.R. Littman. 2007. Transcriptional regulation of Th17 cell differentiation. *Semin. Immunol.* 19:409–417. Otettu 4.3.16

.

[Interleukin-17 as a drug target in human disease.](#)

Ivanov S, Lindén A.

Trends Pharmacol Sci. 2009 Feb;30(2):95-103. doi:

Otettu 3.2.16

[Similar articles](#)

Epidermal clearance of *Candida albicans* is mediated by IL-17 but independent of fungal innate immune receptors.

Iwasawa MT, Miyachi H, Wakabayashi S, Sugihira T, Aoyama R, Nakagawa S, Katayama Y, Yoneyama M, Hara H, Iwakura Y, Matsumoto M, Inohara N, Koguchi-Yoshioka H, Fujimoto M, Núñez G, Matsue H, Nakamura Y, Saijo S.

Int Immunol. 2022 Jul 26;34(8):409-420. doi: 10.1093/intimm/dxac019.

PMID: 35641096 Otettu 27.8.22

Iversen L, Eidsmo L, Austad J, et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study. J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1930–1939. Otettu 2.3.20

Real-world drug survival of guselkumab, ixekizumab and **secukinumab** for psoriasis.

Iznardo H, Vilarrasa E, López-Ferrer A, Puig L.

Br J Dermatol. 2021 Apr 29. doi: 10.1111/bjd.20416.

Online ahead of print.

PMID: 33913516 Otettu 28.11.22

Effect of **interleukin-17A** inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor.

Izumiyama T, Mori Y, Oizumi I, Hamada S, Kurishima H, Terui H, Omori-Shimada R, Yamasaki K, Itoi E.

J Orthop Surg (Hong Kong). 2021

May-Aug;29(2):23094990211012286. doi:

10.1177/23094990211012286.

PMID: 33938296 Free article. Otettu 30.8.22

Jack C, Mashiko S, Arbour N et al. Persistence of interleukin (IL)-17A γ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy. Br J Dermatol 2017;177:267–270. Ei oteta

Jacobs JP, Wu HJ, Benoist C, Mathis D (2009) IL-17-producing T cells can augment autoantibody-induced arthritis. Proc Natl Acad Sci U S A 106: 21789– 21794. Otettu 29.2.16

[Targeted therapies for uveitis in spondyloarthritis: A narrative review.](#)

Jacquot R, Kodjikian L, Chapurlat R, Sève P.

Joint Bone Spine. 2024 Feb 1;91(5):105697. doi: 10.1016/j.jbspin.2024.105697. Online ahead of print.

PMID: 38309516 [Free article.](#) Otettu 4.3.24

L. D. Jager, R. Dabelic, L. W. Waiboci et al., “The kinase inhibitory region of SOCS-1 is sufficient to inhibit T-helper 17 and other immune functions in experimental allergic encephalomyelitis,” *Journal of Neuroimmunology*, vol. 232, no. 1-2, pp. 108–118, 2011. Otettu 18.3.20

Distinct T-cell immunophenotypic signature in a subset of sarcoidosis patients with arthritis.

Jain A, Singh H, Nath A, Chaturvedi S, Ajmani S, Misra DP, Agarwal V.

J R Coll Physicians Edinb. 2020 Sep;50(3):226-232. doi: 10.4997/JRCPE.2020.304.

PMID: 32936094 Otettu 21.9.20

[Increased plasma IL-17F levels in rheumatoid arthritis patients are responsive to methotrexate, anti-TNF, and T cell costimulatory modulation.](#)

Jain M, Attur M, Furer V, Todd J, Ramirez R, Lock M, Lu QA, Abramson SB, Greenberg JD.

Inflammation. 2015 Feb;38(1):180-6. doi: 10.1007/s10753-014-0020-1.

PMID:

[Similar articles](#)

Otettu 3.2.16

24. Jain, R. *et al.* Interleukin-23-induced transcription factor Blimp-1 promotes pathogenicity of T helper 17 cells. *Immunity* **44**, 131–142 (2016). Otettu 27.3.20

[Secukinumab \(AIN-457\) for the treatment of Psoriasis.](#)

Jaleel T, Elmets C, Weinkle A, Kassira S, Elewski B. Expert Rev Clin Pharmacol. 2015 Dec 8. [Epub ahead of print]

PMID:

Expert Rev Clin Pharmacol. 2016 Feb;9(2):187-202. doi: ei ole M Ei oteta

[Similar articles](#)

[You are the tumor queen, microbiome fiend, IL-17.](#)

Jana JA, Overacre-Delgoffe AE.

Immunity. 2024 Jan 9;57(1):11-13. doi:
10.1016/j.immuni.2023.12.011.

PMID: 38198848 Otta M

.

[Increased numbers of circulating polyfunctional Th17
memory cells in patients with seronegative
spondylarthritides.](#)

Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D,
Romero P.

Arthritis Rheum. 2008 Aug;58(8):2307-17. doi: 10.1

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

F.C. Janette, I.R. Maria, R.C. Antonio, Autoimmune inflammation from the Th17 perspective, Autoimmunity Rev. 6 (2007) 169–175. Otettu 29.2.16

Janke, M., Peine, M., Nass, A., Morawietz, L., Hamann, A. and Scheffold, A., In vitro-induced Th17 cells fail to induce inflammation in vivo and show an impaired migration into inflamed sites. Eur. J. Immunol. 2010. 40: 1089–1098. Otettu 29.2.16

.
[IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities.](#)

Jansen DT, Hameetman M, van Bergen J, Huizinga TW, van der Heijde D, Toes RE, van Gaalen FA.

Rheumatology (Oxford). 2015 Apr;54(4):728-35. doi:
Otettu 3.2.16

[Similar articles](#)

Innate Immune Response and Epigenetic Regulation: A
Closely Intertwined Tale in Inflammation.

Jawale D, Khandibharad S, Singh S.

Adv Biol (Weinh). 2024 Sep 12:e2400278. doi:

10.1002/adbi.202400278. Online ahead of print.

PMID: 39267219 Review. Otta M

[Interleukin-17 and interleukin-23 cytokine profiles in
palindromic rheumatism: potential therapeutic targets
and prognostic biomarkers for disease progression to
rheumatoid arthritis.](#)

Javidi-Aghdam K, Akbarzadeh-Khiavi M, Ghasembaglou
A, Rahbari B, Mahdavi AM, Jafarpour M, Safary A,
Khabbazi A.

Mol Biol Rep. 2025 Jul 3;52(1):672. doi:
10.1007/s11033-025-10786-8.
PMID: 40608144 Otta M

Effectiveness of ixekizumab in 709 real-world patients
with axial spondyloarthritis and psoriatic arthritis: a
nationwide cohort study.

Jensen KY, Grøn KL, Glintborg B, Hetland ML.

RMD Open. 2025 Jul 22;11(3):e005806. doi:
10.1136/rmdopen-2025-005806.

PMID: 40701624 **Free PMC article.** Otettu 31.7.25

Jensen KD, Su X, Shin S, Li L, Youssef S, Yamasaki S,
et al. Thymic selection determines ' ' T cell effector fate:

antigen-naive cells make interleukin-17 and antigen-experienced cells make interferon ' . Immunity 2008;29:90–100. Otettu 29.2.16

Psoriasis treatments in the stabilization of atherosclerosis: a systematic review

Ji, Lixin ; Ravi, Sowmya ; Wright, Laura ; Nguyen, Vi ; Wiley, Jose ; Vukelic, Milena ; Kim, Sangkyu

Archives of Dermatological Research, 2024-12, Vol.317 (1), p.159, Article 159

PEER REVIEWED

OPEN ACCESS Otettu 4.6.25

Ji, J. *et al.* Myeloid-derived suppressor cells contribute to systemic lupus erythaematosus by regulating differentiation of Th17 cells and Tregs. *Clin. Sci. (Lond.)* **130**, 1453–1467 (2016). Otettu 8.3.20

Ref. katsottu 10.3.20

Exceptional response of skin symptoms to **secukinumab** treatment in a patient with SAPHO syndrome: Case report and literature review.

Ji Q, et al. *Medicine (Baltimore)*. 2022. PMID: 35984163
Free PMC article. Review. Otettu 26.9.22

Psoriasis treatments in the stabilization of atherosclerosis: a systematic review.

Ji L, Ravi S, Wright L, Nguyen V, Wiley J, Vukelic M, Kim S.

Arch Dermatol Res. 2024 Dec 30;317(1):159. doi: 10.1007/s00403-024-03625-6.

PMID: 39739136 **Free PMC article.** Review. Otettu 21.1.25

The impact of biologics targeting the IL-17 and IL-23 pathways on metabolic indicators in plaque psoriasis.

Jiang W, Li Q, Zheng W.

Arch Dermatol Res. 2025 Mar 28;317(1):643. doi: 10.1007/s00403-025-04174-2.

PMID: 40148675 Clinical Trial. Otta M

Dynamics of Adaptive Immune Cell and NK Cell Subsets in Patients With Ankylosing Spondylitis After IL-17A Inhibition by **Secukinumab**.

Jiang Y, Yang M, Zhang Y, Huang Y, Wu J, Xie Y, Wei Q, Liao Z, Gu J.

Front Pharmacol. 2021 Oct 14;12:738316. doi: 10.3389/fphar.2021.738316. eCollection 2021.

PMID: 34721027 Free PMC article. Otettu 3.3.22

Jiang, W., Su, J., Zhang, X., Cheng, X., Zhou, J., Shi, R., et al. (2014). Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. *Inflamm. Res.* 63, 943–950. doi: Otettu 29.2.16

[Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect.](#)

Jimeno R, Leceta J, Garín M, Ortiz AM, Mellado M, Rodríguez-Frade JM, Martínez C, Pérez-García S, Gomariz RP, Juarranz Y.

J Leukoc Biol. 2015 Aug;98(2):257-69. doi: 10.1189/jlb.3A0714-327R. Epub 2015 May 8.

Otettu 3.2.16

[Similar articles](#)

[Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab.](#)

Jin K, Matsuzaki Y, Akasaka E, Nakano H, Sawamura D.
J Dermatol. 2019 Mar;46(3):e108-e109. Otettu 28.2.20

Effects of **secukinumab** on enthesiophyte and erosion progression in psoriatic arthritis -a one-year double-blind, randomized, placebo-controlled trial utilizing high-resolution peripheral quantitative computed tomography.

Jin Y, Cheng IT, So H, Lai BT, Ying SK, Kwok KY, Griffith J, Hung V, Szeto CC, Lee JJ, Qin L, Tam LS.
Arthritis Rheumatol. 2025 Mar 14. doi:
10.1002/art.43154. Online ahead of print.
PMID: 40083242 Otettu 4.6.25

Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs.

Jin M, Akgün K, Ziemssen T, Kipp M, Günther R, Hermann A.

Int J Mol Sci. 2021 Jul 27;22(15):8042. doi: 10.3390/ijms22158042.

PMID: 34360808 [Free PMC article.](#) Otettu 29.8.22

Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated in symptoms after **secukinumab**: case report.

Jin Y, et al. BMC Neurol. 2022. PMID: 36324078 [Free PMC article.](#) Otettu 22.11.22

miR-378a: an amplifier of the **interleukin-17A** response in keratinocytes.

Johansen C.

Br J Dermatol. 2022 Aug;187(2):137-138. doi: 10.1111/bjd.21592. Epub 2022 Apr 28.
PMID: 35484836 Otettu 27.8.22

Johansen C, Usher P A, Kjellerup R B et al. Br J Dermatol 2009; 160: 319–324. Otettu 4.3.16

Position Statement on **Secukinumab** in the Management of Plaque Psoriasis: The Malaysian Perspective.

Johar A, Thevarajah S, Heng A, Chan LC, Ch'ng CC, Mohd Safdar NA, Muniandy P, Taib T, Tan WC, Tey KE.

Dermatol Res Pract. 2019 May 12;2019:8923168.

Free PMC Article Otettu 28.2.20

Ref. katsottu 12.3.20

Johnson RB, Wood N, Serio FG (2004). Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. *J Periodontol* 75:37-43. Otettu 15.3.20

[A case of new onset ulcerative colitis following secukinumab treatment.](#)

Johnston DN, Veettil R.

Br J Hosp Med (Lond). 2019 Sep 2;80(9):544-545. ei ole M Ei ole GS ei ole M

Neutralizing natural anti-IL-17F autoantibodies protect Autoimmune Polyendocrine Syndrome Type 1 (APS-1) patients from asthma.

Jokinen M, Edelman S, Krohn K, Kankainen M, Ranki A.

Clin Immunol. 2020 Oct;219:108512. doi:

10.1016/j.clim.2020.108512. Epub 2020 Jun 13.

PMID: 32544610 No abstract available.

Otettu 28.11.22

·
[Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation.](#)

Jones GW, Stumhofer JS, Foster T, Twohig JP, Hertzog P, Topley N, Williams AS, Hunter CA, Jenkins BJ, Wang EC, Jones SA.

FASEB J. 2011 Jan;25(1):409-19. doi:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

S. A. Jones, C. E. Sutton, D. Cua et al., “Therapeutic potential of targeting IL-17,” *Nature Immunology*, vol. 13, no. 11, pp. 1022–1025, 2012. Otettu 19.9.20

Mucosal Vaccination with Cyclic Dinucleotide Adjuvants Induces Effective T Cell Homing and IL-17-Dependent Protection against *Mycobacterium tuberculosis* Infection.

Jong RM, Van Dis E, Berry SB, Nguyenla X, Baltodano A, Pastenkos G, Xu C, Fox D, Yosef N, McWhirter SM, Stanley SA.

J Immunol. 2022 Jan 15;208(2):407-419. doi:
10.4049/jimmunol.2100029. Epub 2021 Dec 29.
PMID: 34965963

IL-17A-197G/A and IL-17F-7488T/C polymorphisms and
osteoarthritis susceptibility.

Joob B, et al. Int J Rheum Dis. 2020. PMID: 31793220
Otettu 28.11.22

[Excessive interleukin-1 signaling determines the
development of Th1 and Th17 responses in chronic
inflammation.](#)

Joosten LA.

Arthritis Rheum. 2010 Feb;62(2):320-2. doi: Otettu
3.2.16

[Free Article](#)

[Similar articles](#)

Jordan-Williams, K. L., Poston, S., and Taparowsky, E. J. (2013). BATF regulates the development and function of IL-17 producing iNKT cells. BMC Immunol. 14:16. doi: 10.1186/1471-2172-14-16 Otettu 29.2.16

[Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System \(FAERS\) Database.](#)

Joshi A, Gawey L, Saadi C, Naidoo P, Rick JW, Park SY, Cogen AL, Daveluy SD, Hsiao JL, Shi VY.

J Am Acad Dermatol. 2025 Feb

18:S0190-9622(25)00313-5. doi:

10.1016/j.jaad.2025.02.031. Online ahead of print.

PMID: 39978679 Otta M

Joshi S, Pantalena LC, Liu XK, et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol. 2011;31(17):3653-3669. Otettu 21.3.20

Ref. katsottu 22.3.20

[Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review.](#)

Joshi R, Latremouille-Viau D, Meiselbach MK, Xie J, Park Y, Sunkureddi P.

Drugs Real World Outcomes. 2019 Mar;6(1):1-9. doi: 10.1007/s40801-018-0146-9.

PMID: 30617811 **Free PMC Article** Otettu 28.2.20

Ref. katsottu 12.3.20

Interleukin 27 is a novel cytokine with anti-inflammatory effects against spondyloarthritis through the suppression of Th17 responses.

Jouhault Q, Cherqaoui B, Jobart-Malfait A, Glatigny S, Lauraine M, Hulot A, Morelle G, Hagege B, Ermoza K, El Marjou A, Izac B, Saintpierre B, Letourneur F, Rémy S, Anegon I, Boissier MC, Chiocchia G, Breban M, Araujo LM.

Front Immunol. 2023 Feb 2;13:1072420. doi:

10.3389/fimmu.2022.1072420. eCollection 2022.

PMID: 36818477 [Free PMC article.](#) Otettu 14.6.23

Neutrophil breaching of the blood vessel pericyte layer during diapedesis requires mast cell-derived IL-17A.

Joulia R, Guerrero-Fonseca IM, Girbl T, Coates JA, Stein M, Vázquez-Martínez L, Lynam E, Whiteford J, Schnoor M, Voehringer D, Roers A, Nourshargh S, Voisin MB.

Nat Commun. 2022 Nov 17;13(1):7029. doi:

10.1038/s41467-022-34695-7.

PMID: 36396641 [Free PMC article.](#) otettu 12.10.23

Jovanovic DV, DiBattista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier J-P. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1beta and TNFalpha, by human macrophages. *J Immunol* 1998;160:3513–21. Otettu 29.2.16

Jovanovic DV, Martel-Pelletier J, Di Battista JA, et al.: Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. *Arthritis Rheum* 2000, 43:1134–1144. Otettu 29.2.16

Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study.

Joven B, Manteca CF, Rubio E, Raya E, Pérez A, Hernández R, Manrique S, Núñez M, Díaz-Cerezo S, Moyano S, Lacetera A, García-Vicuña R.

Adv Ther. 2023 Oct 7. doi:

10.1007/s12325-023-02693-w. Online ahead of print.

PMID: 37804475 Otettu 12.10.23

.
[Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells.](#)

Ju JH, Heo YJ, Cho ML, Jhun JY, Park JS, Lee SY, Oh HJ, Moon SJ, Kwok SK, Park KS, Park SH, Kim HY.

Arthritis Rheum. 2012 Nov;64(11):3543-52. doi:
10.1002/art.34601.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Treatment Failure in Axial Spondyloarthritis: Insights for
a Standardized Definition.

Juanola X, Ramos MJM, Belzunegui JM,
Fernández-Carballido C, Gratacós J.

Adv Ther. 2022 Feb 24. doi:

10.1007/s12325-022-02064-x. Online ahead of print.

PMID: 35201604 Review. Otettu 3.3.22

Treatment Failure in Axial Spondyloarthritis: Insights for
a Standardized Definition.

Juanola X, Ramos MJM, Belzunegui JM,
Fernández-Carballido C, Gratacós J.

Adv Ther. 2022 Apr;39(4):1490-1501. doi:
10.1007/s12325-022-02064-x. Epub 2022 Feb 24.
PMID: 35201604 [Free PMC article](#). Review. Otettu
26.8.22

Activated CLL cells regulate IL-17F-producing Th17 cells
in miR155-dependent and outcome-specific manners.

Jung B, Ferrer G, Chiu PY, Aslam R, Ng A, Palacios F,,
Cardillo M, Kolitz JE, Allen SL, Barrientos JC, Rai KR,
Chiorazzi N, Sherry B.

JCI Insight. 2022 Jun 22;7(12):e158243. doi:
10.1172/jci.insight.158243.

PMID: 35511436 [Free PMC article](#). Otettu 27.8.22

Jungel A, Distler JH, Kurowska-Stolarska M, et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macro- phages of patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1468. Otettu 29.2.16

Juvel SC, Zhang L. Double negative regulatory T cells in transplantation and autoim- munity: recent progress and future directions. J Mol Cell Biol 2012;4(1):48–58. Otettu 29.2.16

Therapeutic Response to **Secukinumab** in a 36-Year-Old Woman with Hidradenitis Suppurativa.

Jørgensen AR, Yao Y, Thomsen SF.

Case Rep Dermatol Med. 2018 Apr 16;2018 Otettu 3.9.2018

Ref. katsottu 6.3.2020

Free PMC Article

Similar articles

Anti-IL-17A treatment reduces serum inflammatory, angiogenic and tissue remodeling biomarkers accompanied by less synovial high endothelial venules in peripheral spondyloarthritis.

Kaaij MH, Helder B, van Mens LJJ, van de Sande MGH, Baeten DLP, Tas SW.

Sci Rep. 2020 Dec 3;10(1):21094. doi: 10.1038/s41598-020-78204-6.

PMID: 33273664 **Free PMC article.** Otettu 13.12.20

Deciphering the role of IL17RA in psoriasis and chronic mucocutaneous candidiasis: shared pathways and distinct manifestations

Kadhi, Ayat ; Eid, Edward ; Massaad, Michel J ; El-Rassy, Inaam ; Khoury, Dana Maria ; Shimomura, Yutaka ; Rubeiz, Nelly ; Kurban, Mazen ; Nemer, Georges
Frontiers in immunology, 2025-01, Vol.15, p.1516408 Otettu 4.6.25

PEER REVIEWED
OPEN ACCESS

Enthesitis in patients with psoriatic arthritis treated with **secukinumab** or adalimumab: a post hoc analysis of the EXCEED study.

Kaeley GS, Schett G, Conaghan PG, McGonagle D, Behrens F, Goupille P, Gaillez C, Parikh B, Bakewell C. *Rheumatology (Oxford)*. 2023 Apr 25:kead181. doi: 10.1093/rheumatology/kead181. Online ahead of print. PMID: 37097894 [Free article](#). Otettu 12.6.23

Kagami, S., Rizzo, H.L., Kurtz, S.E., Miller, L.S., and Blauvelt, A. (2010). IL-23 and IL-17A, but not IL-12 and

IL-22, are required for optimal skin host defense against *Candida albicans*. *J. Immunol.* 185, 5453–5462. Otettu 21.3.20

Kagami S, Rizzo H L, Lee J J et al. *J Invest Dermatol* 2010; 130: 1373–1383.
Otettu 29.2.16

Secukinumab: A life-changing treatment for Netherton syndrome?

Kaikati J, Merhy R, Sarkis AS, Tomb R.

Ann Dermatol Venereol. 2023 Mar;150(1):61-63. doi: 10.1016/j.annder.2022.08.005. Epub 2022 Nov 22.
PMID: 36428119 otta M

Secukinumab-induced interstitial pneumonia in a patient with psoriasis vulgaris.

Kajihara I, Yamada-Kanazawa S, Maeda-Otsuka S, Jinnin M, Akaike K, Ihn H.

J Dermatol. 2017 Dec;44(12):e322-e323. doi: Otettu
28.5.18

Similar articles

Kakeda M, Schlapbach C, Danelon G, Tang MM, Cecchinato V, Yawalkar N, et al. Innate immune cells express IL-17A/F in acute generalized exan- thematous pustulosis and generalized pustular psoriasis. Arch Dermatol Res 2014;306:933e8. Otettu 21.3.20

IBD-like Lesions in a **Secukinumab**-treated Patient.

Kakizoe K, Fujioka S, Noda M, Torisu T.

Intern Med. 2021 Nov 20. doi:

10.2169/internalmedicine.8475-21. Online ahead of print.

PMID: 34803103 Otettu 3.3.22

Secukinumab-Induced Lupus Erythematosus: A Case Report and Literature Review.

Kaler J, Kaeley GS.

J Clin Rheumatol. 2020 Aug 17. doi:

10.1097/RHU.0000000000001511. Online ahead of Otettu 28.11.22

Cytokines in Immune-mediated "Non-infectious" Uveitis.

Kalogeropoulos D, Kanavaros P, Vartholomatos G,
Moussa G; Soon Wai Ch'ng; Kalogeropoulos C.

Klin Monbl Augenheilkd. 2023 Dec 22. doi:
10.1055/a-2202-8704. Online ahead of print.

PMID: 38134911 English. Otta M

State-of-the-Art Review on the Treatment of Axial
Spondyloarthritis.

Kaltsonoudis E, Karagianni P, Memi T, Pelechas E.

Med Sci (Basel). 2025 Mar 16;13(1):32. doi:
10.3390/medsci13010032.

PMID: 40137452 **Free PMC article.** Review. Otettu
4.6.25

Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid.

Kamata M, Asano Y, Shida R, Maeda N, Yoshizaki A, Miyagaki T, Kawashima T, Tada Y, Sato S.

J Dermatol. 2019 Jun;46(6):e216-e217. Otettu 28.2.20

Secukinumab Persistence in Patients with Psoriatic Arthritis: An Adalimumab-Matched Retrospective Cohort Database Study (FLYWAY).

Kameda H, Ishii K, Kiriyaama J, Mikami T, Uratsuji H, Morita A.

Rheumatol Ther. 2025 Mar 12. doi:

10.1007/s40744-025-00749-7. Online ahead of print.

PMID: 40072816 **Free article.** Otettu 4.6.25

Serum and Synovial Fluid Levels of **Interleukin-17A** in Primary Knee Osteoarthritis Patients: Correlations With Functional Status, Pain, and Disease Severity.

Kamel S, Khalaf R, Moness H, Ahmed S.

Arch Rheumatol. 2022 Mar 3;37(2):187-194. doi: 10.46497/ArchRheumatol.2022.7931. eCollection 2022 Jun.

PMID: 36017202 [Free PMC article.](#) Otettu 27.8.22

Role of **Interleukin-17** family cytokines in disease severity of patients with knee osteoarthritis.

Kamiab Z, Khorramdelazad H, Kafi M, Jafarzadeh A, Mohammadi-Shahrokhi V, Bagheri-Hosseini Z, Saeed Askari P, Abbasifard M.

Adv Rheumatol. 2024 Jan 24;64(1):11. doi: 10.1186/s42358-024-00351-5.

PMID: 38268022 Otettu 13.3.24

[Inhibition of IL-17A by **secukinumab** shows no evidence of increased *Mycobacterium tuberculosis* infections.](#)

Kammüller M, Tsai TF, Griffiths CE, Kapoor N, Kolattukudy PE, Brees D, Chibout SD, Safi J Jr, Fox T.

Clin Transl Immunology. 2017 Aug 25;6(8):e152. doi: Otettu 27.5.18

[**Free PMC Article**](#)

[Similar articles](#)

Epidemiological survey of patients with pustular psoriasis in the Japanese Society for Psoriasis Research from 2017 to 2020.

Kamiya K, et al. J Dermatol. 2022. PMID: 36152301
Otettu 20.11.22

Kamiyama T, Watanabe H, Iijima M, Miyazaki A, Iwamoto S. Coexpression of CCR6 and CD146 (MCAM) is a marker of effector memory T-helper 17 cells. *J Dermatol* 2012; 39:838–42. Otettu 4.3.16

Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis.

Kampylafka E, Tascilar K, Lerchen V, Linz C, Sokolova M, Zekovic A, Kleyer A, Simon D, Rech J, Sticherling M, Schett G, Hueber AJ.

Arthritis Res Ther. 2020 Sep 9;22(1):207. doi: 10.1186/s13075-020-02268-y.

PMID: 32907626 [Free PMC article](#). Otettu 19.9.20

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with **secukinumab**: results from the prospective PSARTROS study.

Kampylafka E, d'Oliveira I, Linz C, Lerchen V, Stemmler F, Simon D, Englbrecht M, Sticherling M, Rech J, Kleyer A, Schett G, Hueber AJ.

Arthritis Res Ther. 2018 Jul 27;20(1):153. doi: Otettu
3.9.18

Free PMC Article

Similar articles

Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study.

Kampylafka E, Simon D, d'Oliveira I, Linz C, Lerchen V, Englbrecht M, Rech J, Kleyer A, Sticherling M, Schett G, Hueber AJ.

Arthritis Res Ther. 2019 Jul 26;21(1):178. doi: **Free PMC Article** **Otettu 28.2.20**

Ref. katsottu 26.3.20

[\[Th17 cells\].](#)

Kamradt T.

Z Rheumatol. 2007 Feb;66(1):54-5. German. No abstract available.

PMID:

17896424 Otettu 3.2.16

[Similar articles](#)

Kanai T, Nemoto Y, Kamada N, Totsuka T, Hisamatsu T, Watanabe M, Hibi T. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease. Curr Opin Gastroenterol. 2009; 25:306–313.
Otettu 17.3.20

[Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated.](#)

Kanda N.

Int J Mol Sci. 2021 Mar 15;22(6):2979. doi:
10.3390/ijms22062979.

PMID: 33804147 [Free PMC article.](#) Otettu 31.8.22

Kaneko S, Kondo Y, Yokosawa M, Furuyama K,
Segawa S, Tsuboi H, et al. The ROR
gammat-CCR6-CCL20 axis augments Th17 cells
invasion into the synovia of rheumatoid arthritis
patients. *Mod Rheumatol* (2018):1–12.

Otettu 19.9.20

H. K. Kang, M. Liu, and S. K. Datta, “Low-dose peptide
tolerance therapy of lupus generates plasmacytoid

dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells,” *Journal of Immunology*, vol. 178, no. 12, pp. 7849–7858, 2007. Otettu 22.3.20

.

[Interleukin-17 in various ocular surface inflammatory diseases.](#)

Kang MH, Kim MK, Lee HJ, Lee HI, Wee WR, Lee JH. J Korean Med Sci. 2011 Jul;26(7):938-44. doi: 10.3346/jkms.2011.26.7.938. Epub 2011 Jun 20. PMID:

[Free PMC Article](#)

[Similar articles](#)

Select item 21737885 Otettu 3.2.16

IL-23 induces regulatory T cell plasticity with implications for inflammatory skin diseases.

Kannan AK, et al. [Sci Rep. 2019. PMID: 31776355](#) [Free PMC article.](#) Otettu 7.9.22

Kao C Y, Chen Y, Thai P et al. J Immunol 2004; 173: 3482–3491. Otettu 29.2.16

Kao CY, Huang F, Chen Y, Thai P, Wachi S, Kim C, et al: Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-kappaB-dependent signalling pathway. J Immunol 2005;175:6676–6685. Otettu 12.3.20
Ref. ei oteta

Metabolic reprogramming of **interleukin-17**-producing gammadelta T cells promotes ACC1-mediated de novo lipogenesis under psoriatic conditions.

Kao YS, Lauterbach M, Lopez Krol A, Distler U, Godoy GJ, Klein M, Argüello RJ, Boukhallouk F, Vallejo Fuente S, Braband KL, Nurbekova A, Romero M, Mamareli P, Silva L, Damasceno LEA, Rampoldi F, Berod L, Lynch L, Hiller K, Sparwasser T.

Nat Metab. 2025 May;7(5):966-984. doi:

10.1038/s42255-025-01276-z. Epub 2025 May 13.

PMID: 40360755 **Free PMC article.** Otettu 31.7.25

The effect of **secukinumab** treatment on hematological parameters in ankylosing spondylitis and psoriatic arthritis.

Karataş A, Gerçek AN, Öz B, Gözel N, Pişkin Sağır R, Gür M, Koca SS.

Eur J Rheumatol. 2020 Sep 8. doi:

10.5152/eurjrheum.2020.20109. Online ahead of print.

PMID: 32910771 Otettu 19.9.20

The frequency, predictors, and treatment options of spondyloarthritis in primary Sjögren's syndrome: a single-center experience.

Karataş B.

J Investig Med. 2025 Jun 9:10815589251349102. doi: 10.1177/10815589251349102. Online ahead of print.

PMID: 40488278 Otta M

31. Karbach, S., A. L. Croxford, M. Oelze, R. Sch€uler, D. Minwegen, J. Wegner, L. Koukes, N.

Yogev, A. Nikolaev, S. Reißig, et al. 2014.
Interleukin 17 drives vascular inflammation,
endothelial dysfunction, and arterial hypertension in
psoriasis-like skin disease. Arterioscler. Thromb.
Vasc. Biol. 34: 2658–2668. Otettu 19.3.20

[Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.](#)

Karle A, Spindeldreher S, Kolbinger F.
MAbs. 2016 Jan 28:0. [Epub ahead of print]

28. MABS. 2016;8(3):536–50. doi:10.1080/

ei oteta

[Similar articles](#)

Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis.

Kartasheva-Ebertz DM, Pol S, Lagaye S.

Front Immunol. 2021 Jun 15;12:691073. doi:

10.3389/fimmu.2021.691073. eCollection 2021.

PMID: 34211477 [Free PMC article](#). Otettu 30.8.22

Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review.

Kashetsky N, Mufti A, Alabdulrazzaq S, Lytvyn Y, Sachdeva M, Rahat A, Yeung J.

J Cutan Med Surg. 2022 Jan-Feb;26(1):79-86. doi:

10.1177/12034754211035667. Epub 2021 Aug 8.

PMID: 34365863 Otettu 3.3.22

Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. *Annu Rev Immunol* 2007;25:221– 42
Otettu 29.2.16

[Neutrophils are essential as a source of IL-17 in the effector phase of arthritis.](#)

Katayama M, Ohmura K, Yukawa N, Terao C, Hashimoto M, Yoshifuji H, Kawabata D, Fujii T, Iwakura Y, Mimori T.
PLoS One. 2013 May 6;8(5):e62231. d. Print 2013.
Erratum in: PLoS One. 2013;8(12).
PMID:

[Free PMC Article](#)

[Similar articles](#)

Select item 23666857324. Otettu 3.2.16

CD4⁺CD25⁺LAG3⁺ T Cells With a Feature of Th17 Cells Associated With Systemic Lupus Erythematosus Disease Activity.

Kato R, Sumitomo S, Tsuchida Y, Tsuchiya H, Nakachi S, Sakurai K, Hanata N, Nagafuchi Y, Kubo K, Tateishi S, Kanda H, Okamura T, Yamamoto K, Fujio K.

Front Immunol. 2019 Jul 12;10:1619. doi: 10.3389/fimmu.2019.01619. eCollection 2019. PMID: 31354747 Otettu 21.9.20

[The roles of IFN-γ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts.](#)

Kato H, Endres J, Fox DA.

Mod Rheumatol. 2013 Nov;23(6):1140-50. doi: 10.1007/s10165-012-0811-x. Epub 2013 Jan 11.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody **Secukinumab** in Treatment of Ankylosing Spondylitis: A Meta-Analysis.

Katsevman GA, Mariscal G, Barrios C,

Domenech-Fernández P, Ziembinski C, Bhatia S.

Monoclon Antib Immunodiagn Immunother. 2020

Oct;39(5):160-166. doi: 10.1089/mab.2020.0022. Epub 2020 Oct 1.

PMID: 33001775 Otettu 13.12.20

Systemic and local **interleukin-17** and linked cytokines associated with Sjögren's syndrome immunopathogenesis.

Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM.

Am J Pathol. 2009 Sep;175(3):1167-77. doi: 10.2353/ajpath.2009.. Epub 2009 Aug 21.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

[Improvement of recalcitrant psoriatic lesions on the lower legs by changing the injection site of **secukinumab** from the abdomen to lower legs.](#)

Katsuo K, Honda T, Kabashima K.

J Dermatol. 2020 Feb;47(2):e54-e55. Otettu 20.2.20

Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukin 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a “fine-tuning cytokine” in inflammation processes. Arthritis Rheum 2001;44:2176–84. Otettu 4.3.16

[IL-23/IL-17 in a Paradoxical Association with Primary Membranous Nephropathy.](#)

Kaur P, Prabhakar A, Pal D, Nada R, Kohli HS, Kumar V, Ramachandran R.

Inflammation. 2024 Feb 23. doi: 10.1007/s10753-024-01992-w. Online ahead of print.

PMID: 38393549 Otta M

[Biologic and Non-Biologic Therapies for Scalp Psoriasis:
A Network Meta-analysis of Randomized Controlled
Trials.](#)

Kaur H, Behroozian T, Lansang RP, Caini S, Doccioli C, Abu-Hilal M.

Dermatol Pract Concept. 2025 Apr 1;15(2):4793. doi: 10.5826/dpc.1502a4793.

PMID: 40401874 [Free PMC article](#). Review. Otettu
4.6.25

Spondyloarthritis and the Human Leukocyte Antigen (HLA)-B*27 Connection.

Kavadichanda CG, Geng J, Bulusu SN, Negi VS, Raghavan M.

Front Immunol. 2021 Mar 8;12:601518. doi:

10.3389/fimmu.2021.601518. eCollection 2021.

PMID: 33763060 [Free PMC article](#). Otettu 30.8.22

Comparative effectiveness of abatacept, apremilast, **secukinumab** and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.

Kawalec P, Holko P, Moćko P, Pilc A.

Rheumatol Int. 2018 Feb;38(2):189-201. doi:

10.1007/s00296-017-3919-7. Epub 2017 Dec 28.

Review.

PMID:

29285605 Otettu 27.5.18

Free PMC Article

[Similar articles](#)

Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials.

Kavanaugh A, Baraliakos X, Gao S, Chen W, Sweet K, Chakravarty SD, Song Q, Shawi M, Rahman P.

Adv Ther. 2023 May;40(5):2439-2456. doi:

10.1007/s12325-023-02475-4. Epub 2023 Mar 30.

PMID: 36995469 **Free PMC article.** Otettu 14.6.23

Kavanaugh A, McInnes I, Hall S, Chinoy H, Kivitz A, Kandala S, Patekar M, Mpofu S. Secukinumab efficacy in anti-TNF-naive and anti-TNF-IR patients with psoriatic arthritis: results of a phase 3 multicenter, double-blind, placebo-controlled study (FUTURE 2). Ann Rheum Dis. 2015;74:345. Abstrakti. Ei oteta.

Efficacy of Subcutaneous **Secukinumab** in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.

Kavanaugh A, McInnes IB, Mease PJ, Hall S, Chinoy H, Kivitz AJ, Wang Z, Mpofu S.

J Rheumatol. 2016 Sep;43(9):1713-7. doi:

Otettu 27.5.18

Free Article

[Similar articles](#)

Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.

Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Pricop L, Mpofu S; FUTURE-1 Study Group.

Arthritis Care Res (Hoboken). 2017 Mar;69(3):347-355.

Otettu 27.5.18

Free Article

[Similar articles](#)

Kawashiri, S. Y. *et al.* Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells *in vitro* and serum CCL20 is reduced *in vivo* by biologic disease-modifying antirheumatic drugs. *J. Rheumatol.* 36, 2397–2402 (2009). Otettu 25.3.20

Ref. katsottu 29.3.2020

Which Is the Best Option for AxSpA Patients After First TNFi Failure: Switch to **Secukinumab** or Cycling With Other TNFi?

Kaya MN, Tecer D, Kılıç Ö, Yılmaz S.

Int J Rheum Dis. 2025 Apr;28(4):e70212. doi:

10.1111/1756-185X.70212.

PMID: 40223485 Otta M

[Tumor Necrosis Factor and Interleukin Modulators for Pathologic Pain States: A Narrative Review.](#)

Kaye AD, Perilloux DM, Hawkins AM, Wester GC, Ragaland AR, Hebert SV, Kim J, Heisler M, Kelkar RA, Chami AA, Shekoochi S, Kaye AM.

Pain Ther. 2024 Jun;13(3):481-493. doi:

10.1007/s40122-024-00603-8. Epub 2024 May 9.

PMID: 38724743 [Free PMC article](#). Review. Otettu 29.5.24

Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and monocyte/lymphocyte ratio: A post hoc analysis of three randomised clinical trials.

Kearney N, Gorecki P, Acciarri L, Buyze J, Akawung A, Merola JF, Kirby B.

Dermatology. 2025 Apr 10:1-35. doi:

10.1159/000545148. Online ahead of print.

PMID: 40209685 [Free article](#). Otettu 4.6.25

Comparison of Guidelines for the Use of Interleukin-17 Inhibitors for Psoriasis in the United States, Britain, and Europe: A Critical Appraisal and Comprehensive Review.

Kearns DG, Uppal S, Chat VS, Wu JJ.

J Clin Aesthet Dermatol. 2021 Jun;14(6):55-59. Epub 2021 Jun 1.

PMID: 34804357 [Free PMC article.](#) Otettu 3.3.22

[Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis.](#)

Kehlen A, Thiele K, Riemann D, Langner J.
Clin Exp Immunol. 2002 Mar;127(3):539-46.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Kehlen A, Pachnio A, Thiele K, Langner J. 2003. Gene expression induced by interleukin-17 in fibroblast-like synoviocytes of patients with rheumatoid arthritis: upregulation of hyaluronan-binding protein TSG-6. Arthritis Res Ther 5(4):R186–R192. Otettu 29.2.16

KeijsersRR,HendriksAG,vanErpPEetal.J

Invest Dermatol 2013; 134: 1276–1284. Otettu 29.2.16

Keijsers R R, van der Velden H M, van Erp P E
et al. Br J Dermatol 2013; 168: 1294–1302. Otettu
29.2.16

.
[Cellular sources of IL-17 in psoriasis: a paradigm shift?](#)

Keijsers RR, Joosten I, van Erp PE, Koenen HJ, van de
Kerkhof PC.

Exp Dermatol. 2014 Nov;23(11):799-803. doi:

Otettu 3.2.16

[Similar articles](#)

.
[Targeting interleukin-17 in patients with active
rheumatoid arthritis: rationale and clinical potential.](#)

Kellner H.

Ther Adv Musculoskelet Dis. 2013 Jun;5(3):141-52. doi

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

[Enrichment of circulating **interleukin-17**-secreting interleukin-23 receptor-positive \$\gamma/\delta\$ T cells in patients with active ankylosing spondylitis.](#)

Kenna TJ, Davidson SI, Duan R, Bradbury LA, McFarlane J, Smith M, Weedon H, Street S, Thomas R, Thomas GP, Brown MA.

Arthritis Rheum. 2012 May;64(5):1420-9. doi:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

.

[The role of IL-17-secreting mast cells in inflammatory joint disease.](#)

Kenna TJ, Brown MA.

Nat Rev Rheumatol. 2013 Jun;9(6):375-9. doi: Epub

Otettu 3.2.16

[Similar articles](#)

Kennedy, J. et al. Mouse IL-17: a cytokine preferentially expressed by alpha beta TCR + CD4–CD8-T cells. J. Interferon Cytokine Res. 16, 611–617 (1996). Otettu 4.3.16

The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our understanding and management of disease.

Kenyon M, Maguire S, Rueda Pujol A, O'Shea F, McManus R.

Rheumatol Int. 2022 Aug 8. doi:

10.1007/s00296-022-05174-5. Online ahead of print.

PMID: 35939079 Review. Otettu 27.8.22

Assessment of T helper 17-associated cytokines in thromboangiitis obliterans.

Keramat S, et al. *J Inflamm Res.* 2019. PMID: 31564950
Free PMC article. Otettu 8.9.22

[Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.](#)

Kerschbaumer A, Sepriano A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JWW, Burmester GR, de Wit M, Falzon L, Landewé R.

Ann Rheum Dis. 2020 Feb 7. pii: annrheumdis-2019-216656. doi: 10.1136/annrheumdis-2019-216656. [Epub ahead of print]

PMID: 32033937 **Free Article** Otettu 28.2.20

Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORyt, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients.

Khadem Azarian S, et al. *Immunopharmacol Immunotoxicol*. 2020. PMID: 31856612 Clinical Trial.
Ei ole M

S. A. Khader, G. K. Bell, J. E. Pearl et al., "IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during *Mycobacterium tuberculosis* challenge," *Nature Immunology*, vol. 8, no. 4, pp. 369–377, 2007. Otettu 28.3.20

Khader, S.A., S.L. Gaffen, and J.K. Kolls. 2009. Th17 cells at the crossroads of innate and adaptive immunity

against infectious diseases at the mucosa. *Mucosal Immunol.* 2:403–411. Otettu 12.3.20

Ref. ei katsot

Khader SA, Gopal R. IL-17 in protective immunity to intracellular pathogens. *Virulence.* 2010 Sep-Oct;1(5):423–427. Otettu 12.3.20

Tissue-resident memory T cells in the skin.

Khalil S, et al. *Inflamm Res.* 2020. PMID: 31989191
Review. Otettu 7.9.22

Khan R, Gupta S, Sharma A. Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-beta) in patients with vitiligo. J Am Acad Dermatol 2012;66:510–1. Otettu 12.3.20

Autoimmune Neuroinflammatory Diseases: Role of Interleukins.

Khan AW, Farooq M, Hwang MJ, Haseeb M, Choi S. Int J Mol Sci. 2023 Apr 27;24(9):7960. doi: 10.3390/ijms24097960. PMID: 37175665 [Free PMC article](#). Review. otettu 14.6.23

[Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs.](#)

Khan D, Ansar Ahmed S.

Front Genet. 2015 Jul 14;6:236. doi:

[Free PMC Article](#)

[Similar articles](#)

Otettu 3.2.16

[Advances in the management of psoriatic arthritis in adults.](#)

Kharouf F, Gladman DD.

BMJ. 2024 Nov 21;387:e081860. doi:

10.1136/bmj-2024-081860.

PMID: 39572047 Review. Otettu 21.1.25

[Genetic variations in **interleukin-17** gene: a review on SNP rs2275913 and its clinical implications.](#)

Khatonier R, Khan AM.

Gene. 2025 Jul 30:149708. doi:
10.1016/j.gene.2025.149708. Online ahead of print.
PMID: 40750055 Review. Otta M

Intra-articular injections of biological disease-modifying
anti-rheumatic drugs in inflammatory arthropathies: an
up-to-date narrative review.

Khayyat SGA, Conticini E, Falsetti P, Fogliame G,
Gentileschi S, Baldi C, Bardelli M, Migliore A, Cantarini L,
Frediani B.

Joint Bone Spine. 2023 Jun 2:105598. doi:
10.1016/j.jbspin.2023.105598. Online ahead of print.
PMID: 37271277 Otta M

In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome.

Khotimchenko M, Brunk NE, Hixon MS, Walden DM, Hou H, Chakravarty K, Varshney J.

Pharm Res. 2022 Mar 21. doi:

10.1007/s11095-022-03231-z. Online ahead of print.

PMID: 35313359 Otettu 28.11.22

New-Onset Crohn's Disease following Initiation of **Secukinumab**: A Case Report and Review of the Role of IL-17 in the Pathogenesis of Crohn's Disease.

Khoury A, Moreno C, Niland B.

Case Rep Gastrointest Med. 2023 May

22;2023:1769290. doi: 10.1155/2023/1769290.

eCollection 2023.

PMID: 37260537 Free PMC article. Otettu 12.6.23

Rheumatoid arthritis synovial fluid shows enrichment of T-cells producing GM-CSF which are polyfunctional for TNF α and IFN γ .

Khullar A, Dhir V, Saikia B, Yadav AK, Leishangthem B, Prasad CB, Jayaprakash S, Jain S, Naidu GSRSNK, Sharma SK, Sharma A, Jain S.

Clin Exp Rheumatol. 2024 Feb 12. doi: 10.55563/clinexprheumatol/dyjbvf. Online ahead of print.

PMID: 38372731 Otettu 13.3.24

Insulin and IGF-1 have both overlapping and distinct effects on CD4⁺ T cell mitochondria, metabolism, and function.

Kiernan K, Alwarawrah Y, Nichols AG, Danzaki K, MacIver NJ.

Sci Rep. 2024 Feb 21;14(1):4331. doi: 10.1038/s41598-024-54836-w.

PMID: 38383709 **Free PMC article.** Otettu 13.3.24

A Novel Mechanism for Th17 Inflammation in Human Type 2 Diabetes Mellitus.

Kiernan K, et al. Trends Endocrinol Metab. 2020. PMID: 31767267 Otettu 28.11.22

Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006;18:670–675. Otettu 29.2.16

Generalized Pustular Psoriasis as a Systemic
Inflammatory Disease: Experience With 38 Japanese
Cases Over 15 Years at a Single Institution.

Kikuchi N, Kusano M, Yamamoto T.

Cureus. 2025 Jul 16;17(7):e88108. doi:

10.7759/cureus.88108. eCollection 2025 Jul.

PMID: 40821152 [Free PMC article.](#) Otettu 22.8.25

Killeen, M. E., L. Ferris, E. A. Kupetsky, L. Falo, Jr., and A. R. Mathers. 2013. Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J. Immunol. 190: 4324–4336. Otettu 29.2.16

Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with **Secukinumab**.

Kiltz U, Sfikakis PP, Gaffney K, Bounas A, Gullick N, Lespessailles E, Brandt-Juergens J, Rashkov R, Schulz B, Pournara E, Jagiello P.

Rheumatol Ther. 2022 Aug;9(4):1129-1142. doi:

10.1007/s40744-022-00460-x. Epub 2022 Jun 8.

PMID: 35674938 [Free PMC article.](#) [Otettu 26.8.22](#)

Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.

Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, Gullick N, Conrad C, Rigopoulos D, Lespessailles E, Romanelli M, Ghislain PD, Brandt-Jürgens J, Rashkov R, Aassi M, Orsenigo R, Perella C, Pournara E, Gathmann S, Jagiello P, Veit J, Augustin M.

Adv Ther. 2020 Jun;37(6):2865-2883. doi:

10.1007/s12325-020-01352-8. Epub 2020 May 6.

PMID: 32378070 [Free PMC article.](#) Otettu 20.9.20

Current treatment of axial spondylarthritis : Clinical efficacy].

Kiltz U, et al. Z Rheumatol. 2020. PMID: 31531695
Review. German. Otettu 28.11.22

147.

[Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?](#)

Kiltz U, Heldmann F, Baraliakos X, Braun J.
Curr Opin Rheumatol. 2012 May;24(3):252-60. doi:
10.1097/BOR.0b013e3283524b82. Review.

PMID:

22450391 Otettu 3.2.16

[Similar articles](#)

[\[Head-to-head studies on radiographic progression in axial spondyloarthritis\].](#)

Kiltz U, Haibel H.

Z Rheumatol. 2024 May 21. doi:

10.1007/s00393-024-01518-7. Online ahead of print.

PMID: 38771349 Review. German. Otta M

[Current treatment of axial spondylarthritis : Clinical efficacy\].](#)

Kiltz U, Braun J.

Z Rheumatol. 2020 Feb;79(1):13-22. Otettu 28.2.2020

Ref. katsottu 6.3.2020

Real-world effectiveness and rheumatologist satisfaction with **secukinumab** in the treatment of patients with axial spondyloarthritis.

Kiltz U, Keininger DL, Holdsworth EA, Booth N, Howell O, Modi N, Tian H, Conaghan PG.

Clin Rheumatol. 2022 Feb;41(2):471-481. doi: 10.1007/s10067-021-05957-4. Epub 2021 Nov 20. PMID: 34800174 Otettu 28.11.22

Regulation of Th17 Cytokine-Induced Osteoclastogenesis via SKI306X in Rheumatoid Arthritis.

Kim HR, Kim KW, Kim BM, Won JY, Min HK, Lee KA, Kim TY, Lee SH.

J Clin Med. 2019 Jul 10;8(7):1012. doi: 10.3390/jcm8071012. PMID: 31295961 Otettu 23.9.20

Interleukin-17 Can Be the Target of Novel Treatment Strategies for Particulate Matter-Induced Allergic Diseases.

Kim BG, Park MK.

Allergy Asthma Immunol Res. 2022 Jan;14(1):5-7. doi: 10.4168/aair.2022.14.1.5.

PMID: 34983103 [Free PMC article](#). Otettu 27.8.22

Secukinumab improves mild-to-moderate psoriasis: A randomized, placebo-controlled exploratory clinical trial.

Kim J, Lee J, Hawkes JE, Li X, Kunjraiva N, Rambhia D, Cueto I, Moreno A, Hur H, Garcet S, Zhou W, Cao J, Krueger JG.

J Am Acad Dermatol. 2022 May

9:S0190-9622(22)00791-5. doi:

10.1016/j.jaad.2022.04.060. Online ahead of print.

PMID: 35551962 [Free article](#). Otettu 26.8.22

[Increased **interleukin-17** production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis.](#)

Kim KW, Cho ML, Park MK, Yoon CH, Park SH, Lee SH, Kim HY.

Arthritis Res Ther. 2005;7(1):R139-48. Epub 2004 Nov
Otetu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY, Yoon CH, et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF- κ B- and p38 MAPK-dependent signalling pathways. *Rheumatology (Oxford)* 2007;46:57–64.

Otettu 29.2.16

Altered distribution, activation and increased IL-17 production of mucosal-associated invariant T cells in patients with acute respiratory distress syndrome.

Kim TO, Park KJ, Cho YN, Jin HM, Jo YG, Kim HS, Ju JK, Shin HJ, Kho BG, Kee SJ, Park YW.

Thorax. 2022 Sep;77(9):865-872. doi:

10.1136/thoraxjnl-2021-217724. Epub 2022 Jan 27.

PMID: 35086913 Otettu 27.8.22

Progression of Pre-Existing Vitiligo during **Secukinumab** Treatment for Psoriasis.

Kim JC, Lee ES.

Ann Dermatol. 2023 May;35(Suppl 1):S117-S121. doi: 10.5021/ad.21.078.

PMID: 37853881 Free PMC article. Otettu 4.3.24

Kim KW, Cho ML, Kim HR, Ju JH, Park MK, Oh HJ, et al. 2007c. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. *Arthritis Rheum* 56(4):1076–1086. Otettu 29.2.16

Kim KW, Kim HR, Park JY, Park JS, Oh HJ, Woo YJ, et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. *Arthritis Rheum* 2012;64:1015–23. Otettu 29.2.16

Interleukin-17 inhibitors in myasthenia gravis: really bad or maybe good?

Kim S, Eun MY, Seok HY.

Neurol Sci. 2023 Apr 11. doi:
10.1007/s10072-023-06796-8. Online ahead of print.
PMID: 37041395 Otta M

[Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid **arthritis**.](#)

Kim J, Kang S, Kim J, Kwon G, Koo S.

Ann Lab Med. 2013 Jan;33(1):52-9. doi:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

[Angiogenesis in rheumatoid **arthritis** is fostered directly by toll-like receptor 5 ligation and indirectly through **interleukin-17** induction.](#)

Kim SJ, Chen Z, Chamberlain ND, Volin MV, Swedler W, Volkov S, Sweiss N, Shahrara S.

Arthritis Rheum. 2013 Aug;65(8):2024-36. doi: 10.1002/art.37992.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Activation and increased production of **interleukin-17** and tumour necrosis factor- α of mucosal-associated invariant T cells in patients with periodontitis.

Kim OS, Park KJ, Jin HM, Cho YN, Kim YS, Kwon SH, Koh JT, Ju JK, Kee SJ, Park YW.

J Clin Periodontol. 2022 Jul;49(7):706-716. doi: 10.1111/jcpe.13648. Epub 2022 Jun 1.

PMID: 35569027 Otettu 28.11.22

Kim JS, Jordan MS. Diversity of IL-17-producing T lymphocytes. Cell Mol Life Sci. 2013;70:2271–90.

Otettu 15.3.20

Ref. katsottu 22.3.20

1,25-dihydroxy Vitamin D3 and **Interleukin-6** Blockade Synergistically Regulate Rheumatoid Arthritis by Suppressing **Interleukin-17** Production and Osteoclastogenesis.

Kim H, et al. J Korean Med Sci. 2020. PMID: 32056400
[Free PMC article.](#) Otettu 6.9.22

Neutrophil extracellular traps and extracellular histones potentiate **IL-17** inflammation in periodontitis.

Kim TS, Silva LM, Theofilou VI, Greenwell-Wild T, Li L, Williams DW, Ikeuchi T, Brenchley L; NIDCD/NIDCR Genomics and Computational Biology Core; Bugge TH,

Diaz PI, Kaplan MJ, Carmona-Rivera C, Moutsopoulos NM.

J Exp Med. 2023 Sep 4;220(9):e20221751. doi: 10.1084/jem.20221751. Epub 2023 Jun 1. PMID: 37261457 Otta M

Kim, H.Y., Lee, H.J., Chang, Y.J., Pichavant, M., Shore, S.A., Fitzgerald, K.A., Iwakura, Y., Israel, E., Bolger, K., Faul, J., et al. (2014). Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity- associated airway hyperreactivity. Nat. Med. 20, 54–61. Otettu 29.3.20

A cost per responder analysis of **secukinumab** vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective.

Kim D, Kim H, Cho S, Park MC.

Int J Rheum Dis. 2019 Jun 18. doi: Otettu 28.2.20

Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.

Kimball AB, Ravichandran S; SUNSHINE and SUNRISE trial teams.

Lancet. 2024 Feb 17;403(10427):617-618. doi:

10.1016/S0140-6736(23)01615-X.

PMID: 38368012 No abstract available. Otettu 4.3.24

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.

Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG, Paul C, Giamarellos Bourboulis EJ, Villani AP, Schwinn A, Ruëff F, Pillay Ramaya L, Reich A, Lobo I, Sinclair R, Passeron T, Martorell A, Mendes-Bastos P, Kokolakis G, Becherel PA, Wozniak MB, Martinez AL, Wei X, Uhlmann L, Passera A, Keefe D, Martin R, Field C, Chen L, Vandemeulebroecke M, Ravichandran S, Muscianisi E. *Lancet*. 2023 Mar 4;401(10378):747-761. doi: 10.1016/S0140-6736(23)00022-3. Epub 2023 Feb 3. PMID: 36746171 Clinical Trial. Otta M

Kimura, A., Naka, T. and Kishimoto, T., IL-6-dependent and -independent pathways in the development of

interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. USA 2007. 104: 12099–12104. Otettu 29.2.16

Kimura, A., Naka, T., Nohara, K., Fujii-Kuriyama, Y. and Kishimoto, T., Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc. Natl. Acad. Sci. USA 2008. 105: 9721–9726. Otettu 29.2.16

.

[IL-6: regulator of Treg/Th17 balance.](#)

Kimura A, Kishimoto T.

Eur J Immunol. 2010 Jul;40(7):1830-5. doi:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Kimura A, Kishimoto T. Int Immunopharmacol
2011; 11: 319–322. Otettu 29.2.16

H.G.M. Kingston, Induction, function and regulation of
IL- 17 producing T cells, Eur. J. Immunol. 38 (2008)
2636–2649. Otettu 29.2.16

[Impetigo herpetiformis with IL-36RN mutation
successfully treated with **secukinumab**.](#)

Kinoshita M, Ogawa Y, Takeichi T, Okamoto T, Osada A,
Shimada S, Sugiura K, Akiyama M, Kawamura T,
Tsukamoto K.

Eur J Dermatol. 2018 Jun 1;28(3):381-382. doi:
10.1684/ejd.2018.3259. No abstract available.

PMID:

30105995 ei ole M Ei ole PUBMED Ei oteta

[Similar articles](#)

Sarcoidosis manifesting during treatment with **secukinumab** for psoriatic arthritis.

Kirby C, Herlihy D, Clarke L, Mullan R.

BMJ Case Rep. 2021 Feb 22;14(2):e240615. doi: 10.1136/bcr-2020-240615.

PMID: 33619146 [Free PMC article.](#) Otettu 8.8.21

Tissue-resident memory Th17 cells maintain stable fungal commensalism in the oral mucosa.

Kirchner FR, LeibundGut-Landmann S.

Mucosal Immunol. 2021 Mar;14(2):455-467. doi: 10.1038/s41385-020-0327-1. Epub 2020 Jul 27.

PMID: 32719409 [Free PMC article.](#) Otettu 3.9.22

Kircik L, Fowler J, Weiss J, et al. Efficacy of secukinumab for moderate-to-severe head and neck psoriasis over 52 weeks: pooled analysis of four phase 3 studies. *Dermatol Ther (Heidelb)*. 2016;6:627–638. Otettu 6.3.20

Ref. katsottu 10.3.20

Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, Shnier R, Portek IJ. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two- year

prospective study (the DAMAGE study cohort). Arthritis Rheum 2006;54:1122–31. Otettu 4.3.16

.
[Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.](#)

Kirkham BW, Kavanaugh A, Reich K.
Immunology. 2014 Feb;141(2):133-42. doi:
Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Efficacy of **secukinumab** on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study.

Kirkham B, Nash P, Reina D, Navarra S, Quebe-Fehling E, Gaillez C, Sastre C, Mease PJ.

Clin Exp Rheumatol. 2022 Jul 28. doi:
10.55563/clinexprheumatol/vezf95. Online ahead of
print.

PMID: 35916290 Otettu 26.8.22

Kirkham B, McInnes IB, Mease P, Kremer J, Kandala S, Pricop L, Mpofu S. THU0421 secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (future 2). Ann Rheum Dis. 2015;74:351.
Abstrakti. Ei oteta.

[Treatment adjustment in biologic therapies for moderate-to-severe plaque psoriasis: a German retrospective chart review \(TABU\).](#)

Kirsten N, Rubant S, Gomis-Kleindienst S,
Pfeiffer-Vornkahl H, Augustin M.
J Dtsch Dermatol Ges. 2024 Jul 27. doi:
10.1111/ddg.15448. Online ahead of print.
PMID: 39073011 Otettu 27.924

[The anti-IL-17A antibody **secukinumab** does not attenuate ozone-induced airway neutrophilia in healthy volunteers.](#)

Kirsten A, Watz H, Pedersen F, Holz O, Smith R, Bruin G, Koehne-Voss S, Magnussen H, Waltz DA.
Eur Respir J. 2013 Jan;41(1):239-41. doi:. No abstract available.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Kisand, K., A. S. Bøe Wolff, K. T. Podkrajsek, L. Tserel, M. Link, K. V. Kisand, E. Ersvaer, J. Perheentupa, M. M. Erichsen, N. Bratanic, et al. 2010. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. *J. Exp. Med.* 207:299–308 Otettu 15.3.20

Ref. ei katsot

Kishi, Y. *et al.* Protein C receptor (PROCR) is a negative regulator of Th17 pathogenicity. *J. Exp. Med.* **213**, 2489–2501 (2016). Otettu 27.3.20

Ref. katsottu 29.3.20

Efficacy and safety of **secukinumab** in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).

Kishimoto M, Taniguchi A, Fujishige A, Kaneko S, Haemmerle S, Porter BO, Kobayashi S.

Mod Rheumatol. 2020 Jan;30(1):132-140. Otettu 28.2.20

Ref. katsottu 10.3.20

Clinical utility of **secukinumab** in moderate-to-severe scalp psoriasis: evidence to date.

Kivelevitch D, Amin S, Menter A.

Clin Cosmet Investig Dermatol. 2019 Apr

24;12:249-253. doi: 10.2147/CCID.S165040. **Free**

PMC Article Otettu 28.2.20

Efficacy and Safety of Intravenous **Secukinumab** for the Treatment of Active Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled Phase III INVIGORATE-2 Study.

Kivitz A, Sedova L, Churchill M, Kotha R, Singhal A, Torres A, Valenzuela G, Whelan S, Dumortier T, Zhu X, Martin R, Pricop L.

Arthritis Rheumatol. 2024 Sep 19. doi: 10.1002/art.42997. Online ahead of print.
PMID: 39300596 Otta M

Kivitz A, Blanco R, Maradiaga M. Secukinumab reduces signs and symptoms of active ankylosing spondylitis: results from a 16-week, randomized, placebo-controlled phase 3 trial. J Clin Rheumatol 2016;22:108-63. Ei oteta, Abstrakti

Efficacy and Safety of **Secukinumab** in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.

Kivitz AJ, Kremer JM, Legerton CW 3rd, Pricop L, Singhal A.

Rheumatol Ther. 2024 Jun;11(3):675-689. doi:

10.1007/s40744-024-00666-1. Epub 2024 Apr 16.

PMID: 38625671 [Free PMC article.](#) Otettu 29.5.24

Efficacy and Safety of **Secukinumab** 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.

Kivitz AJ, Wagner U, Dokoupilova E, Supronik J, Martin R, Talloczy Z, Richards HB, Porter B.

Rheumatol Ther. 2018 5(2): 447-62 Otettu 3.9.18

Free Article

Similar articles

Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.

Kivitz AJ, Nash P, Tahir H, Everding A, Mann H, Kaszuba A, Pellet P, Widmer A, Pricop L, Abrams K.

Rheumatol Ther. 2019 Sep;6(3):393-407. doi: **Free Article Otettu 28.2.20**

Ref. katsottu 10.3.2020

[Secukinumab Ameliorates Oxidative Damage Induced by Subarachnoid Hemorrhage.](#)

Kiyak V, Gevrek F, Demir O, Katar M.

World Neurosurg. 2024 Aug 16:S1878-8750(24)01221-X. doi: 10.1016/j.wneu.2024.07.080. Online ahead of print.

PMID: 39154958 Otta M

Klatt, N.R., and Brenchley, J.M. (2010). Th17 cell dynamics in HIV infection. Curr. Opin. HIV AIDS 5, 135–140. Otettu 21.3.20

Ref. ei katsot

Real Life Efficacy and Safety of **Secukinumab** in
Biologic-Experienced Patients With Psoriatic Arthritis.

Klavdianou K, Lazarini A, Grivas A, Tseronis D, Tsalapaki C, Rapsomaniki P, Antonatou K, Thomas K, Boumpas D, Katsimbri P, Vassilopoulos D.

Front Med (Lausanne). 2020 Jun 19;7:288. doi:
10.3389/fmed.2020.00288. eCollection 2020.

PMID: 32637422 Otettu 20.9.20

New developments in ankylosing spondylitis-status in
2021.

Klavdianou K, Tsiami S, Baraliakos X.

Rheumatology (Oxford). 2021 Dec 24;60(Suppl
6):vi29-vi37. doi: 10.1093/rheumatology/keab523.

PMID: 34951921 Free PMC article. Otettu 27.8.22

Kleczynska W, Jakiela B, Plutecka H, Milewski M, Sanak M, Musial J. Imbalance between TH17 and regulatory T-cells in systemic lupus erythematosus. *Folia Histochem Cytobiol* 2011;49(4):646–53.

Otettu 18.3.20

Ref. katsottu 18.3.20

Klein U, Liang E, Vogel B, Kolbinger F, Bruin G, Lloyd P. Immunogenicity of the anti-IL-17A antibody secukinumab in healthy subjects and patients. *J Invest Dermatol* 2013;133:Suppl 1:S172. ei oteta

Klein U, Liang E, Vogel B, et al. Immunogenicity of the novel anti-il-17a antibody, secukinumab, with intravenous and subcutaneous dosing regimens in healthy subjects and patients. *Ann Rheum Dis* 2013;72(Suppl 3):630. Otta M Otta myöhemmin

Kleynwiefeld, M., A. Manzel, J. Titze, H. Kvakan, N. Yosef, R. A. Linker, D. N. Muller, and D. A. Hafler. 2013. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. *Nature* 496: 518–522 Otettu 29.2.16

Kleynwiefeld, M., Hafler, D. A. (2013) The plasticity of human Treg and Th17 cells and its role in autoimmunity. *Semin. Immunol.* 25, 305–312. Otettu 29.2.16

Kleinschek, M. A., Owyang, A. M., Joyce-Shaikh, B., Langrish, C. L., Chen, Y., Gorman, D. M., et al. (2007). IL-25 regulates Th17 function in autoimmune inflammation. *J. Exp. Med.* 204, 161–170. d Otettu 29.2.16

Kleinschek, M.A., Boniface, K., Sadekova, S., Grein, J., Murphy, E.E., Turner, S.P., Raskin, L., Desai, B., Faubion, W.A., de Waal Malefyt, R., et al. (2009). Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. *J. Exp. Med.* 206, 525–534. Otettu 27.3.20

Ref. ei katsot.

Kleinstein, K., Heesch, S., Schattling, C., Sander-Juelch, U., Mock, K., Riecken, B., Fehse, B., Fleischer, and M. Jacobsen. 2012. SOCS3 promotes interleukin-17 expression of human T cells. *Blood* 120: 4374–4382. Otettu 29.2.16

[Cost-Effectiveness Analysis of **Secukinumab** Compared to Ustekinumab In The Treatment of Moderate to Severe Plaque Psoriasis In The Czech Republic.](#)

Klimes J, Mollon P, Graham C, Rajnoch J, Dostal F, Skalicky D, Jordan P, Depta J.

Value Health. 2015 Nov;18(7):A424. doi: 10.1016/j.jval.2015.09.575. Epub 2015 Oct 20. No abstract available.

PMID:

Abstraktia ei oteta

[Similar articles](#)

[Efficacy and NSAID-sparing effect of **secukinumab** 150 mg in ankylosing spondylitis: results from phase IV ASTRUM study.](#)

Kiltz U, Baraliakos X, Brandt-Jürgens J, Wagner U, Lieb S, Sieder C, Mann C, Braun J.

Ther Adv Musculoskelet Dis. 2024 Jun
5;16:1759720X241255486. doi:
10.1177/1759720X241255486. eCollection 2024.
PMID: 38846755 **Free PMC article.** Otettu 27.9.24

Current treatment of axial spondylarthritis : Clinical
efficacy].

Kiltz U, Braun J.

Z Rheumatol. 2020 Feb;79(1):13-22. doi:
10.1007/s00393-019-00707-z.
PMID: 31531695 Otettu 21.9.20

Secukinumab for treatment of nail psoriasis: results from the TRANSFIGURE trial.

Kloczko E, Maybury CM.

Br J Dermatol. 2019 Nov;181(5):885-886. Otettu 28.2.20

The preclinical discovery and development of **secukinumab** for the treatment of moderate-to-severe hidradenitis suppurativa.

Knecht-Gurwin K, Matusiak L, Szepietowski JC.

Expert Opin Drug Discov. 2025 Apr;20(4):405-417. doi: 10.1080/17460441.2025.2482058. Epub 2025 Mar 19. PMID: 40106842 Review. Otta M

Kneilling M, Rocken M. Exp Dermatol 2009; 18: 488–496. Otettu 4.3.16

CMTM4 is a subunit of the IL-17 receptor and mediates autoimmune pathology.

Knizkova D, Pribikova M, Draberova H, Semberova T, Trivic T, Synackova A, Ujevic A, Stefanovic J, Drobek A, Huranova M, Niederlova V, Tsyklauri O, Neuwirth A, Tureckova J, Stepanek O, Draber P.

Nat Immunol. 2022 Nov;23(11):1644-1652. doi:

10.1038/s41590-022-01325-9. Epub 2022 Oct 21.

PMID: 36271145 [Free PMC article.](#) Otettu 12.10.23

Secukinumab in a patient with sarcoidosis.

Kobak S, Gungen AC, Gungen BD, Tutpinar Y, Guler M.

Scand J Rheumatol. 2020 Sep 1:1-2. doi: 10.1080/03009

Otettu 20.9.20

Secukinumab-induced Raynaud's phenomenon: first report in the literature.

Kobak S.

Ther Adv Drug Saf. 2020 Feb 22;11:2042098620905976. doi: 10.1177/2042098620905976. eCollection 2020.

Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut. 2008; 57:1682–1689. Otettu 15.3.20

[Does YouTube provide high quality information?
Assessment of **secukinumab** videos.](#)

Kocyigit BF, Akaltun MS.

Rheumatol Int. 2019 Jul;39(7):1263-1268. doi:
Otettu 28.2.20

REf. katsottu 26.3.20

.
[Interleukin-17 acts independently of TNF-alpha under arthritic conditions.](#)

Koenders MI, Lubberts E, van de Loo FA,
Oppers-Walgreen B, van den Bersselaar L, Helsen MM,
Kolls JK, Di Padova FE, Joosten LA, van den Berg WB.
J Immunol. 2006 May 15;176(10):6262-9.

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006;65(Suppl 3):iii29–iii33. Otettu 4.3.16

[Translational mini-review series on Th17 cells: are T helper 17 cells really pathogenic in autoimmunity?](#)

Koenders MI, van den Berg WB.

Clin Exp Immunol. 2010 Feb;159(2):131-6. doi: 10.1111/j.1365-2249.2009.04039.x. Epub 2009 Nov 11. Review.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

[**Secukinumab** for rheumatology: development and its potential place in therapy.](#)

Koenders MI, van den Berg WB.

Drug Des Devel Ther. 2016 Jun 24;10:2069-80. doi:

Otettu 27.5.18

Free PMC Article

[Similar articles](#)

Koenen HJ, Smeets RL, Vink PM et al. (2008) Human CD25^{high} Foxp3^{pos} regulatory T cells differentiate into IL-17-producing cells. Blood 112:2340–5 Otettu 29.2.16

24. Kofler, D. M. *et al.* Decreased RORC-dependent silencing of prostaglandin receptor EP2 induces autoimmune Th17 cells. *J. Clin. Invest.* **124**, 2513–2522 (2014). Otettu 27.3.20

Understanding the pathogenic significance of altered calcium-calmodulin signaling in T cells in autoimmune diseases.

Koga T.

Clin Immunol. 2024 Mar 7:110177. doi:

10.1016/j.clim.2024.110177. Online ahead of print.

PMID: 38460894 Review. Otta M

52. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol. 2008;128:2625–30. Otettu 22.3.20

Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus.

Koga T, Ichinose K, Kawakami A, Tsokos GC.
Front Immunol. 2021 Feb 1;11:624971. doi:
10.3389/fimmu.2020.624971. eCollection 2020.
PMID: 33597953 [Free PMC article](#). Otettu 31.8.22

IL-17 and IL-21: Their Immunobiology and Therapeutic Potentials.

Koh CH, Kim BS, Kang CY, Chung Y, Seo H.
Immune Netw. 2024 Jan 19;24(1):e2. doi:
10.4110/in.2024.24.e2. eCollection 2024 Feb.
PMID: 38455465 [Free PMC article](#). Review. Otettu
13.3.24

[Interleukin-17 gene expression in patients with rheumatoid arthritis.](#)

Kohno M, Tsutsumi A, Matsui H, Sugihara M, Suzuki T, Mamura M, Goto D, Matsumoto I, Ito S, Suguro T, Sumida T.

Mod Rheumatol. 2008;18(1):15-22. Epub 2007 Dec 20.

PMID: 18253116

[Similar articles](#)

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and **secukinumab**: real-world data from the Czech Republic BIOREP registry.

Kojanova M, Hugo J, Velackova B, Cetkovska P, Fialova J, Dolezal T, Tichy M, Gkalpakiotis S; BIOREP study group.

J Dermatolog Treat. 2022 May 29:1-11. doi:

10.1080/09546634.2022.2082354. Online ahead of print.

PMID: 35635185 e10101

Kokkonen H, Söderström I, Rocklöv J, Hallmans G,
Lejon K, Rantapää
Dahlqvist S. Up-regulation of cytokines and chemokines
predates the
onset of rheumatoid arthritis. *Arthritis Rheum*
2010;62:383-91. Otettu 29.2.16

KOLBINGER F, HUPPERTZ C, MIR A *et al.*: IL-17A and
multiple sclerosis: signaling pathways, produc- ing cells
and target cells in the central nervous sys- tem. *Curr*
Drug Targets 2016; 17: 1882-93. Otta M Ei ole GS
Ei ole PUBMED Otta myöhemmin

18. Kolbinger F, Loesche C, Valentin M-A, Jiang X, Cheng Y, Jarvis P, et al. b-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. *J Allergy Clin Immunol* 2017;139:923-932, e8. Otettu 18.3.20
19. Ref. katsottu 22.3.20

Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety.

Kolbinger F, Di Padova F, Deodhar A, Hawkes JE, Huppertz C, Kuiper T, McInnes IB, Ritchlin CT, Rosmarin D, Schett G, Carballido JM, Häusermann P, Calonder C, Vogel B, Rondeau JM, Bruin G.

Pharmacol Ther. 2021 Jun 23:107925. doi: 10.1016/j.pharmthera.2021.107925. Online ahead of print.

PMID: 34171337 **Free article.** Review. Otettu 8.8.21

Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis.

Koller-Smith L, Oakley S.

Rheumatology (Oxford). 2021 Dec 17:keab918. doi: 10.1093/rheumatology/keab918. Online ahead of print. PMID: 34919658 Otettu 28.11.22

Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467–76. Otettu 29.2.16

Inverse responses of the skin and nail lesions of psoriatic **arthritis** to an anti-**interleukin**-17A antibody and an anti-tumor necrosis factor- α antibody.

Komatsu-Fujii T, Honda T, Otsuka A, Kabashima K.
J Dermatol. 2019 Nov;46(11):e440-e441. doi:
10.1111/1346-8138.15006. Epub 2019 Jun 28.
PMID: 31254299 Otettu 23.9.20

[Pathogenic conversion of Foxp3+ T cells into TH17 cells
in autoimmune arthritis.](#)

Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora
M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H.
Nat Med. 2014 Jan;20(1):62-8.

Otettu 3.2.16

[Similar articles](#)

[Arthritogenic T cells in autoimmune arthritis.](#)

Komatsu N, Takayanagi H.
Int J Biochem Cell Biol. 2015 Jan;58:92-6. doi:
10.1016/j.biocel.2014.11.008. Epub 2014 Nov 28.
Review.

PMID:

Otettu 3.2.16

[Similar articles](#)

342.

[Improvement of nail lesions in a patient with psoriatic arthritis by switching the treatment from an anti-interleukin-17A antibody to an anti-tumor necrosis factor- \$\alpha\$ antibody.](#)

Komatsu-Fujii T, Honda T, Otsuka A, Kabashima K.

J Dermatol. 2019 May;46(5):e158-e160. Otettu 28.2.20

.

[Exacerbation of depression in a psoriatic arthritis patient possibly induced by **secukinumab**.](#)

Komori T, Otsuka A, Honda Y, Kanameishi S, Honda T, Kabashima K.

Eur J Dermatol. 2016 Oct 1;26(5):506-507. Otettu 9.3.20

Ref. katsottu 16.3.20

[Similar articles](#)

[Oral lichen planus associated with candidiasis during **secukinumab** treatment.](#)

Komori T, Honda T, Endo Y, Kaku Y, Otsuka A, Kabashima K.

J Dermatol. 2017 Apr;44(4):e60-e61. doi: Otettu
28.5.18

[Similar articles](#)

Delayed drug hypersensitivity reaction to **secukinumab** in a patient with hidradenitis suppurativa.

Konda S, Shetty N, Friedman B, Veenstra J.

BMJ Case Rep. 2022 May 17;15(5):e249684. doi:
10.1136/bcr-2022-249684.

PMID: 35580946 otettu 30.11.22

Delayed drug hypersensitivity reaction to **secukinumab** in a patient with hidradenitis suppurativa.

Konda S, Shetty N, Friedman B, Veenstra J.

Drug Ther Bull. 2023 Jul 5:dtb.2023.249684rep. doi: 10.1136/dtb.2023.249684rep. Online ahead of print. PMID: 37407276 No abstract available. Otta M

Kondo T, Takata H, Matsuki F, Takiguchi M: Cutting edge: Phenotypic characterization and differentiation of human CD8⁺ T cells producing IL- 17. J Immunol 2009, 182:1794-1798. Otettu 29.2.16

Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis.

Konen FF, Witte T, Ernst D, Hagin D, Jendretzky KF, Möhn N, Nay S, Grote-Levi L, Sühs KW, Klotz L, Pfeuffer S, Pul R, Kleinschnitz C, Pawlitzki M, Meuth SG, Skripuletz T.

Neurol Res Pract. 2025 Jul 17;7(1):48. doi: 10.1186/s42466-025-00414-y.

PMID: 40676697 [Free PMC article](#). Review. Otettu 28.7.25

New insights into the metabolism of Th17 cells.

Kono M.

Immunol Med. 2023 Mar;46(1):15-24. doi: 10.1080/25785826.2022.2140503. Epub 2022 Nov 3.

PMID: 36326754 Review. Otettu 12.10.23

Psoriasis Onset during Anti-TNF Treatment for Hidradenitis Suppurativa: Successful Remission of Both Conditions with **Secukinumab**.

Kontochristopoulos G, Kanni T, Marnelakis I, Agiasofitou E, Liakou A, Rigopoulos D.

Skinmed. 2023 Mar 29;21(1):57-58. eCollection 2023.

PMID: 36987833 Otta M

[Update on the role of Interleukin 17 in rheumatologic autoimmune diseases.](#)

Konya C, Paz Z, Apostolidis SA, Tsokos GC.

Cytokine. 2015 Oct;75(2):207-15. doi:

Maksullinen

Otettu 29.2.16

[Similar articles](#)

Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis.

Koo BS, Jo S, Kwon E, Shin JH, Hur JW, Kim TH.

Korean J Intern Med. 2020 Mar;35(2):465-473. doi: 10.3904/kjim.2018.364. Epub 2019 Dec 16.

PMID: 31830775 Otettu 21.9.20

H. Kopf, G. M. de la Rosa, O. M. Z. Howard, and X. Chen, "Rapamycin inhibits differentiation of Th17 cells and pro- motes generation of Foxp3+ T regulatory cells," *International Immunopharmacology*, vol. 7, no. 13, pp. 1819–1824, 2007. Otettu 22.3.20

The management of enthesitis in clinical practice.

Koppikar S, Eder L.

Curr Opin Rheumatol. 2020 Jul;32(4):380-386. doi: 10.1097/BOR.0000000000000715.

PMID: 32412994 Review. otettu 30.11.22

Korber A, Thaci D, von Kiedrowski R, et al.

Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):411–419. Otettu 2.3.20

Korber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. *Drugs Aging*. 2018 Feb;35(2):135–144. Otettu 2.3.20

Ref. katsottu 10.3.20

[Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis.](#)

Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N, Mordin M, Tying S. *J Dermatolog Treat*. 2017 Aug;28(5):384-389. doi:

Otettu 28.2.20

Ref. katsottu 2.3.2020

[Similar articles](#)

Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. *Nature* 2007;448:484–7. Otettu 29.2.16

Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. *Semin Immunol* 2007;19:362–71. Otettu 29.2.16

42. Korn, T. et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3⁺ regulatory T cells. *Proc. Natl. Acad. Sci. USA* **105**, 18460–18465 (2008). Otettu 16.3.20

43. Ref. ei katsot

Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485–517 Otettu 29.2.16

T. Korn, F. Petermann, Development and function of interleukin 17- producing gammadelta T cells, Ann. N Y Acad. Sci. 1247 (2012) 34e45. Otettu 29.2.16

[Serum IL-17 and TNFalpha as prognostic biomarkers in systemic sclerosis patients: a prospective study.](#)

Kosałka-Węgiel J, Lichołai S, Pacholczak-Madej R, Dziedzina S, Milewski M, Kuzmiersz P, Korona A, Gąsior J, Matyja-Bednarczyk A, Kwiatkowska H, Zaręba L,

Siwiec-Koźlik A, Koźlik-Siwiec P, Wach A, Pociąg-Marciak W, Sanak M, Musiał J, Bazan-Socha S, Korkosz M. Rheumatol Int. 2024 Jan;44(1):119-128. doi: 10.1007/s00296-023-05499-9. Epub 2023 Dec 5. PMID: 38051374 [Free PMC article](#). Otettu 13.3.24

Clinical relevance of estimating circulating **interleukin-17** and **interleukin-23** during methylprednisolone therapy in Graves' orbitopathy: A preliminary study.

Kościeszko M, Popławska-Kita A, Pawłowski P, Lipińska D, Hryniewicka J, Jankowska D, Górska M, Krętowski A, Myśliwiec J.

Adv Med Sci. 2021 Sep;66(2):315-320. doi: 10.1016/j.advms.2021.07.002. Epub 2021 Jul 10. PMID: 34256242 [Free article](#). Otettu 30.8.22

Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. *Ann Rheum Dis* 2002;61:704–13. Otettu 29.2.16

[Optimizing **Secukinumab** Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report.](#)

Kostaki D, Aquila E, Macaluso L, Mattozzi C, Richetta AG.

Case Rep Dermatol. 2019 Sep 23;11(Suppl 1):17-22.

Free PMC Article Otettu 28.2.20

Ref. katsottu 12.3.20

Kotke S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT,

Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345–52.
Otettu 29.2.16

Kotke S, Kamatani N. The Role of IL-17 in Joint Destruction. Drug News Perspect. 2002; 15:17– 23. ta
M ei ole GS Ei oteta

Ei ole PUBMED

[Role of osteoclasts and **interleukin-17** in the pathogenesis of rheumatoid arthritis: crucial 'human osteoclastology'.](#)

Kotke S, Yago T, Kawamoto M, Nanke Y.
J Bone Miner Metab. 2012 Mar;30(2):125-35. doi:
Otettu 3.2.16

[Similar articles](#)

Kotke S, Nanke Y, Yago T, Kawamoto M, Kobashigawa T, Yamanaka H. Elevated ratio of Th17 cell-derived Th1 cells (CD161(+)Th1 Cells) to CD161(+)Th17 cells in peripheral blood of early-onset rheumatoid arthritis patients. *Biomed Res Int.* (2016) 2016:4186027. Otettu 9.3.20

Ref. katsottu 10.3.20

[IL-17A-producing CD8⁺ T cells in pancreatic cancer.](#)

Kotsiliti E.

[Nat Rev Gastroenterol Hepatol. 2023 Apr;20\(4\):202. doi: 10.1038/s41575-023-00757-4.](#)

[PMID: 36813843 Otta M](#)

IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via I κ B ζ -dependent induction of ELF3.

Kouri VP, Olkkonen J, Nurmi K, Peled N, Ainola M, Mandelin J, Nordström DC, Eklund KK.

Rheumatology (Oxford). 2022 Jul 6:keac385. doi: 10.1093/rheumatology/keac385. Online ahead of print. PMID: 35792833 Otettu 27.8.22

[Neutrophils produce interleukin-17B in rheumatoid synovial tissue.](#)

Kouri VP, Olkkonen J, Ainola M, Li TF, Björkman L, Konttinen YT, Mandelin J.

Rheumatology (Oxford). 2014 Jan;53(1):39-47. doi: 10.1093/rheumatology/ket309. Epub 2013 Sep 19.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Secukinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients aged six years and older.

Krajewski PK, Szepietowski JC.

Expert Rev Clin Immunol. 2023 May 23:1-6. doi: 10.1080/1744666X.2023.2214365. Online ahead of print.

PMID: 37191153 Otta M

[Pathological and Therapeutical Implications of Pyroptosis in Psoriasis and Hidradenitis Suppurativa: A Narrative Review.](#)

Krajewski PK, Tsoukas M, Szepietowski JC.

Curr Issues Mol Biol. 2024 Jan 11;46(1):663-676. doi: 10.3390/cimb46010043.

PMID: 38248345 [Free PMC article](#). Review. Otettu
13.3.24

Kramer JM, Yi L, Shen F, Maitra A, Jiao X, Jin T, et al.
Evidence for ligand- independent multimerization of the
IL-17 receptor. J Immunol 2006;176: 711–5. Otettu
29.2.16

[Interleukin-17: a new paradigm in inflammation,
autoimmunity. and therapy.](#)

Kramer JM, Gaffen SL.
J Periodontol. 2007 Jun;78(6):1083-93. Review.
PMID:

Otettu 3.2.16

[Similar articles](#)

Long-term efficacy, safety and tolerability of **secukinumab** in children and adolescents with severe chronic plaque psoriasis: Two-year results from a Phase III double-blind, randomized controlled trial.

Krasowska D, Gambichler T, Cortés C, Horev A, Compagno N, Dahale SS, Papanastasiou P, Keefe D.

J Eur Acad Dermatol Venereol. 2023 Mar 27. doi: 10.1111/jdv.19063. Online ahead of print.

PMID: 36971771 Otta M

24. Krausgruber, T. *et al.* T-Bet is a key modulator of IL-23-driven pathogenic CD4⁺ T cell responses in the intestine. *Nat. Commun.* **7**, 11627 (2016).

Otettu 27.3.20

25. Ref. katsottu 29.3.20

Krebs, C. F. *et al.* Plasticity of Th17 cells in autoimmune kidney diseases. *J. Immunol.* **197**, 449–457 (2016). Otettu 12.3.20

Ref. katsottu 15.3.20

Tissue-specific therapy in immune-mediated kidney diseases: new ARGuments for targeting the IL-23/IL-17 axis.

Krebs CF, Turner JE, Riedel JH, Panzer U.

J Clin Invest. 2021 Jun 15;131(12):e150588. doi: 10.1172/JCI150588.

PMID: 34128472 [Free PMC article.](#) Otettu 30.8.22

Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis.

Krefting F, Scheib C, Benson S, Hölsken S, Placke JM, Wedemeyer H, Sondermann W.

Psoriasis (Auckl). 2025 Mar 1;15:29-44. doi: 10.2147/PTT.S502296. eCollection 2025.

PMID: 40046951 [Free PMC article.](#) Otettu 4.6.25

Kreymborg K, Etzensperger R, Dumoutier L, Haak S, Rebollo A, Buch T, Heppner FL, Renauld JC, Becher B (2007) IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the

development of autoimmune encephalomyelitis. J
Immunol 179:8098–8104 Otettu 12.3.20

The cardiometabolic safety of **interleukin 23** versus
interleukin 17 inhibitors in psoriasis: A large-scale
global cohort study.

Kridin K, Mruwat N, Thaci D, Ludwig RJ.

J Eur Acad Dermatol Venereol. 2023

May;37(5):e683-e685. doi: 10.1111/jdv.18830. Epub
2023 Jan 9. Otta M

Risk of COVID-19 infection, hospitalization, and mortality
in patients with psoriasis treated by **interleukin-17**
inhibitors.

Kridin K, Schonmann Y, Solomon A, Damiani G, Tzur Bitan D, Onn E, Weinstein O, Cohen AD.
J Dermatolog Treat. 2022 Jun;33(4):2014-2020. doi:
10.1080/09546634.2021.1905766. Epub 2022 Mar 21.
PMID: 33759683 **Free article.** **Otettu 30.8.22**

New-Onset, Treatment-Resistant Inflammatory Bowel
Disease after Administration of **Secukinumab** for Plaque
Psoriasis: A Case Report and Review of the Existing
Literature.

Krikelis M, Papathanasiou E, Leonidakis G, Pardalis P,
Michopoulos S, Zampeli E.
Mediterr J Rheumatol. 2024 Mar 31;35(1):150-155. doi:
10.31138/mjr.030124.ntt. eCollection 2024 Mar.
PMID: 38736963 **Free PMC article.** **Otettu 29.5.24**

Comparative early effectiveness across 14 PsA drugs
and 5 classes of PsA treatment: 3-month results from
the PRO-SPIRIT study.

Kristensen LE, Ng KJ, Ngantcha M, Morel J, Lubrano E, Tillett W, Alten R, Chandran V, Martinez Ferrer À, Zhu B, Kennedy D, Holzkämper T, Gullick N, Kronbergs A, Fakhouri W, de la Torre I, McGonagle DG.

RMD Open. 2024 Sep 20;10(3):e004318. doi: 10.1136/rmdopen-2024-004318.

PMID: 39306343 [Free PMC article.](#) Otettu 27.9.24

[ERAP1 and ERAP2 Gene Variants as Potential Clinical Biomarkers of Anti-IL-17A Response in Psoriasis Vulgaris.](#)

Kronborg L, Hansen EO, Bertelsen T, Rittig AH, Emmanuel T, Jørgensen S, Hjuler KF, Iversen L, Johansen C.

Clin Exp Dermatol. 2024 Apr 15;llae128. doi: 10.1093/ced/llae128. Online ahead of print.

PMID: 38616723 Otta M

Defenders or defectors: mucosal-associated invariant T cells in autoimmune diseases.

Kronenberg M, Riffelmacher T.

Curr Opin Immunol. 2025 Apr;93:102542. doi: 10.1016/j.coi.2025.102542. Epub 2025 Feb 27. PMID: 40020256 Review. Otta M

Regulation of the mesenchymal stem cell fate by **interleukin-17**: Implications in osteogenic differentiation.

Krstić J, Mojsilović S, Mojsilović SS, Santibanez JF.

World J Stem Cells. 2021 Nov 26;13(11):1696-1713. doi: 10.4252/wjsc.v13.i11.1696.

PMID: 34909118 [Free PMC article](#). Review Otettu
27.8.22

Krstic A, Mojsilovic S, Jovcic G, Bugarski D. The potential of inter-leukin-17 to mediate hematopoietic response. Immunol Res 2012; 52:34–41.
Otettu 29.2.16

[Comparative Analysis of the Long-Term Real-World Efficacy of Interleukin-17 Inhibitors in a Cohort of Patients with Moderate-to-Severe Psoriasis Treated in Poland.](#)

Kruczek W, Frątczak A, Litwińska-Inglot I, Polak K, Pawlus Z, Rutecka P, Bergler-Czop B, Miziołek B.

J Clin Med. 2025 Aug 1;14(15):5421. doi:

10.3390/jcm14155421.

PMID: 40807042 [Free PMC article.](#) Otettu 22.8.25

IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.

Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, Wang CQ, Fuentes-Duculan J, Hartmann N, Peters T, Koroleva I, Hillenbrand R, Letzkus M, Yu X, Li Y, Glueck A, Hasselberg A, Flannery B, Suárez-Fariñas M, Hueber W.

J Allergy Clin Immunol. 2019 Sep;144(3):750-763. doi:

10.1016/j.jaci.2019.04.029. Epub 2019 May 24.

PMID: 31129129 Otettu 23.9.20

J.G. Krueger, S. Fretzin, M. Suarez-Farinas, P.A. Haslett, K.M. Phipps, G.S. Cameron, J. McColm, A. Katcharian, I. Cueto, T. White, S. Banerjee, R.W. Hoffman, IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis, J Allergy Clin Immunol. 130 (2012) 145–154. Otettu 29.2.16

IL-17A inhibition by **secukinumab** induces early clinical, histopathologic, and molecular resolution of psoriasis.

Krueger JG, Wharton KA Jr, Schlitt T, Suprun M, Torene RI, Jiang X, Wang CQ, Fuentes-Duculan J, Hartmann N, Peters T, Koroleva I, Hillenbrand R, Letzkus M, Yu X, Li Y, Glueck A, Hasselberg A, Flannery B, Suárez-Fariñas M, Hueber W.

J Allergy Clin Immunol. 2019 May 24. pii:
[2019;144:750-73.](#)

S0091-6749(19)30682-7. doi: **Free Article Otettu
28.2.20**

Secukinumab versus guselkumab in the complete
resolution of ustekinumab-resistant psoriatic plaques:
The ARROW study.

Krueger J, Langley RG, Nigen S, Kasperek T, Comite GD,
Ortmann CE, Garcet S, Kolbinger F, Reich K.

Exp Dermatol. 2023 Jun 5. doi: [10.1111/exd.14828.](#)

Online ahead of print.

PMID: [37272375](#) Otettu 12.6.23

Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis.

Krueger JG, Murrell DF, Garcet S, Navrazhina K, Lee PC, Muscianisi E, Blauvelt A.

J Allergy Clin Immunol. 2020 Sep

28:S0091-6749(20)31332-4. doi:

10.1016/j.jaci.2020.09.021. Online ahead of print.

PMID: 33002515 **Free article.** Otettu 13.12.20

12. Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178:6730-6733. Otettu 15.3.20

Kryczek I, Wei S, Vatan L, et al. Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17⁺ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol. 2007;179:1423-1426. Otettu 15.3.20

Ref. ei katsot

Kryczek I, Bruce A T, Gudjonsson J E et al. J Immunol
2008; 181: 4733–4741. Otettu 29.2.16

Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga
W, Wei S, et al. Phenotype, distribution, generation,
and
functional and clinical relevance of Th17 cells in the
human tumor environments. [Blood](#). 2009
Aug;114(6):1141–9. Otettu 12.3.20
Ref. katsottu 15.3.20

Kryczek I, Wei S, Szeliga W, Vatan L, Zou W.
Endogenous IL-17 contributes to reduced tumor growth
and metastasis. [Blood](#). 2009;114:357- 359 Otettu
15.3.20

Reef. ei katsot

Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, et al. Human TH17 cells are long-lived effector memory cells. [Sci Transl Med](#). 2011 Oct;3(104):104ra100. Otettu 12.3.20

Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, Huang E, Greenson J, Chang A, Rolinski J, Radwan P, Fang J, Wang G, Zou W. IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. *J Immunol*. 2011; 186:4388–4395 Otettu 17.3.20

Ref. ei katsot

[Risk of Melanoma and Non-Melanoma Skin Cancer in Patients with Psoriasis and Psoriatic Arthritis Treated](#)

with Targeted Therapies: A Systematic Review and Meta-Analysis.

Krzysztofik M, Brzewski P, Cuber P, Kacprzyk A, Kulbat A, Richter K, Wojewoda T, Wysocki WM.

Pharmaceuticals (Basel). 2023 Dec 21;17(1):14. doi: 10.3390/ph17010014.

PMID: 38276003 [Free PMC article](#). Review. Otettu 13.3.24

Kuchroo, V. K., and A. Awasthi. 2012. Emerging new roles of Th17 cells. Eur. J. Immunol. 42: 2211–2214. Otettu 29.2.16

IL-17-Producing Cells in Tumor Immunity: Friends or Foes?

Kuen DS, Kim BS, Chung Y.

Immune Netw. 2020 Feb 7;20(1):e6. doi:

10.4110/in.2020.20.e6. eCollection 2020 Feb.

PMID: 32158594 [Free PMC article](#). Otettu 6.9.22

Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K, Harder B, Okada S, Ostrander CD, Kreindler JL, Aujla SJ, Reardon B, Moore M, Shea P, Schreckhise R, Bukowski TR, Presnell S, Guerra-Lewis P, Parrish-Novak J, Ellsworth JL, Jaspers S, Lewis KE, Appleby M, Kolls JK, Rixon M, West JW, Gao Z, Levin SD (2007) Identification of the IL-17 receptor related molecule IL- 17RC as the receptor for IL-17F. J Immunol 179:5462–5473 Otettu 29.2.16

[Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis.](#)

Kugyelka R, Kohl Z, Olasz K, Mikecz K, Rauch TA,
Glant TT, Boldizsar F.
Mediators Inflamm. 2016;2016:6145810. Epub 2016 Jan
20. Review.
Otettu 4.2.21
[Similar articles](#)

[A case of psoriasis with IgA nephropathy successfully
treated with **secukinumab**.](#)

Kulaklı S, Akagün T.
Int J Dermatol. 2024 Feb;63(2):e35-e37. doi:
10.1111/ijd.16903. Epub 2023 Nov 11.
PMID: 37950460 No abstract available. Otta M

Role of **interleukin-17** in cartilage and bone destruction in rheumatoid arthritis.

Kuligowska M, Odrowaz-Sypniewska G.

Ortop Traumatol Rehabil. 2004 Apr 30;6(2):235-41.

PMID:

ei ole M Ei oteta Ei ole PUBMED

[Similar articles](#)

RORyt protein modifications and IL-**17**-mediated inflammation.

Kumar R, Theiss AL, Venuprasad K.

Trends Immunol. 2021 Nov;42(11):1037-1050. doi: 10.1016/j.it.2021.09.005. Epub 2021 Oct 9.

PMID: 34635393 Review. Otettu 30.11.22

V. Kumar, Innate lymphoid cells: new paradigm in immunology of inflammation, Immunol. Lett. 157 (2014) 23e37. Otettu 29.2.16

[Biologics in Systemic Lupus Erythematosus: Recent Evolutions and Benefits.](#)

Kundnani NR, Levai MC, Popa MD, Borza C, Iacob M, Mederle AL, Blidisel A.

Pharmaceutics. 2024 Sep 6;16(9):1176. doi: 10.3390/pharmaceutics16091176.

PMID: 39339212 [Free PMC article](#). Review. Otettu 24.10.24

Temporal expression patterns of distinct cytokines and M1/M2 macrophage polarization regulate rheumatoid **arthritis** progression.

Kung CC, Dai SP, Chiang H, Huang HS, Sun WH.

Mol Biol Rep. 2020 May;47(5):3423-3437. doi:

10.1007/s11033-020-05422-6. Epub 2020 Apr 10.

PMID: 32277445 Otettu 21.9.20

Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.

Kunwar S, Dahal K, Sharma S.

Rheumatol Int. 2016 Aug;36(8):1065-75. doi: Otettu

28.5.18

[Similar articles](#)

Kupetsky EA, Mathers AR, Ferris LK. Anti-cytokine therapy in the treatment of psoriasis. *Cytokine*. 2013; 61:704–712. [PubMed: 23410503] Otettu 29.2.16

Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Increased interleukin-17 production in patients with systemic sclerosis. *Arthritis Rheum*. 2000;43:2455–63. Otettu 29.2.16

Kurebayashi, Y., Nagai, S., Ikejiri, A., Ohtani, M., Ichiyama, K., Baba, Y., Yamada, T., Egami, S., Hoshii, T., Hirao, A., et al. (2012). PI3K-Akt- mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ. *Cell Rep*. 1, 360–373. Otettu 29.3.20

Serum KL-6 levels in Japanese patients with psoriasis treated with **secukinumab**.

Kurita M, Kikuchi S, Umezawa Y, Asahina A, Nakagawa H, Yanaba K.

J Dermatol. 2019 Apr;46(4):e115-e116. Otettu 28.2.20

Dramatic **secukinumab**-mediated improvements in refractory leprosy-related neuritis via the modulation of T helper 1 (Th1) and T helper 17 (Th17) immune pathways.

Kurizky PS, Mott JOCD, Bezerra NVF, Sousa MCDS, Corazza D, Borges TKDS, Gomes CM.

Rev Soc Bras Med Trop. 2021 Dec 17;54:e03362021.

doi: 10.1590/0037-8682-0336-2021. eCollection 2021.

PMID: 34932761 **Free PMC article.** Otettu 3.3.22

Kurschus, F. C., Croxford, A. L., Heinen, A. P., Wortge, S., Ielo, D., and Waisman, A. (2010). Genetic proof for the transient nature of the Th17 phenotype. Eur. J.

Immunol. 40, 3336–3346. doi: 10.1002/eji.2010 40755
Otettu 29.2.16

.
[New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and **secukinumab**.](#)

Kurzeja M, Rudnicka L, Olszewska M.

Am J Clin Dermatol. 2011 Apr 1;12(2):113-25. doi: 10.2165/11538950-000000000-00000. Review.

PMID:

Otettu 29.2.16

[Similar articles](#)

[A case of generalized pustular psoriasis following Moderna/NIAID COVID-19 vaccination successfully treated with **secukinumab**.](#)

Kusano M, Mukaiyama R, Yamamoto T.

An Bras Dermatol. 2024 Sep-Oct;99(5):773-775. doi: 10.1016/j.abd.2023.07.016. Epub 2024 Jun 26.

PMID: 38937220 **Free PMC article.** Otettu 27.9.24

Drug survival of interleukin 17 inhibitors after switch from interleukin 23 inhibitors in psoriasis: An observational cohort study.

Kushnir-Grinbaum D, Ziv M.

J Am Acad Dermatol. 2024 Sep

7:S0190-9622(24)02728-2. doi:

10.1016/j.jaad.2024.07.1514. Online ahead of print.

PMID: 39182683 No abstract available. Otta M

Complexity of enthesitis and new bone formation in ankylosing spondylitis: current understanding of the immunopathology and therapeutic approaches.

Kusuda M, Haroon N, Nakamura A.

Mod Rheumatol. 2022 Apr 18;32(3):484-492. doi:

10.1093/mr/roab057.

PMID: 34918137 Free article. otettu 30.11.22

Kuwabara T, Ishikawa F, Kondo M, et al. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. Mediators Inflamm. 2017. Otettu 7.3.20

Ref. katsottu 15.3.20

<https://doi.org/10.1155/2017/3908061>.

Secukinumab Provides Sustained Reduction in Fatigue in Patients with Ankylosing Spondylitis: Long-term Results of Two Phase III Randomized Controlled Trials.

Kvien TK, Conaghan PG, Gossec L, Strand V, Østergaard M, Poddubnyy D, Williams N, Porter B, Shete A, Gilloteau I, Deodhar A.

Arthritis Care Res (Hoboken). 2020 Nov 23. doi: 10.1002/acr.24517. Online ahead of print.

PMID: 33227175 Otettu 13.12.20

Drug Retention Rate and Factors Associated with Discontinuation of **Interleukin-17** Inhibitors in Patients with Axial Spondyloarthritis.

Kwon OC, Park MC.

Yonsei Med J. 2023 Dec;64(12):697-704. doi: 10.3349/ymj.2023.0151.

PMID: 37992741 **Free PMC article.** Otettu 14.3.23

Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea.

Kwon OC, Lee HS, Yang J, Paul T, Jin H, Lee Y, Park MC.

Rheumatology (Oxford). 2025 Jan 24;keaf038. doi: 10.1093/rheumatology/keaf038.

Online ahead of print.

PMID: 39854270 Otettu 2.3.25

Cardiovascular risk according to biological agent exposure in patients with ankylosing spondylitis: a nationwide population-based study

Kwon, Oh Chan ; Lee, Hye Sun ; Yang, Juyeon ; Park, Min-Chan

Clinical rheumatology, 2025-01, Vol.44 (1), p.257-266 Otta M

Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis.

Kwon OC, Lee HS, Yang J, Park MC.

Rheumatology (Oxford). 2024 Jan 18:keae003. doi:

10.1093/rheumatology/keae003. Online ahead of print.

PMID: 38243710 Otta M

Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis.

Kwon OC, Lee HS, Yang J, Park MC.

Rheumatology (Oxford). 2024 Jan 18:keae003. doi: 10.1093/rheumatology/keae003. Online ahead of print.

Otta M

Risk of Cancers According to the Use of Biological Agents in Patients With Radiographic Axial Spondyloarthritis: A Nationwide Population-Based Cohort Study

Kwon, Oh Chan ; Lee, Hye Sun ; Yang, Juyeon ; Park, Min-Chan

Journal of clinical rheumatology, 2025-01 Otta M

Cardiovascular risk according to biological agent exposure in patients with ankylosing spondylitis: a nationwide population-based study.

Kwon OC, Lee HS, Yang J, Park MC.

Clin Rheumatol. 2025 Jan;44(1):257-266. doi: 10.1007/s10067-024-07225-7. Epub 2024 Nov 7. PMID: 39509079 Otta M

Factors affecting drug survival of an alternative TNF inhibitor and **secukinumab** in patients with ankylosing spondylitis switching from the first TNF inhibitor.

Kwon OC, Park JH, Park MC.

Ther Adv Musculoskelet Dis. 2021 Apr 12;13:1759720X211009021. doi: 10.1177/1759720X211009021. eCollection 2021. PMID: 33912250 Free PMC article. Otettu 8.8.21

A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing **Secukinumab** Survival and Long-Term Efficacy and Safety Among Greek Patients with Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp.

Kyrmanidou E, Kemanetzi C, Stavros C, Trakatelli MG, Patsatsi A, Madia X, Ignatiadi D, Kalloniati E, Apalla Z, Lazaridou E.

Dermatol Pract Concept. 2024 Apr 1;14(2):e2024119.
doi: 10.5826/dpc.1402a119.

PMID: 38810083 **Free PMC article.** Otettu 6.6.24

Treatment of psoriasis with **secukinumab** : Practical guidance].

Körber A, Augustin M, Behrens F, Gerdes S, von Kiedrowski R, Schäkel K, Sticherling M, Wilsmann-Theis D, Wohlrab J, Simon JC.

Hautarzt. 2021 Nov;72(11):984-991. doi:
10.1007/s00105-021-04871-9. Epub 2021 Aug 20.
PMID: 34417630 **Free PMC article.** Otettu 3.3.22

Successful use of **secukinumab** in a 4-year-old patient with deficiency of interleukin-36 antagonist.

Köstner K, Prelog M, Almanzar G, Fesq H, Haas JP, Hügle B.

Rheumatology (Oxford). 2018 May 1;57(5):936-938.

Otettu 28.5.18

[Similar articles](#)

[\[Update on Behçet syndrome\].](#)

Kötter I, Ruffer N, Krusche M.

Z Rheumatol. 2024 Oct 1. doi:
10.1007/s00393-024-01576-x. Online ahead of print.
PMID: 39354126 Review. German. Otta M

Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment
by human

IL-17 via C-X-C chemokine release in the airways. *J*
Immunol. 1999;

162(4):2347–2352. Otettu 12.3.20

Laggner U, Di Meglio P, Perera G K et al. J
Immunol 2011; 187: 2783–2793. Otettu 29.2.16

Lai Kwan Lam Q, King Hung Ko O, Zheng BJ, Lu L:
Local BAFF gene silencing suppresses Th17-cell
generation and ameliorates autoimmune arthritis. Proc
Natl Acad Sci USA 2008, 105:14993-14998. Otettu
29.2.16

10. Laird, R.M., Laky, K. & Hayes, S.M. Unexpected
role for the B cell-specific Src family kinase B
lymphoid kinase in the development of
IL-17-producing $\gamma\delta$ T cells. J. Immunol. **185**,
6518–6527 (2010). Otettu 25.3.20
11. Ref. ei katsot

Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH. Caspase-1-processed cytokines IL-1' and IL-18 promote IL-17 production by ' ' and CD4 T cells that mediate auto-immunity. J Immunol 2011;186:5738–48. Otettu 29.2.16

Treatment of Psoriasis with IL-17 Inhibitors: Comparison of Long-Term Effectiveness and Drug Survival of **Secukinumab** vs Ixekizumab in Real-World Practice.

Lam J, Cazzaniga S, Seyed Jafari SM, Maul JT, Feldmeyer L, Bossart S, Yawalkar N, Heidemeyer K. Psoriasis (Auckl). 2025 Mar 27;15:71-84. doi: 10.2147/PTT.S509495. eCollection 2025. PMID: 40166484 **Free PMC article.** Otettu 4.6.25

Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C.

Br J Dermatol. 2023 Feb 10;188(2):198-207. doi: 10.1093/bjd/ljac040.

PMID: 36763857 Clinical Trial. Otettu 12.6.23

Secukinumab in plaque psoriasis--results of two phase 3 trials.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tying S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group.

N Engl J Med. 2014 Jul 24;371(4):326-38. doi::

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233–40. Otettu 29.2.16

Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology.

Lanna C, et al. Expert Rev Clin Pharmacol. 2022. PMID: 36189480 ei ole M

Successful therapy of plaque-type psoriasis with **secukinumab** in patients with multiple comorbidities treated with previous biologic therapies.

Lasagni C, Bigi L, Conti A, Pellacani G.

J Dermatolog Treat. 2018;29(sup2):5-8. Otettu 3.3.20

Ref. katsottu 4.3.20

Cytokines of the IL-17 family in psoriasis.

Lauffer F, Eyerich K, Boehncke WH, Asadullah K, Beissert S, Ghoreschi K, Schön MP.

J Dtsch Dermatol Ges. 2020 Jul;18(7):675-681. doi:

10.1111/ddg.14124. Epub 2020 May 24.

PMID: 32447845 Review. Otettu 4.9.22

IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema.

Lauffer F, et al. J Eur Acad Dermatol Venereol. 2020.

PMID: 31793105 Otettu 30.11.22

Laurence A, O'Shea JJ. T(H)-17 differentiation: of mice and men. Nat Immunol. 2007; 8:903–905. [PubMed:]
Otettu 29.2.16

.
[Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.](#)

Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, Hennighausen L, Shevach EM, O'shea JJ.
Immunity. 2007 Mar;26(3):371-81.

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

[Minimal impact of **IL-17** and IL-12/23 inhibition on SARS-CoV-2/COVID-19 antibody response in psoriasis patients.](#)

Lavin L, Ungar B, Sa B, Guttman-Yassky E.

Arch Dermatol Res. 2023 Nov 21;316(1):5. doi: 10.1007/s00403-023-02746-8.

PMID: 37987858 Otta M

[The interleukin-23/interleukin-17 axis in spondyloarthritis.](#)

Layh-Schmitt G, Colbert RA.

Curr Opin Rheumatol. 2008 Jul;20(4):392-7. doi: 10.1097/BOR.0b013e328303204b. Review.

PMID:

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Lazarevic V, Chen X, Shim JH, Hwang ES, Jang E, Bolm AN, Oukka M, Kuchroo VK, Glimcher LH: T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORgammat. Nat Immunol 2011, 12:96-104. Otettu 29.2.16

[Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics.](#)

Lazaridou E, Apalla Z, Ravanidis S, Stefanou G, Vellopoulou K, Tsolakidis A, Mathioudakis K, Kourlaba G. Arch Dermatol Res. 2025 Jan 28;317(1):310. doi: 10.1007/s00403-024-03746-y. PMID: 39873811 Otta M

Drug survival for biologics in psoriasis patients: real world evidence for Greece during the period 2016-2020.

Lazaridou E, Kourlaba G, Ravanidis S, Gounelas G, Stefanou G, Tsolakidis A, Mathioudakis K, Apalla Z.

Clin Exp Dermatol. 2024 Jul 6;llae240. doi: 10.1093/ced/llae240. Online ahead of print.

PMID: 38970536 Otta M

Systemic effects of **IL-17** in inflammatory **arthritis**.

Lazzerini PE, Laghi-Pasini F, Boutjdir M, Capecchi PL.

Front Cardiovasc Med. 2019 Dec 10;6:183. doi: 10.3389/fcvm.2019.00183. eCollection 2019.

PMID: 31921897 **Free PMC article.** Otettu 21.9.20

[Pain relief with **secukinumab** treatment.](#)

Leake I.

Nat Rev Rheumatol. 2018 Jul 9. doi:

Otettu 4.2.21

[Similar articles](#)

Lebson, L., Gocke, A., Rosenzweig, J., Alder, J., Civin, C., Calabresi, P. A., et al. (2010). Cutting edge: the transcription factor Kruppel-like factor 4 regulates the differentiation of Th17 cells independently of RORgammat. J. Immunol. 185, 7161–7164. doi: 10.4049/jimmunol.1002750 Otettu 29.2.16

M. Lebwohl, L. Iversen, L. Eidsmo et al., “Long-term psoriasis control following secukinumab discontinuation indicates disease modification of moderate-to-severe

psoriasis,” *Clinical and Mechanistic Results*, vol. 10, pp. S7–S31, 2017. Otta M Ei ole GS

Ei ole PUBMED Otta myöhemmin

Letter in response to Egeberg A, Bryld LE, Skov L, Drug survival of **secukinumab** and ixekizumab for moderate-to-severe plaque psoriasis.

Lebwohl MG.

J Am Acad Dermatol. 2019 Otettu 28.2.20

Ref. katsottu 6.3.2020

Investigation of plaque psoriasis relapse after **secukinumab** withdrawal in patients from two Phase 3 studies.

Lebwohl M, Iversen L, Eidsmo L, Krueger JG, Suárez-Fariñas M, Tomalin L, Kolbinger F, You R, Milutinovic M.

Clin Exp Dermatol. 2023 Oct 11:llad329. doi: 10.1093/ced/llad329. Online ahead of print. PMID: 37820029 Otettu 12.10.23

[Brodalumab: Seven-Year US Pharmacovigilance Report.](#)

Lebwohl MG, Koo JY, Armstrong AW, Strober BE, Yoon SH, Rawnsley NN, Goehring EL Jr, Jacobson AA. Dermatol Ther (Heidelb). 2025 Jul 29. doi: 10.1007/s13555-025-01497-w. Online ahead of print. PMID: 40730908 Otettu 31.7.25

The risk of malignancy in patients with **secukinumab**-treated psoriasis, psoriatic arthritis and

ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up.

Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, Jehl V, Marfo K, Primatesta P, Shete A, Trivedi V, Mease PJ.

Br J Dermatol. 2021 Apr 8. doi: 10.1111/bjd.20136.

Online ahead of print.

PMID: 33829482 Otettu 30.11.22

Cytokines, Vascular Endothelial Growth Factors, and PlGF in Autoimmunity: Insights From Rheumatoid Arthritis to Multiple Sclerosis.

Lee YE, Lee SH, Kim WU.

Immune Netw. 2024 Feb 16;24(1):e10. doi:

10.4110/in.2024.24.e10. eCollection 2024 Feb.

PMID: 38455464 **Free PMC article.** Review. Otettu 13.3.24

Aberrant bone formation and dysregulated bone homeostasis in ankylosing spondylitis.

Lee GW.

World J Stem Cells. 2025 May 26;17(5):106934. doi:
10.4252/wjsc.v17.i5.106934.

PMID: 40503364 [Free PMC article.](#) Otettu 31.7.25

[IL-17-producing cells in ankylosing spondylitis patients show gender-based differences in gene expression.](#)

Lee CM, Chan ER, Schueller D, Breitman M, Haghiac M, Magrey M.

Clin Exp Rheumatol. 2024 Mar 3. doi:
10.55563/clinexprheumatol/do7osn. Online ahead of
print.

PMID: 38436300 Otettu 13.3.24

[mtSTAT3 suppresses rheumatoid arthritis by regulating Th17 and synovial fibroblast inflammatory cell death with IL-17-mediated autophagy dysfunction](#)

Lee, Seon-Yeong ; Moon, Jeonghyeon ; Lee, A Ram ; Moon, Young-Mee ; Choi, Jeong Won ; Lee, Chae Rim ; Jeon, Su Been ; Sohn, Hee Su ; Youn, Jeehee ; Shin, Dongyun ; Park, Sung-Hwan ; Cho, Mi-La
Experimental and Molecular Medicine, 2025, 57(0), , pp.221-234 Otettu 4.6.25

Comparative efficacy and safety of **secukinumab** and ixekizumab in patients with active ankylosing spondylitis.

Lee YH, Song GG.

Z Rheumatol. 2020 Jul 9. doi:

10.1007/s00393-020-00837-9. Online ahead of print.

PMID: 32648054 Otettu 20.9.20

Comparative Efficacy and Safety of Janus Kinase Inhibitors and **Secukinumab** in Patients with Active

Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.

Lee YH.

Pharmacology. 2022 Jul 11:1-8. doi:

10.1159/000525627. Online ahead of print.

PMID: 35817017 [Free article.](#) Otettu 26.8.22

Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS, Goddard AD, Yansura DG, Vandlen RL, Wood WI, Gurney AL (2001) IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 276:1660–1664
Ei oteta

Lee KA, Kang MH, Lee YS, Kim YJ, Kim DH, Ko HJ, et al. A distinct subset of natural killer T cells produces IL-17,

contributing to airway infiltration of neutrophils but not to airway hyperreac- tivity. *Cell Immunol* 2008;251:50–5.

Otettu 29.2.16

IL-17 Induced Stromal Cell-Derived Factor-1 and Profibrotic Factor in Keloid-Derived Skin Fibroblasts via the STAT3 Pathway.

Lee SY, et al. *Inflammation*. 2020. PMID: 31814061 [Free PMC article](#). Otettu 7.9.22

Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease.

Lee JY, et al. *Cell*. 2020. PMID: 31866067 [Free PMC article](#). Otettu 7.9.22

Lee YK, Mukasa R, Hatton RD, Weaver CT.
Developmental plasticity of Th17 and Treg
cells. Curr Opin Immunol 2009;21:274–80. Otettu
29.2.16

Lee YK, et al. Late developmental plasticity in the T
helper 17 lineage. Immunity. 2009; 30:92– 107.
Otettu 29.2.16

Lee JH, Cho ML, Kim JI, Moon YM, Oh HJ, Kim GT, et
al. Interleukin 17 (IL-17) in-
creases the expression of Toll-like receptor-2, 4, and 9
by increasing IL-1beta and
IL-6 production in autoimmune arthritis. J Rheumatol
2009;36:684–92. Otettu 4.3.16

Lee WW, Kang SW, Choi J, Lee SH, Shah K, Eynon EE, et al. Regulating human Th17 cells via differential expression of IL-1 receptor. Blood 2010;115:530–40.
Otettu 29.2.16

Lee, Y. et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13, 991–999 (2012). Otettu 4.3.16

[The role of **interleukin-17** in bone metabolism and inflammatory skeletal diseases.](#)

Lee Y.

BMB Rep. 2013 Oct;46(10):479-83. Review.

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Prognostic signature of interferon- γ and interleukin-17A in early rheumatoid arthritis.

Lee K, Min HK, Koh SH, Lee SH, Kim HR, Ju JH, Kim HY.

Clin Exp Rheumatol. 2022 May;40(5):999-1005. doi:

10.55563/clinexprheumatol/mkbvch. Epub 2021 Jul 23.

PMID: 34369364 [Free article.](#) Otettu 29.8.22

Lee SY, Han SJ, Nam SM et al (2013) Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non- Sjögren syndrome dry eye patients. Am J Ophthalmol 156(2):247–253 Otettu

4.3.16 Maksullinen

Ref. ei katsot.

Lee E, Zarei M, La Senna C. et al. Psoriasis Targeted Therapy: Characterization of Interleukin 17A Expression in Subtypes of Psoriasis. *J Drugs Dermatol* 2015;14:1133–1136. Ei oteta

Lee YH, Song GG. Comparative efficacy and safety of secukinumab and adalimumab in patients with active ankylosing spondylitis: a Bayesian network meta-analysis of randomized controlled trials. *J Rheum Dis*. 2017;24(4):211–219. Otettu 20.3.20

[Drug survival of **secukinumab** for psoriasis in a real-world setting.](#)

Lee EB, Amin M, Egeberg A, Wu JJ.

J Dermatolog Treat. 2018 May 24:1-2. doi: [10.1016/j.jdermat.2018.05.001](#) M
doi: [10.1016/j.jdermat.2018.05.001](#) GS Ei oteta

[Similar articles](#)

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.

Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, Bao W, Dee CMA, Guana A, Tsai TF.

J Dermatol. 2019 Jul 25. doi: [10.1016/j.jdermat.2019.07.001](#) Otettu 28.2.2020

Risk of Herpes Zoster and Postherpetic Neuralgia in Patients with Psoriasis Treated with Biologics: A nationwide study using target trial emulation framework.

Lee CN, Hsieh MH, Chen CY, Yang CC, Liao TC, Lai EC.

Br J Dermatol. 2025 Mar 20:ljaf101. doi:

10.1093/bjd/ljaf101. Online ahead of print.

PMID: 40112174 Otta M

Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of **Secukinumab** for the Treatment of Moderate to Severe Plaque Psoriasis.

Lee JE, Wang J, Florian J, Wang YM, Kettl D, Marcus K, Woitach A.

Clin Pharmacol Ther. 2019 Jul;106(1):78-80. doi:

10.1002/cpt.1478. Epub 2019 Jun 12. No abstract

Otettu 28.2.20

Severe colitis complicating **secukinumab** (Cosentyx®) therapy.

Lee ASW, Levell NJ, Shah SN, Gaffney K, Tremelling MAW.

Clin Exp Dermatol. 2019 Dec 19. Otettu 28.2.20

Risk of Herpes Zoster and Postherpetic Neuralgia in Patients with Psoriasis Treated with Biologics: A nationwide study using target trial emulation framework.

Lee CN, Hsieh MH, Chen CY, Yang CC, Liao TC, Lai EC.

Br J Dermatol. 2025 Mar 20:ljaf101. doi:

10.1093/bjd/ljaf101. Online ahead of print.

PMID: 40112174 Otta M

Severe colitis complicating **secukinumab** (Cosentyx()) therapy.

Lee ASW, Levell NJ, Shah SN, Gaffney K, Tremelling MAW.

Clin Exp Dermatol. 2020 Apr;45(3):344-345. doi:
Otettu 30.11.22

Association between Mycoplasma pneumoniae pneumonia and **interleukin-17**: insights and interpretative cautions from a meta-analysis.

Leerach N, Sitthisak S, Kittit T, Teerawattanapong N, Mahikul W, Lamlertthon S, Chaiyakunapruk N, Tasaanapak K.

Transl Pediatr. 2025 Jul 31;14(7):1737-1740. doi:
10.21037/tp-2025-377. Epub 2025 Jul 11.

PMID: 40800201 **Free PMC article.** Otettu 22.8.25

Secukinumab responses vary across the spectrum of congenital ichthyosis in adults.

Lefferdink R, Rangel SM, Chima M, Ibler E, Pavel AB, Kim H, Wu B, Abu-Zayed H, Wu J, Jackson K, Singer G, Choate KA, Guttman-Yassky E, Paller AS.

Arch Dermatol Res. 2022 Feb 26. doi:

10.1007/s00403-022-02325-3. Online ahead of print.

PMID: 35218370 Otta M Otta myöhemmin

Implication of **IL-17** in Bone Loss and Structural Damage in Inflammatory Rheumatic Diseases.

Le Goff B, Bouvard B, Lequerre T, Lespessailles E, Marotte H, Pers YM, Cortet B.

Mediators Inflamm. 2019 Aug 14;2019:8659302. doi:

10.1155/2019/8659302. eCollection 2019.

PMID: 31485194 Otettu 21.9.20

LeGrand A, Fermor B, Fink C, Pisetsky DS, Weinberg JB, Vail TP, *et al.* (2001). Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. *Arthritis Rheum* 44:2078-2083. Otettu 15.3.20

LeibundGut-LandmannS, GrossO, RobinsonMJ, OsorioF, Slack EC, Tsoni SV, *et al.* Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. *Nat Immunol* 2007;8:630–8. Otettu 4.3.16

Leijten EF, van Kempen TS, Boes M, Michels-van Amelsfort JM, Hijnen D, Hartgring SA, et al. Enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid. *Arthritis Rheumatol* 2015;67:2673–8. Otettu 20.9.20

Tissue-Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis.

Leijten EF, van Kempen TS, Olde Nordkamp MA, Pouw JN, Kleinrensink NJ, Vincken NL, Mertens J, Balak DMW, Verhagen FH, Hartgring SA, Lubberts E, Tekstra J, Pandit A, Radstake TR, Boes M.

Arthritis Rheumatol. 2021 Jul;73(7):1220-1232. doi: 10.1002/art.41652. Epub 2021 May 25.

PMID: 33452865 [Free PMC article](#). Otettu 1.9.22

Delineation of the molecular determinants of the unique allosteric binding site of the orphan nuclear receptor ROR γ t.

Leijten-van de Gevel IA, Brunsveld L.

J Biol Chem. 2020 Jul 3;295(27):9183-9191. doi:

10.1074/jbc.RA120.013581. Epub 2020 May 20.

PMID: 32439807 [Free PMC article](#). Otettu 4.9.22

Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, SchulzeKoops H, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010;62:2876–85. Otettu 25.12.20

Increased plasticity of non-classic Th1 cells toward the Th17 phenotype.

Leipe J, Pirronello F, Klose A, Schulze-Koops H, Skapenko A.

Mod Rheumatol. 2020 Sep;30(5):930-936. doi: 10.1080/14397595.2019.1667473. Epub 2019 Oct 17. PMID: 31512538 Otettu 21.9.20

Altered T cell plasticity favours Th17 cells in early arthritis.

Leipe J, Pirronello F, Schulze-Koops H, Skapenko A.

Rheumatology (Oxford). 2020 Feb 6:kez660. doi: 10.1093/rheumatology/kez660. Online ahead of print. PMID: 32030419 Otettu 21.9.20

Ref. katsottu 29.9.20

[Role of Th17 cells in human autoimmune arthritis.](#)

Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, Skapenko A.

Arthritis Rheum. 2010 Oct;62(10):2876-85.

Otettu 3.2.16

Linkki ei onnistu tekstiin

[Free Article](#)

[Similar articles](#)

[Increased Th17 cell frequency and poor clinical outcome in rheumatoid arthritis are associated with a genetic variant in the IL4R gene. rs1805010.](#)

Leipe J, Schramm MA, Prots I, Schulze-Koops H, Skapenko A.

Arthritis Rheumatol. 2014 May;66(5):1165-75. doi: 10.1002/art.38343.

PMID:

Otettu 3.2.16

[Free Article](#)

[Similar articles](#)

Bone Involvement in Patients with Spondyloarthropathies.

Lems W, Miceli-Richard C, Haschka J, Giusti A, Chistensen GL, Kocijan R, Rosine N, Jørgensen NR, Bianchi G, Roux C.

Calcif Tissue Int. 2022 Apr;110(4):393-420. doi: 10.1007/s00223-021-00933-1. Epub 2022 Jan 23. PMID: 35066596 Review. Otta M Otta myöhemmin

Lenarczyk A, Helsloot J, Farmer K, Peters L, Sturgess A, Kirkham B: Antigen-induced IL-17 response in the peripheral blood mononuclear cells (PBMC) of healthy controls. Clin Exp Immunol 2000;122:41–48. Otettu 19.3.20

[Osteopontin receptor-dependent regulation of Th1 and Th17 responses in autoimmune diseases: comment on the article by Chen et al.](#)

Leng RX, Pan HF, Ye DQ.

Arthritis Rheum. 2011 Feb;63(2):568; author reply 568-9. doi: 10.1002/art.30127. No abstract available.

PMID:

21280012 Otetu 3.2.16

[Free Article](#)

[Similar articles](#)

[Mucosal fungi promote gut barrier function and social behavior via Type 17 immunity.](#)

Leonardi I, Gao IH, Lin WY, Allen M, Li XV, Fiers WD, De Celie MB, Putzel GG, Yantiss RK, Johncilla M, Colak D, Iliev ID.

Cell. 2022 Mar 3;185(5):831-846.e14. doi:
10.1016/j.cell.2022.01.017. Epub 2022 Feb 16.
PMID: 35176228 Otettu 30.11.22

Leonaviciene L., Bradunaite R. and Astrauskas V.
(2004): Proinflammatory cytokine interleukin-17 and
its role in pathogenesis of rheumatoid arthritis.
Medicina, **40**, 419–422. Ei oteta

[Biologics as a novel treatment option for palmoplantar
pustulosis: a comprehensive review.](#)

Leong HF, Wang WH, Peng F.

Postepy Dermatol Alergol. 2024 Jun;41(3):262-269. doi:
10.5114/ada.2024.141128. Epub 2024 Jun 30.

PMID: 39027700 **Free PMC article.** Review. Otettu
27.9.24

Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and/or spondyloarthritis and initiating treatment with **secukinumab**.

Lerma Garrido JJ, Gracia Pérez A, Pérez Torres A, Rueda Cid A, Molina Almela C, Pastor Cubillo MD, Campos Fernández C, Balaguer Trull I, Carmona L, Calvo Catalá J. *Reumatol Clin*. 2020 Sep 26:S1699-258X(20)30194-7. doi: 10.1016/j.reuma.2020.07.010. Online ahead of print.

PMID: 32994150 English, Spanish. ei oteta

[Regulatory T Cell Dysregulation in Vitiligo: A Meta-Analysis and Systematic Review of Immune Mechanisms and Therapeutic Perspectives.](#)

Lerner G, Nikolaou M, Stoffel C, Schmauch E, Kündig T, Passeron T, Seneschal J, van Geel N, Held U, Kolios AGA.

Int J Dermatol. 2025 Jul 14. doi: 10.1111/ijd.17959.
Online ahead of print.
PMID: 40660423 Review. Otettu 31.7.25

Lester SR, Bain JL, Johnson RB, Serio FG (2007)
Gingival concentrations of interleukin-23 and -17 at
healthy sites and at sites of clinical attachment loss. J
Periodontol 78:1545–1550 Otettu 12.3.20

[Mucosal-Associated Invariant T Cells in Rheumatic
Diseases.](#)

Lesturgie-Talarek M, Gonzalez V, Beaudoin L, Sénot N,
Miceli-Richard C, Allanore Y, Lehuen A, Avouac J.
Arthritis Rheumatol. 2025 May 21. doi:
10.1002/art.43242. Online ahead of print.
PMID: 40395188 Review. Otettu 31.7.25

New-Onset Inflammatory Bowel Diseases Among IL-17 inhibitors-Treated Patients: Results From The Case-Control MISSIL Study.

Letarouilly JG, Pham T, Pierache A, Acquacalda É, Banneville B, Barbarot S, Baudart P, Bauer É, Claudepierre P, Constantin A, Dernis E, Felten R, Gaudin P, Girard C, Gombert B, Goupille P, Guennoc X, Henry-Desailly I, Jullien D, Karimova E, Lanot S, Le Dantec L, Pascart T, Plastaras L, Sultan N, Truchet X, Varin S, Wendling D, Gaboriau L, Staumont-Sallé D, Peyrin-Biroulet L, Flipo RM.

Rheumatology (Oxford). 2021 Nov 3:keab819. doi: 10.1093/rheumatology/keab819. Online ahead of print. PMID: 34730790 Otettu 30.11.22

[Efficacy and safety of intravenous **secukinumab** in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.](#)

Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL; AIN457A2208 Study Group. Ophthalmology. 2015 May;122(5):939-48. doi:

Otettu 3.2.16 Maksullinen

[Similar articles](#)

Leung S, Liu X, Fang L, Chen X, Guo T, Zhang J. The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. *Cell Mol Immunol*. 2010;7:182–189. Otettu 19.3.20

Ref. ei katsot

Lewis B J, Rajpara S, Haggart A M et al. Clin Exp Immunol 2013; 173: 38–46. Otettu 4.3.16

Lexberg, M.H. et al. Th memory for interleukin-17 expression is stable in vivo. Eur. J. Immunol. 38, 2654–2664 (2008). Otettu 25.3.20

Ley K, Smith E, Stark MA. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol Res. 2006;34(3):229–242. ei oteta

Li H, Chen J, Huang A et al. Cloning and characterization of IL-17B and IL-17C, two new

members of the IL-17 cytokine family. Proc Natl Acad Sci USA 2000;97:773-8. Otettu 4.3.16

Interleukin-17 in Liver Disease Pathogenesis.

Li N, Yamamoto G, Fuji H, Kisseleva T.

Semin Liver Dis. 2021 Nov;41(4):507-515. doi: 10.1055/s-0041-1730926. Epub 2021 Jun 15. PMID: 34130335 Review. Ei ole M

Case Report: Successful Treatment of Secukinumab-Induced SAPHO Syndrome With Tofacitinib.

Li M, Wu P, Yong SB, Leong PY.

Int J Rheum Dis. 2025 Jun;28(6):e70305. doi: 10.1111/1756-185X.70305.

PMID: 40443046 No abstract available. Otta M

Li MO, et al. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. *Immunity*. 2007; 26:579–591. [PubMed:] Otettu 4.3.16

Li X, Kim KW, Cho ML et al. IL-23 induces receptor activator of NF-kappaB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-kappaB signal pathways. *Immunol Lett* 2010;127:100-7.

Otettu 20.9.20

Secukinumab and Upadacitinib Treatment for
Papillon-Lefevre Syndrome in 2 Cases.

Li J, Wang Z, Xu Z.

JAMA Dermatol. 2025 Jul 9. doi:

10.1001/jamadermatol.2025.1639. Online ahead of
print.

PMID: 40632515 Otta M

Li L, Kim J, Boussiotis VA. IL-1beta-mediated signals
preferentially drive conversion of regulatory T cells but
not conventional T cells into IL-17-producing cells. J
Immunol. 2010; 185:4148–4153. Otettu 17.3.20

Novel Small-Molecule Treatment and Emerging
Biological Therapy for Psoriasis.

Li Y, Cheng Y, Cai Y, Duan Z, Xu H, Huang Y, Ma X, Xin X,
Yin L.

Biomedicines. 2025 Mar 23;13(4):781. doi:
10.3390/biomedicines13040781.
PMID: 40299379 [Free PMC article](#). Review. Otettu
4.6.25

Li, L., Patsoukis, N., Petkova, V., and Boussiotis, V. A.
(2012). Runx1 and Runx3 are involved in the generation
and function of highly suppressive IL-17- producing T
regulatory cells. PLoS ONE 7:e45115. doi:
10.1371/journal.pone.0045115 Otettu 4.3.16

Li L, Boussiotis VA (2013) The role of IL-17-producing
Foxp3+ CD4+ T cells in inflammatory bowel disease and
colon cancer. Clin Immunol 148:246–253. Otettu
7.3.20

Ref. katsottu 16.3.20

<https://doi.org/10.1016/j.clim.2013.05.003>

Safety of Interleukin Inhibitors in Psoriatic Patients with Latent Tuberculosis Infection Without Chemoprophylaxis: A Systematic Review.

Li J, Xiang X, Wang Z, Miao C, Chen Y, Xu Z.

Acta Derm Venereol. 2025 Mar 3;105:adv42081. doi: 10.2340/actadv.v105.42081.

PMID: 40026108 [Free PMC article.](#) Otettu 4.6.25

CD137 might be a pivotal regulator of Th1/Th17-driven autoimmunity and B-cell hyperactivity in hyperthyroidism.

Li S, Li K, Li J, Wang Y, Shi Q.

Mol Immunol. 2025 Aug;184:89-99. doi:

10.1016/j.molimm.2025.06.006. Epub 2025 Jun 19.

PMID: 40541003 Otta M

Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells.

Li H, Adamopoulos IE, Moulton VR, Stillman IE, Herbert Z, Moon JJ, Sharabi A, Krishfield S, Tsokos MG, Tsokos GC.

Nat Commun. 2020 Jun 5;11(1):2859. doi: 10.1038/s41467-020-16636-4.

PMID: 32503973 **Free PMC article.** Otettu 4.9.22

Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease.

Li R, Lei H, Wang C, Liu X.

Eur J Med Res. 2025 Jan 19;30(1):37. doi:
10.1186/s40001-025-02295-y.
PMID: 39828702 **Free PMC article.** Otettu 2.3.25

[Pathologic finding of increased expression of
interleukin-17 in the synovial tissue of rheumatoid
arthritis patients.](#)

Li N, Wang JC, Liang TH, Zhu MH, Wang JY, Fu XL,
Zhou JR, Zheng SG, Chan P, Han J.

Int J Clin Exp Pathol. 2013 Jun 15;6(7):1375-9. Print
2013.

PMID:

23826419 Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

1. Li CR, Mao QX, Chen M, Jia WX, Yao X, Feng SY, et al. Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People's Republic of China. *Drug Des Devel Ther.* 2015; 9: 5591–5594. Otettu 28.3.20
2. <https://doi.org/10.2147/DDDT.S87260> PMID: 26508833

LI Y-F, ZHANG S-X, MA X-W *et al.*: Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with multiple sclerosis: A meta-analysis. *Mult Scler Relat Disord* 2017; 18: 20-25.

Otettu 30.11.22

IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.

Li H, Tsokos GC.

Clin Rev Allergy Immunol. 2021 Feb;60(1):31-45. doi:
10.1007/s12016-020-08823-4. Epub 2020 Nov 13.
PMID: 33185790 [Free PMC article](#). Otettu 2.9.22

Successful treatment of adalimumab-resistant
palmoplantar pustulosis with **secukinumab**: a case
report.

Li QY, Wang G.

Chin Med J (Engl). 2020 Nov 20. doi:
10.1097/CM9.0000000000001246. Online ahead of
print.
PMID: 33237699 ei oteta

Safety of Interleukin Inhibitors in Psoriatic Patients with
Latent Tuberculosis Infection Without
Chemoprophylaxis: A Systematic Review.

Li J, Xiang X, Wang Z, Miao C, Chen Y, Xu Z.
Acta Derm Venereol. 2025 Mar 3;105:adv42081. doi:
10.2340/actadv.v105.42081.
PMID: 40026108 [Free PMC article.](#) Otettu 4.6.25

Liang SC, Tan XY, Luxenberg D Petal.
J Exp
Med 2006; 203: 2271–2279. Otettu 4.3.16

Liao JJ, Huang MC, Goetzl EJ. Cutting edge: alternative
signaling of Th17 cell development by sphingosine
1-phosphate. *J Immunol.* 2007; 178(9):5425-5428.
Otettu 20.9.20

Lim HW, Lee J, Hillsamer P, Kim CH. Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3 + regulatory T cells. J Immunol. 2008; 180:122–129. [PubMed:] Otettu 4.3.16

Lim, H. W., Kang, S. G., Ryu, J. K., Schilling, B., Fei, M., Lee, I. S., et al. (2015). SIRT1 deacetylates ROR γ and enhances Th17 cell generation. J. Exp. Med. 212, 607–617. doi: 10.1084/jem.20132378 Otettu 4.3.16

Lin Y, Slight SR, Khader SA: Th17 cytokines and vaccine-induced immunity. Semin Immunopathol, 2010, 32, 79–90. Otettu 4.3.16

Lin AM, Rubin CJ, Khandpur R et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011;187:490-500. Otettu 4.3.16

[Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF- \$\alpha\$, IL-12/23, IL-17, and IL-23: A population-based retrospective cohort study.](#)

Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY.

PLoS Med. 2025 Apr 17;22(4):e1004591. doi:

10.1371/journal.pmed.1004591. eCollection 2025 Apr.

PMID: 40245096 **Free PMC article.** Otettu 31.7.25

91. Lin, D. et al. IL-17 regulates the expressions of RANKL and OPG in human periodontal ligament cells via TRAF6/TBK1-JNK/NF- κ B pathways. *Immunology* **144**, 472–485 (2015). Otettu 29.3.20

Interleukin-22 Influences the Th1/Th17 Axis.

Lindahl H, Olsson T.

Front Immunol. 2021 Feb 22;12:618110. doi:

10.3389/fimmu.2021.618110. eCollection 2021.

PMID: 33692792 **Free PMC article.** Otettu 30.8.22

1. Linden A, Adachi M. Neutrophilic airway inflammation and IL-17. *Allergy*. 2002;57:769-775. Otettu 19.3.20

Linden A: Neutrophils, interleukin-17 and obstructive airway disease. *Allergol Int* 2003;52: 173–182. Otettu 19.3.20

Ref ei otet.

IL-17A: A promising target in viral lung infections.

Lindén A.

Respirology. 2021 Nov;26(11):1012-1013. doi: 10.1111/resp.14158. Epub 2021 Sep 27.

PMID: 34580948 **Free article**. Otettu 29.8.22

Linden A, Laan M, Anderson G. Neutrophils, interleukin-17A and lung disease. Eur Respir J. 2005;25:159-172. Otettu 19.3.20

Ref. katsottu 20.3.20

Comparison of treatment retention and response to **secukinumab** versus tumour necrosis factor inhibitors in psoriatic arthritis.

Lindström U, Glintborg B, Di Giuseppe D, Schjødt Jørgensen T, Gudbjornsson B, Lederballe Grøn K, Aarrestad Provan S, Michelsen B, Lund Hetland M, Wallman JK, Nordström D, Trokovic N, Love TJ, Krogh NS, Askling J, Jacobsson LTH, Kristensen LE.

Rheumatology (Oxford). 2020 Dec 26:keaa825. doi: 10.1093/rheumatology/keaa825. Online ahead of print. PMID: 33367900 Otettu 4.2.21

Anterior uveitis in patients with spondyloarthritis treated with **secukinumab** or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?

Lindström U, Bengtsson K, Olofsson T, Di Giuseppe D, Grintborg B, Forsblad-d'Elia H, Jacobsson LTH, Askling J.

Ann Rheum Dis. 2021 Jun

15:annrheumdis-2021-220420. doi:

10.1136/annrheumdis-2021-220420. Online ahead of print.

PMID: 34130984 Otettu 8.8.21

Ling Y, Puel A. IL-17 and infections. *Actas Dermosifiliogr.* 2014;105 (Suppl 1):34–40.

Ei ole M

Anders Lindén, A role for cytoplasmic adaptor protein Act-1 in mediating IL-17 signaling, Science. 398 (2007) 1–8. ei oteta

[MAIT cells altered phenotype and cytotoxicity in lupus patients are linked to renal disease severity and outcome.](#)

Litvinova E, Bounaix C, Hanouna G, Da Silva J, Noailles L, Beaudoin L, Padden M, Bellamri N, Lehuen A, Daugas E, Monteiro RC, Flament H.

Front Immunol. 2023 Oct 10;14:1205405. doi:

10.3389/fimmu.2023.1205405. eCollection 2023.

PMID: 37885889 **Free PMC article.** Otettu 14.3.23

IL-17A is a common and critical driver of impaired lung function and immunopathology induced by influenza virus, rhinovirus and respiratory syncytial virus.

Liu X, Nguyen TH, Sokulsky L, Li X, Garcia Netto K, Hsu AC, Liu C, Laurie K, Barr I, Tay H, Evers F, Foster PS, Yang M.

Respirology. 2021 Nov;26(11):1049-1059. doi: 10.1111/resp.14141. Epub 2021 Sep 1. PMID: 34472161 Otettu 30.11.22

Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8⁺ T cells in autoimmunity and cancer.

Liu J, Chang HW, Huang ZM, Nakamura M, Sekhon S, Ahn R, Munoz-Sandoval P, Bhattarai S, Beck KM, Sanchez IM, Yang E, Pauli M, Arron ST, Fung-Leung WP, Munoz E, Liu X, Bhutani T, North J, Fourie AM, Rosenblum MD, Liao W.

J Allergy Clin Immunol. 2021 Jun;147(6):2370-2380. doi: 10.1016/j.jaci.2020.11.028. Epub 2020 Dec 9. PMID: 33309739 [Free PMC article.](#) Otettu 2.9.22

Lichen planus associated with **secukinumab** treatment for plaque psoriasis.

Liu V, Moiin A, Diaz C.

Dermatol Online J. 2023 Apr 15;29(2). doi: 10.5070/D329260779.

PMID: 37220295 otettu 12.6.23

Phase 2 randomized, double-blind study of IL-17 targeting with **secukinumab** in atopic dermatitis.

Ungar B, Pavel AB, Li R, Kimmel G, Nia J, Hashim P, Kim HJ, Chima M, Vekaria AS, Estrada Y, Xu H, Peng X, Singer GK, Baum D, Mansouri Y, Taliercio M, Guttman-Yassky E.

J Allergy Clin Immunol. 2020 May

16:S0091-6749(20)30684-9. doi:

10.1016/j.jaci.2020.04.055. Online ahead of print.

PMID: 32428528 Otettu 20.9.20

Littman, D.R., and Rudensky, A.Y. (2010). Th17 and regulatory T cells in mediating and restraining inflammation. *Cell* 140, 845–858. Otettu 4.3.16

Transcriptomic Profiling of Plaque Psoriasis and Cutaneous T-Cell Subsets during Treatment with **Secukinumab**.

Liu J, Chang HW, Grewal R, Cummins DD, Bui A, Beck KM, Sekhon S, Yan D, Huang ZM, Schmidt TH, Yang EJ, Sanchez IM, Nakamura M, Bhattarai S, Thibodeaux Q, Ahn R, Pauli M, Bhutani T, Rosenblum MD, Liao W.

JID Innov. 2021 Dec 30;2(3):100094. doi:

10.1016/j.xjidi.2021.100094. eCollection 2022 May.

PMID: 35757784 **Free PMC article.** Otettu 26.8.22

Liu, X. K., X. Lin, and S. L. Gaffen. 2004. Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. *J. Biol. Chem.* 279: 52762–52771. Otettu 19.3.20

C.Liu,W.Qian,Y.Qianetal.,“Act1,aU-box E3 ubiquitin ligase for IL-17 signaling,” *Science Signaling*, vol. 2, no. 92, article no. ra63, 2009. Otettu 20.9.20

Liu X, Leung S, Wang C et al. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. *Nat Med* 2010;16:191–7. Otettu 4.3.16

Liu L, Okada S, Kong XF et al. (2011) Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. *J Exp Med* 208:1635–48 Otettu 8.3.20

Ref. katsottu 15.3.20

Liu, H., and C. Rohowsky-Kochan. 2011. Interleukin-27-Mediated Suppression of Human Th17 Cells Is Associated with Activation of STAT1 and Suppressor of Cytokine Signaling Protein 1. *J. Interferon Cytokine Res.* 31:459–469 Otettu 15.3.20

Ref. ei katsot

Liu S, Song X, Chrunk BA, Shanker S, Hoth LR, Marr ES, et al. Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nat Commun 2013;4:1888. Otettu 4.3.16

[CD4+ tissue-resident memory Th17 cells are a major source of IL-17A in Spondyloarthritis synovial tissue.](#)

Liu F, Shi H, Turner JD, Anscombe R, Li J, Sekine T, Hammitzsch A, Agarwal D, Mahony C, Chen J, Kendrick B, Du D, Tong Q, Duan L, Dooley K, Fang H, Korsunsky I, Madhu R, Cribbs AP; Cartography Consortium; Friedrich M, Marsden BD, Chen YL, Ogg G, Adams A, Chen W, Leonardo S, McCann FE, Buckley CD, Rooney T, Freeman T, Uhlig HH, Dendrou C, Croft A, Filer A, Bowness P, Chen L.

Ann Rheum Dis. 2025 Jul;84(7):1151-1163. doi: 10.1016/j.ard.2025.04.018. Epub 2025 May 24. PMID: 40413112 **Free article.** Otettu 31.7.25

179.

[IL-17, a potential therapeutic target for Sjögren's syndrome?](#)

Liu SS, Ding Y, Lou JQ.

Clin Rheumatol. 2015 Sep;34(9):1657-8. doi:

10.1007/s10067-014-2621-3. Epub 2014 Apr 22. No abstract available.

PMID:

Otettu 3.2.16

[Similar articles](#)

Liu, H. P., Cao, A. T., Feng, T., Li, Q., Zhang, W., Yao, S., et al. (2015). TGF-beta converts Th1 cells into Th17 cells through stimulation of Runx1 expression. Eur. J. Immunol. 45, 1010–1018. Otettu 4.3.16

[Elevated serum levels of IL-6 and **IL-17** may associate with the development of ankylosing spondylitis.](#)

Liu W, Wu YH, Zhang L, Liu XY, Xue B, Wang Y, Liu B, Jiang Q, Kwang HW, Wu DJ.

Int J Clin Exp Med. 2015 Oct 15;8(10):17362-76.

Otettu 27.5.18

[Free PMC Article](#)

[Similar articles](#)

Liuzzo G, Troia F, Pedicino D. Interleukin-17 in atherosclerosis and cardiovascular disease: the good, the bad, and the unknown. Eur Heart J. 2013;34:556-559. Otettu 15.3.20

Ref. ei katsot

[Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.](#)

Lluch-Galcerá JJ, Carrascosa JM, González-Quesada A, Rivera-Díaz R, Sahuquillo-Torralba A, Llamas-Velasco M, Gómez-García FJ, Herrera-Acosta E, de la Cueva P, Baniandrés-Rodríguez O, Lopez-Estebanz JL, Belinchón I, Ferrán M, Mateu A, Rodríguez L, Riera-Monroig J, Abalde-Pintos MT, Carretero G,

García-Donoso C, Pujol-Marco C, Del Alcázar E, Santamaría-Domínguez C, Suárez-Pérez JA, Nieto-Benito LM, Ruiz-Genao DP, Salgado-Boquete L, Descalzo MÁ, García-Doval I.

Br J Dermatol. 2024 Feb 16;190(3):355-363. doi: 10.1093/bjd/ljad382.

PMID: 37846976 Otta M

Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed **secukinumab**: a case series.

Lo Y, Tsai TF.

Br J Dermatol. 2019 May 30. doi: 10.1111/bjd.18174.
Ottu 28.2.20

From PsO to PsA: the role of T_{RM} and Tregs in psoriatic disease, a systematic review of the literature.

Lobão B, Lourenço D, Giga A, Mendes-Bastos P.

Front Med (Lausanne). 2024 Feb 9;11:1346757. doi:
10.3389/fmed.2024.1346757. eCollection 2024.
PMID: 38405187 [Free PMC article](#). Review. Otettu
4.3.24

The Interplay between Immune System and Microbita in Osteoporosis.

Locantore P, Del Gatto V, Gelli S, Paragliola RM,
Pontecorvi A.

Mediators Inflamm. 2020 Feb 26;2020:3686749. doi:
10.1155/2020/3686749. eCollection 2020.
PMID: 32184701 [Free PMC article](#). Otettu 6.9.22

Lochner M, Peduto L, Cherrier M, Sawa S, Langa F, Varona R, et al. In vivo equilibrium of proinflammatory IL-17 and regulatory IL-10 Foxp3 ROR γ T cells. *J Exp Med* 2008; 205:1381–93. Otettu 4.3.16

Lockhart E, Green AM, Flynn JL (2006) IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during *Mycobacterium tuberculosis* infection. *J Immunol* 177:4662–9 Otettu 9.3.20

Ref. katsottu 22.3.20

Loesche C, Kolbinger F, Valentin MA, Jarvis P, Ceci M, Wieczorek G, Khokhlovich E, Koroleva I, Bruin G, Sinner F, Aigner B, Patel DD (2016) Interleukin-17A blockade with secukinumab results in decreased neutrophil infiltration in psoriasis: minimally-invasive mea-

surement by tape stripping. Adv Precision Med 1:1–9
Otettu 7.3.20

Ref. katsottu 13.3.20

Adverse events with **IL-17** and **IL-23** inhibitors for
psoriasis and psoriatic **arthritis**: a systematic review
and meta-analysis of phase III studies.

Loft ND, Vaengebjerg S, Halling AS, Skov L, Egeberg A.
J Eur Acad Dermatol Venereol. 2020
Jun;34(6):1151-1160. doi: 10.1111/jdv.16073. Epub
2019 Dec 9.

PMID: 31721310 Otettu 21.9.20

Lohr, J., Knoechel, B., Wang, J.J., Villarino, A.V. &
Abbas, A.K. Role of IL-17 and regulatory T lymphocytes

in a systemic autoimmune disease. J. Exp. Med. 203, 2785–2791 (2006). Otettu 4.3.16

Dermatophytosis in a psoriatic patient treated with secukinumab: an underrated adverse effect?

Loi C, Patrizi A, Sechi A, Tartari F, Magnano M, Bardazzi F.

G Ital Dermatol Venereol. 2018 Aug;153(4):590-591.
doi: 10.23736/S0392-0488.17.05600-0. No abstract available.

PMID:

29767491 ei oteta Ei ole PUBMED

[Similar articles](#)

Upregulated IL-17A secretion and CCR6 co-expression in Treg subsets are related to the imbalance of Treg/Th17 cells in active UC patients.

Long Y, et al. [Scand J Immunol. 2020. PMID: 31660620](#)
[Free article.](#) Otettu 8.9.22

Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.

Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, Sauder M, Vender RB, Maari C, Papp KA.

[J Cutan Med Surg. 2023 Jan-Feb;27\(1_suppl\):3S-24S.](#)

[doi: 10.1177/12034754221141680. Epub 2022 Dec 15.](#)

[PMID: 36519621 Review.](#) Otta M

[Efficacy and retention rate of **secukinumab** in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry.](#)

Lopalco G, Morrone M, Atzeni F, Bazzani C, Bianchi FP, Cantatore FP, Caporali R, Carletto A, Cauli A, Chimenti MS, Colella S, Conti F, Corrado A, Favalli EG, Floris A, Fornaro M, Foti R, Foti R, Fracassi E, Frediani B, Gentileschi S, Gorla R, Gremese E, Praino E, Ramonda R, Rotondo C, Sebastiani M, Semeraro A, Ferraccioli G, Lapadula G, Iannone F.

Ther Adv Musculoskelet Dis. 2025 Jan 31;17:1759720X251315138. doi:
10.1177/1759720X251315138. eCollection 2025.
PMID: 39897378 [Free PMC article](#). Otettu 1.3.25

[Secukinumab \(AIN457\) for the treatment of psoriasis.](#)

López-Ferrer A, Vilarrasa E, Puig L.

Expert Rev Clin Immunol. 2015;11(11):1177-88. doi:
10.1586/1744666X.2015.1095092. Epub 2015 Oct 1.

PMID:

ei ole M Ei oteta

[Similar articles](#)

[A pathogenic IFN \$\alpha\$, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients.](#)

López P, Rodríguez-Carrio J, Caminal-Montero L, Mozo L, Suárez A.

Sci Rep. 2016 Feb 5;6:20651. doi: 10.1038/srep20651.

PMID:

26847824 Otettu 27.5.18

[Free PMC Article](#)

[Similar articles](#)

Secukinumab versus ustekinumab for skin clearance
in patients with moderate to severe psoriasis after a
year of treatment: Real-world practice.

López Jiménez P, Suárez Pérez J, Herrera Acosta E,
Aguilera Arjona J, Mendiola Fernández MV, Bosch
García R, Herrera Ceballos E.

Dermatol Ther. 2019 Jul;32(4):e12937. doi:

Otettu 28.2.20

Safe Treatment With **Secukinumab** in a Patient With Axial Spondyloarthritis and a History of a *Leishmania donovani* Infection.

López-Medina C, Doblas A, Escudero-Contreras A, Collantes-Estévez E.

J Rheumatol. 2023 Sep 1;jrheum.2023-0004. doi: 10.3899/jrheum.2023-0004. Online ahead of print. Otettu 12.10.23

Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis.

López-Mejías R, Genre F, Remuzgo-Martínez S, Pulito-Cueto V, Sevilla-Pérez B, Llorca J, Ortego-Centeno N, Mijares V, Lera-Gómez L, Leonardo MT, Peñalba A, Cabero MJ, Martín-Penagos L, Miranda-Fillooy JA, Navas Parejo A, Sánchez Pérez J, de Argila D, Rubio E, León

Luque M, Blanco-Madrigal JM, Galíndez-Agirregoikoa E, Martín J, Blanco R, Castañeda S, González-Gay MA. Clin Exp Rheumatol. 2020 Mar-Apr;38 Suppl 124(2):166-170. Epub 2020 Mar 25. PMID: 32242803 [Free article.](#) Otettu 5.9.22

Editorial: The IL-17 Cytokine Family in Tissue Homeostasis and Disease.

Lorè NI, Chen K, Bulek K.

Front Immunol. 2021 Feb 24;12:641986. doi: 10.3389/fimmu.2021.641986. eCollection 2021.

PMID: 33717197 [Free PMC article.](#) Otettu 30.8.22

Safety of **secukinumab** for the treatment of active ankylosing spondylitis.

Loricera J, Galíndez-Aguirregoikoa E, Blanco R.

Expert Opin Drug Saf. 2021 Jan 20:1-8. doi: 10.1080/14740338.2021.1851363. Online ahead of print.

PMID: 33470130 Ei ole M

Louten J, Boniface K, de Waal Malefyt R: Development and function of TH17 cells in health and disease. J Allergy Clin Immunol 2009, 123:1004-1011. Otettu 4.3.16

Lowes, M. A., T. Kikuchi, J. Fuentes-Duculan, I. Cardinale, L. C. Zaba, A. S. Haider, E. P. Bowman, and J. G. Krueger. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. *J. Invest. Dermatol.* 128: 1207–1211. Otettu 4.3.16

Lowes MA, Russell CB, Martin DA et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.

Trends Immunol 2013; 34:174–81. Otettu 4.3.16

1. Lu R, Zeng X, Han Q, Lin M, Long L, Dan H, et al. Overexpression and selectively regulatory roles of IL-23/IL-17 axis in the lesions of oral lichen planus. *Mediat Inflamm.* (2014) 2014:701094. doi: 10.1155/2014/701094

Successful **secukinumab** treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report.

Lu J, Tang S, Yu N, Yi X, Li Y.

J Int Med Res. 2020 Nov;48(11):300060520969494. doi: 10.1177/0300060520969494.

PMID: 33161790 [Free PMC article.](#) Otettu 13.12.20

Successful treatment of psoriasis-associated uveitis with ixekizumab after failure of **secukinumab** and risankizumab.

Lua ACY, Chee SP, Oon HHB.

Singapore Med J. 2024 Jan 2. doi:

10.4103/singaporemedj.SMJ-2023-133. Online ahead of print.

PMID: 38421149 [Free article.](#) Otettu 31.3.24

Lubberts E, Joosten LAB, Oppers B, Van den Bersselaar L, Coenen- de Roo CJ, Kolls JK, Schwarzenberger P, Van de Loo FA, Van den Berg WB. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001;167:1004–13. Otettu 4.3.16

.

[The role of IL-17 and family members in the pathogenesis of arthritis.](#)

Lubberts E.

Curr Opin Investig Drugs. 2003 May;4(5):572-7. Review.

PMID:

ei ole M ei ole GS Ei oteta

[Similar articles](#)

Lubberts E, Huang W, Schwarzenberger P, Schurr J, Peschon J, van den Berg WB, Kolls JK. Requirement of local synovial IL-17 receptor signaling in the progression of chronic synovitis and bone erosion in arthritis. *Arthritis Res. Ther* 2004;6:58.

Abstrakti ei oteta

Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. *Arthritis Res Ther* 2005;7:29. ei oteta

[IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?](#)

Lubberts E.

Cytokine. 2008 Feb;41(2):84-91. Epub 2007 Nov 26.

[Similar articles](#)

Select item. Otettu 3.2.16

[Th17 cytokines and arthritis.](#)

Lubberts E.

Semin Immunopathol. 2010 Mar;32(1):43-53. doi::

Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 2015;11:415–29. Otettu 2.3.20

Ref. katsottu 23.3.20

Basic Science Session 2. Recent Advances in Our Understanding of Psoriatic Arthritis Pathogenesis.

Lubberts E, Scher JU, FitzGerald O.

J Rheumatol. 2022 Jun;49(6 Suppl 1):16-19. doi: 10.3899/jrheum.211321. Epub 2022 Feb 15.

PMID: 35169059 ei ole M

Secukinumab for ankylosing spondylitis and psoriatic arthritis.

Lubrano E, Perrta FM.

Ther Clin Risk Manag. 2016 Oct 21;12:1587-1592.

Otettu 27.5.18

Free PMC Article

Similar articles

Impaired **Interleukin-27**-Mediated Control of CD4+ T Cell Function Impact on Ectopic Lymphoid Structure Formation in Patients With Sjögren's Syndrome.

Lucchesi D, Coleby R, Pontarini E, Prediletto E, Rivellese F, Hill DG, Derrac Soria A, Jones SA, Humphreys IR, Sutcliffe N, Tappuni AR, Pitzalis C, Jones GW, Bombardieri M.

Arthritis Rheumatol. 2020 Sep;72(9):1559-1570. doi: 10.1002/art.41289. Epub 2020 Jul 21.

PMID: 32307922 Otettu 21.9.20

Secukinumab Therapy for Netherton Syndrome.

Luchsinger I, Knöpfel N, Theiler M, Bonnet des Claustres M, Barbieux C, Schwieger-Briel A, Brunner C, Donghi D, Buettcher M, Meier-Schiesser B, Hovnanian A, Weibel L.

JAMA Dermatol. 2020 Aug 1;156(8):907-911. doi: 10.1001/jamadermatol.2020.1019.

PMID: 32459284 Otettu 4.2.21

D. Luger, P. B. Silver, J. Tang, D. Cua, Z. Chen, Y. Iwakura, E. P. Bowman, N. M. Sgambellone, C. C. Chan, R. R. Caspi, Either a Th17 or a Th1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category. J. Exp. Med. 205, 799–810 (2008). tai 1517-1522 Otettu 4.3.16

[Cycling versus swapping strategies with TNF- \$\alpha\$ inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice.](#)

Lumetti F, Ariani A, Marchesoni A, Becciolini A, Giuggioli D, Sandri G.

Sci Rep. 2024 Oct 22;14(1):24922. doi: 10.1038/s41598-024-75190-x.

PMID: 39438513 [Free PMC article.](#) Otettu 21.1.25

[Cells of the synovium in rheumatoid arthritis. T lymphocytes.](#)

Lundy SK, Sarkar S, Tesmer LA, Fox DA.

Arthritis Res Ther. 2007;9(1):202. Review.

PMID:

17306038 Otettu 3.2.16

[Free PMC Article](#)

[Similar articles](#)

Health Equity and **Secukinumab** for Severe Psoriasis in New Zealand.

Luo A, Oakley A, Han DY, Jarrett P.

Australas J Dermatol. 2025 Jun 9. doi:

10.1111/ajd.14539. Online ahead of print.

PMID: 40488606 Otettu 28.7.25

Visceral Leishmaniasis after Anti-Interleukin 17A (IL-17A) Therapy in a Patient Affected by Psoriatic Arthritis.

Lupia T, et al. Trop Med Infect Dis. 2022. PMID:

36288060 Free PMC article. Otettu 22.11.22

Secukinumab's effect on structural damage progression in psoriatic arthritis: longitudinal mixture modelling of FUTURE-1 and FUTURE-5.

Luttringer O, Fox T, Pricop L, Gaillez C, Karcher H, Wiecek W, Angehrn Z, Amzal B.

Clin Exp Rheumatol. 2020 Nov 17. Online ahead of print.
Otettu 30.11.22

Evaluation of Combination Therapy With **Secukinumab** and Systemic Corticosteroids for Acute Generalized Exanthematous Pustulosis : A Retrospective Cohort Study.

Lv XQ, Ruan SF, Chen JW, Su XH, Qin K, Zeng XT, Chen LH, Xiang N, Gong T, Ji C.

J Am Acad Dermatol. 2025 May

24:S0190-9622(25)02201-7. doi:

10.1016/j.jaad.2025.05.1419. Online ahead of print.

Otta M

1. Ly K, Smith MP, Thibodeaux Q, et al. Anti IL-17 in psoriasis. *Expert Rev Clin Immunol*. 2019 Nov;15(11):1185–1194. doi: 10.1080/17445019.2019.1661111. PMID: 31511111

Tc17 biology and function: Novel concepts.

Lückel C, Picard FSR, Huber M.

Eur J Immunol. 2020 Sep;50(9):1257-1267. doi: 10.1002/eji.202048627. Epub 2020 Aug 2.

PMID: 32697883 [Free article](#). [Otettu 3.9.22](#)

Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. *J Am Acad Dermatol*. 2014;71(1):141-150. doi: 10.1016/j.jaad.2013.08.011. PMID: 24111111

Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.

Lynde C, Riedl E, Maul JT, Torres T, Pinter A, Fabbrocini G, Daniele F, Brnabic A, Reed C, Wilhelm S, Holzkämper T, Schuster C, Puig L.

Adv Ther. 2023 Mar;40(3):869-886. doi: 10.1007/s12325-022-02379-9. Epub 2022 Dec 14. PMID: 36515803 [Free PMC article.](#) ÅTA

[Targeting of interleukin-17 in the treatment of psoriasis.](#)

Lønnberg AS, Zachariae C, Skov L.

Clin Cosmet Investig Dermatol. 2014 Sep 15;7:251-9.

[Free PMC Article](#)

[Similar articles](#)

Otettu 3.2.16